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Abstract 
 
The focal adhesion kinase or FAK plays an important role in detecting and transducing signals that 
are generated by cell-substrate attachment (Focal adhesions). When these pathways are activated 
under atypical conditions they may promote metastasis, uncontrolled proliferation and a chemo-
resistant phenotype. However the mechanisms by which this protein is activated ectopically in human 
oesophageal squamous cell carcinomas cell lines (HOSCC) is unknown. In the current study it was 
hypothesised that the p90 ribosomal S6 kinase, a key member of multiple pro-survival pathways 
(activator of the Y-box binding protein-1), activates FAK. RSK may promote FAK activation directly, 
from its location at the plasma membrane, or it may modulate FAK activation indirectly via the 
regulation of one of its substrates. RSK inhibits the activation of the glycogen synthase kinase 3β 
(GSK3β) by phosphorylation at Ser9. GSK3β also localises at focal adhesions and may therefore play 
a role in mediating FAK activity. To ascertain the role RSK plays in FAK activation, 3 inhibition 
studies were performed. In the first assay, RSK was specifically inhibited within HOSCC and the 
levels of active FAK monitored (two different environmental conditions). FAK activation was 
monitored by detecting the auto-phosphorylation of FAK at Tyr397. A GSK3β inhibition assay was 
then performed in which GSK3β was specifically inhibited and the levels of active FAK monitored. 
Lastly, a dual inhibition assay was performed where both RSK and GSK3β were inhibited 
simultaneously and the levels of active FAK monitored. A 10% SDS-PAGE analysis when coupled 
with western immunoblotting, semi-quantitatively determined the relative abundance of phospho-
FAK (Tyr397), phospho- GSK3β (Ser9) and phospho-𝛽-catenin (Ser33, Ser37 & Thr41) within each 
cell line. The overall net changes in the phospho-protein profile indicated that all of the HOSCC cells 
had distinct cellular responses to the three inhibitor combinations. However RSK did not appear to 
activate/inhibit FAK activity directly, in most of the HOSCC cells, but rather modulated FAK 
activation through the inhibition of GSK3β. The effects the RSK/GSK3β pathway had on FAK 
activation was partially dependent on the HOSCC cells containing active levels of PTEN. 
Interestingly, the inhibition of both GSK3β and RSK reduced the levels of active FAK in 3 of the 5 
HOSCC cell lines, indicating that this might be a good anti-cancer therapeutic. RSK appeared to play 
a more context specific role in FAK activation within the HOSCC cells suggesting that the grading 
system for moderately differentiated carcinomas needs to be improved. This paper also highlights the 
importance of studying the effects the microenvironment has on neoplasmic transformation as varied 
environmental conditions, during the RSK inhibition studies, drastically impacted the effects the RSK 
inhibitor had on FAK activation. 
 
(435 words) 
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Chapter 1 
1. Introduction 
1.1. Cellular adhesion and substrate dependent cells: links to proliferation and the 
transformed state  
Multicellular organisms are the products of cellular collaboration. For cellular collaboration 
to be effective an extensive network of regulatory queues and an elaborate communication 
network are needed in order to maintain tissue homeostasis (Yamada and Geiger, 1997; Fu et 
al., 2012). Cells, which originate from multicellular organisms, are naturally dependent on 
external stimuli for survival and die in its absence (Yamada and Geiger, 1997). The type of 
external stimulation each cell is exposed to depends largely on the microenvironment in 
which the cells are found (Wang et al., 1998). External stimulation, a chemically or 
mechanically derived signal, triggers a variety of intracellular signal transduction cascades 
that ultimately modulate cellular activity and morphology (Yamada and Geiger, 1997).  
The external environment modulates cellular activity, outside-in signalling in a variety of 
ways. Soluble ligands (such as the epidermal growth factor (EGF)), hormones, cytokines, 
neighbouring cells and components of the extracellular matrix (ECM) all act as a form of 
external stimuli to a cell (Yamada and Geiger, 1997; Carpenter and Cohen, 1990). Cellular 
receptors (such as integrins, E-cadherins and epidermal growth factor receptors) detect these 
forms of external stimulation and trigger specific intracellular signal transduction cascades in 
response to the stimuli (Yamada and Geiger, 1997). The signal transduction cascades can 
trigger a variety of cellular responses depending on the origin of the signal. There are several 
signal transduction cascades that relay externally derived signals intracellularly. These 
cascades may alter cell differentiation patterns, trigger cell motility, promote cell 
proliferation or cause cell senescence (Ohashi et al., 2010; Carragher and Frame, 2004).  
Cells are bombarded with signals that are generated by multiple forms of external stimulation 
(Wang et al., 1998; Kholodenko et al., 1997; Nakakuki et al., 2010). This provides cells with 
copious amounts of information about the microenvironment in which they are found, 
making signal interpretation and signal integration a large concern as this may play a role in 
modulating disease (Kholodenko et al., 1997; Nakakuki et al., 2010). In essence cells are 
exposed to several forms of external stimulation simultaneously triggering a wide range of 
internal signal transduction pathways, which the cell must be able to interpret accurately in 
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order to respond to its environment appropriately (Kholodenko et al., 1997; Nakakuki et al., 
2010).  
There are two hypothesised reasons why multiple forms of stimulation may be necessary to 
trigger a specific cellular response (whether it is cellular senescence, migration or 
proliferation). The first being, that several forms of external stimuli may be necessary to 
obtain a strong enough signal to generate a specific cellular response (signal amplification). 
In this case multiple externally triggered signal transduction cascades have a single 
intermediate in common and several pathways need to be activated in order to amplify the 
signal appropriately (Kholodenko et al., 1997). This phenomenon is known as cross talk 
(Logue and Morrison, 2012). Cross talk occurs when different external stimuli activate 
similar pathways via different mechanisms or different pathways converge at a specific 
intermediate (Logue and Morrison, 2012). Cell signalling intermediates may therefore have 
different cellular roles when acting outside of their canonical pathways and these roles may 
underpin disease (Logue and Morrison, 2012).  With the knowledge that intracellular 
signalling pathways may no longer be considered isolated, how these pathways converge may 
be imperative for our understanding of how diseased phenotypes are maintained and 
propagated (Logue and Morrison, 2012).  Points of cross talk are particularly important to 
elucidate when they play a vital role in cell survival regulation (Logue and Morrison, 2012).  
 Lastly, several externally triggered signal transduction pathways may interact/feed into each 
other, either through positive or negative feedback loops, generating spatiotemporal response 
patterns (context dependent cellular responses). This suggests that there is an interplay 
between signal transduction pathways, triggered by different forms of external stimulation, 
and that the resulting cellular response could be dependent on this interplay (Nakakuki et al., 
2010). So intracellular signalling pathways, triggered simultaneously by different forms of 
external stimuli, may either amplify/modify or nullify a resulting cellular response that would 
have otherwise been generated had only one of the forms external stimulation been present 
(Nakakuki et al., 2010). This knowledge challenges scientists that have generally been 
studying signal transduction pathways separately/in isolation (Aksamitiene et al., 2012). 
Deciphering how signal transduction pathways, generated by more than one form of external 
stimuli, integrate to generate a specific cellular response is of paramount importance. The 
understanding that spatiotemporal response patterns are possible and in fact a probable makes 
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the treatment of complex disorders such as cancer more challenging (Aksamitiene et al., 
2012).  
For stationary cells, cell survival and proliferation is dependent on the pro-survival 
intracellular signalling cascades that are triggered by cell-substrate adhesion (Frisch and 
Francis, 1994). These cells, that are heavily reliant on their extracellular matrix (ECM) for 
survival, will often undergo a form of caspase mediated cell death in its absence (when found 
in suspension or under conditions of anchorage independence) (Frankel et al., 2001; Frisch 
and Francis, 1994). This form of cell death, that is triggered when substrate dependent cells 
become detached from their ECM, is known as anoikis. For certain cell types, cell-ECM 
interactions are imperative not only for their ability to divide, but also for their ability to 
maintain the correct cellular morphology (Frisch and Francis, 1994; Hill and Mackenzie, 
1984; Vachon, 2011). This indicates that the signal transduction cascades, that are propagated 
via ECM attachment, are not solely regulating proliferation but also have roles in cellular 
differentiation, survival and cell polarity (Frisch and Francis, 1994; Hill and Mackenzie, 
1984; Vachon, 2011).  For example epithelial and oesophageal cells are more dependent on 
substrate anchorage, needing this interaction for cellular division and the maintenance of the 
correct histo differentiation patterns (Frisch and Francis, 1994; Hill and Mackenzie, 1984; 
Vachon, 2011) 
This dependency on ECM attachment for pro-survival signalling is a precautionary measure 
that protects against inept cellular migration and proliferation (Frisch and Francis, 1994).  
This ensures that cells that may have acquired the ability to proliferate uncontrollably, 
cancerous cells, are still unable to metastasize (Isohata et al., 2009). An example of how cells 
are able to overcome this constraint is through an epithelial-mesenchymal transition (EMT) 
(Isohata et al., 2009; Rees et al., 2006). EMT transitions require a cell to have lost its cell-cell 
interactions allowing the cell to alter its differentiation pattern (Isohata et al., 2009; Rees et 
al., 2006). The cell adopts an embryonic differentiation pattern which is commonly seen in 
mesenchymal cells (Isohata et al., 2009; Rees et al., 2006). These cells are characteristically 
more mobile (Isohata et al., 2009; Rees et al., 2006). In altering its differentiation patterns, 
these cells alter their dependency on certain signal transduction cascades for survival (Isohata 
et al., 2009; Rees et al., 2006). Understanding the molecular mechanisms these cells adopt to 
promote cell survival is imperative in order to obtain a greater understanding of the cancerous 
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state (Carragher and Frame, 2004; Frisch and Francis, 1994; Hill and Mackenzie, 1984; 
Ohashi et al., 2010).   
1.2. Focal adhesion and its role in cell-ECM interactions    
As a signal transduction hub, focal adhesions (FA) are usually responsible for relaying 
signals to, or from, the ECM to the cell (Carragher and Frame, 2004; Vachon, 2011).  These 
signal relays often involve multiple effectors that activate and repress many different proteins 
such as transcription factors, protein kinases and protein phosphatases (Carragher and Frame, 
2004; Wozniak et al., 2004). These signal transduction pathways that are awakened by 
different stimuli alter gene expression patterns, cellular morphology, its proliferative ability 
and even affects cell motility (Carragher and Frame, 2004). These protein complexes (FA) 
can therefore have far reaching effects on cell survival signalling and proliferation (Fanucchi 
and Veale, 2009; Ohashi et al., 2010).  The multifaceted nature of these complexes ensures 
that they can activate or repress many cellular pathways that play a role in controlling cell 
proliferation and differentiation (Carragher and Frame, 2004). Focal adhesions generate 
signals that activate an array of intracellular signalling pathways including the 
phosphatidylinositol-3 kinase (PI3K) pathway and the mitogen-activated protein kinase 
(MAPK) cascade (Vanhaesebroeck and Alessi, 2000; Heavey et al., 2014; Karelina et al., 
2014). 
 Focal adhesion formation is stimulated by cell-ECM interactions and these interactions are 
most commonly modulated by integrins (or growth factor receptors) (Petit and Thiery, 2000; 
Zhong and Rescorla, 2012). Integrins, transmembrane glycoproteins, provide a link between 
the cytosolic machinery (FA) of the cell and the ECM (Dunty et al., 2004; Ly and Corbett, 
2005). For focal adhesions to form, two separate integrin monomers (α and β monomers) 
must cluster together making it possible for the integrins to associate with a specific external 
stimuli (this is modulated by cytosolic proteins) (Jamali, Jamali and Mofrad, 2013; 
Miyamoto, Teramoto, and Gutkind, 1996).  The type of external stimuli may vary and could 
be a ligand, growth factor or ECM component (Jamali, Jamali and Mofrad., 2013; Miyamoto, 
Teramoto, and Gutkind, 1996). Upon binding of a stimulus, the integrin protein`s 
conformation is altered allowing protein binding sites, on its cytoplasmic tails, to interact 
with various proteins which will eventually collectively form a focal adhesion (Jamali, Jamali 
and Mofrad, 2013; Cram and Schwarzbauer, 2004; Margadant et al., 2012). These proteins 
can be recruited by the integrin membrane clustering process or by the proteins that were 
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initially affected by the event (Carragher and Frame, 2004). More than 50 individual proteins 
make up the focal adhesions including protein tyrosine kinases (Petit and Thiery, 2000; 
Zhong and Rescorla, 2012). These proteins play a crucial role in the signal transduction 
cascades that alert the cell to changes in its environment (Zhong and Rescorla, 2012).  
1. 3. FAK, its activators, repressors and role in focal adhesion based signalling 
Focal adhesion kinases (FAK) are one of the first proteins to be recruited by the integrin 
heterodimer in FAs (Fanucchi and Veale, 2009; Mitra and Schlaepfer, 2006; Parsons, 2003). 
FAK is a 125 kDa non-receptor tyrosine kinase (Carragher and Frame, 2004; Panetti, 2002; 
Zachary and Rozengurt, 1992). This protein can be subdivided into 3 domains (Figure 1) 
(Dunty et al., 2004; Jones, et al., 1988; Panetti, 2002; Parsons, 2003). The N-terminal domain 
contains an N-terminal band 4.1, ezrin, radixin, moesin homology (FERM) domain (Jones et 
al., 1988; Panetti, 2002). The chief kinase is located at the centre of the amino acid sequence 
and is linked to a focal adhesion targeting (FAT) domain, at C-terminus (Jones et al., 1988; 
Panetti, 2002). The protein also contains SH2 docking sites which allow proteins that contain 
this domain to bind to FAK (Dunty et al., 2004; Stewart et al., 2002; Zhong and Rescorla, 
2012, Carragher and Frame, 2004). FAK has a built in autophosphorylation site at tyrosine 
397, see Figure 1 (Calalb and Polte, 1995; Dunty et al., 2004; Lim et al., 2008; Panetti, 2002; 
Owen et al., 1999). The autophosphorylation of this site is thought to be inhibited by the 
FERM domain ( which lies within this region) (Calalb and Polte, 1995; Dunty et al., 2004; 
Lim et al., 2008; Panetti, 2002; Owen et al., 1999).   
The activation of FAK is complex in that it is not completely understood and appears to be 
varied within the cell. In previous years the displacement of the FERM domain, by the 
binding of proteins such as the cytoplasmic tails of β1 integrins, was thought to partially 
activate FAK resulting in its autophosphorylation at tyrosine 397 (Calalb and Polte, 1995; 
Zhong and Rescorla, 2012). This in turn would have created a binding site for Src proteins 
(that phosphorylate FAK at Tyr576 and Tyr577) to fully activate the protein (Figure 1) 
(Calalb and Polte, 1995; Zhong and Rescorla, 2012). 
However, more recently the mechanism by which FAK is partially activated 
(autophosphorylation Tyr397) has been called into question with some studies suggesting that 
FAK dimerization is responsible for the partial activation of its kinase activity (Brami-
Cherrier et al., 2014; Katz et al., 2002). These studies suggest that focal adhesions and 
specifically Paxillin recruits FAK to the membrane creating points of local enrichment that 
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promote FAK dimerization (Brami-Cherrier et al., 2014; Katz et al., 2002). The dimers form 
via the association of their N-terminal FERM domains and are thought to be stabilised by a 
FERM: FAT domain interaction (Brami-Cherrier et al., 2014). It is therefore suggested that 
the dimerization event triggers the autophosphorylation of FAK at Tyr397 (Brami-Cherrier et 
al., 2014).  
Regardless of whether FAK is partially activated in monomeric or dimeric form, FAK 
appears to require the activity of Src proteins to fully activate it (in integrin-ECM based 
signalling) (Caron-Lormier and Berry, 2005; Calalb and Polte, 1995; Mitra and Schlaepfer, 
2006; Zhong and Rescorla, 2012).  The activation of this protein is further complicated by the 
fact that FAK has the ability to act as both a scaffolding protein and a protein kinase (Dunty 
et al., 2004). This means that FAK’s activity may not require dimerization when acting in its 
role as a scaffolding protein (Dunty et al., 2004). This adds yet another layer to the 
complexity to the regulation of FAK activity within the cell. 
It is important to note that the FAK/Src complex plays a large role in focal adhesion based 
cell survival signalling (Mitra and Schlaepfer, 2006; Carragher and Frame, 2004; Zhong and 
Rescorla, 2012). This complex does this by recruiting a variety of proteins to FA and 
phosphorylating several of them (Mitra and Schlaepfer, 2006; Carragher and Frame, 2004; 
Zhong and Rescorla, 2012). For example FAK binds p130Cas, see Figure 1 (Mitra and 
Schlaepfer, 2006; Carragher and Frame, 2004; Owen et al., 1999). p130Cas plays a role in 
mediating kinases activity by allowing kinases to come into close proximity with their 
substrates (Mitra and Schlaepfer, 2006; Owen et al., 1999). These adaptor proteins ensure 
that signal transduction cascades are initiated (Carragher and Frame, 2004). FAK SH2 
docking sites, produced by the phosphorylation of FAK at Y925 and Y861 (FAT Domain), 
enables pro-survival signalling molecules such as Grb2 to bind to FAs (Carragher and Frame, 
2004; Owen et al., 1999). Grb2 elicits its response by activating the MAPK pathway (Figure 
2) (Mitra and Schlaepfer, 2006; Carragher and Frame, 2004).  Other proteins that are 
recruited to the focal adhesion complex are vinucullin, VASP, vinexins, ponsin, Arp2/3, α-
actinin, F-actin, PYK2, Abl, PKC, PAK and ILK (Mitra and Schlaepfer, 2006; Bershadsky et 
al., 2006).   
FAK activity is also repressed by activity of the JNK pathway-associated phosphatase 
(JKAP) and phosphatase and tensin homolog (PTEN) (Li et al., 2010; Zhang et al., 2014).  
Both of these protein phosphatases modulate focal adhesions by dephosphorylating FAK 
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thereby inhibiting cell migration (Zhang et al., 2014; Li et al., 2010; Gu et al., 1999). The 
FAK related non-kinase (FRNK) (transcribed by an alternative promoter in the intron of the 
FAK gene) has identical sequence homology to the COOH-terminal domain of FAK and also 
acts as an inhibitor of FAK activity (Aguirre, 2002; Nolan et al., 1999; Xu et al., 1998). 
FRNK is only really ubiquitously expressed during embryonic development making it an 
unlikely player in regulating FAK activity within adult tissues (Nolan et al., 1999). The 
proline-rich tyrosine kinase 2/cell adhesion kinase β (Pyk2/CAKβ) is the only other isoform 
of FAK (Sieg et al., 1998; Sasaki et al., 1995). Pyk2, although a non-receptor tyrosine kinase, 
is not ubiquitously expressed in all cells, as is the case with FAK (Zhang et al., 2014; Zhao et 
al., 2000; Mitra et al., 2005).  In fact the expression of Pyk2 has been limited to the central 
nervous system, hematopoietic and endothelial lineages (Mitra et al., 2005, Zhang et al., 
2014; Zhao et al., 2000). As a result of this it is unlikely that Pyk2 will play a role in 
epithelial cells pro-survival signal transduction cascades (Xu et al., 1998). 
 
             Figure 1.  A schematic representation of the structure and function of the 
            principle focal adhesion kinase. 
The phosphorylation of FAK, Tyr576 and Tyr577, by Src is necessary for the optimal 
activity of the protein. FAK activates substrates such as Grb2, Paxillin and p130Cas. 
The image was modified (Microsoft Paint ©) from the review, Focal adhesion kinase: 
in command and control of cell motility, written by Mitra et al. (2005) (Figure 3; pg 
61).  
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1.4. The pro-survival intracellular signalling mechanisms of FAK 
FAK plays a vital role propagating cell survival based signals, by activating the MAPK 
pathway for example, that its activity is often repressed in cells undergoing a form of 
programmed cell death (Levkau et al., 1998). One of the initial steps following apoptosis 
induction is actually the caspase 3-mediated cleavage of FAK (Levkau et al., 1998). This 
effectively inhibits the focal adhesions ability to trigger cell survival pathways during 
apoptosis (Levkau et al., 1998). It therefore stands to reason that high levels of the active 
form of this protein would cause endothelial and epithelial cells to become resistant to 
anoikis, apoptosis and promote cell-survival based signalling ectopically (Frisch and Jolla, 
1996).  
The role of FAK within the cell is not limited to the membrane level since it occurs within all 
subcellular locations including the nucleus (Fanucchi and Veale, 2009).  The pro-survival 
role of FAK within the nucleus is closely linked to the regulation of p53 turnover (Figure 2) 
(Lim et al., 2008; Van Miltenburg et al., 2014; Dunty et al., 2004).  It is thought that FAK 
acts in its capacity as a scaffolding protein to mediate the interaction between p53, a well-
known tumour suppressor protein, and MDM2 via its FERM domain (Lim et al., 2008). FAK 
therefore aids in the ubiquitin-mediated degradation of p53 (Lim et al., 2008). This ensures 
that the pro-apoptotic gene targets of p53 remain transcriptionally silent (Lim et al., 2008). 
This therefore inhibits proteins such as p21, a pro-apoptotic protein, which promotes cell 
cycle arrest (Graham, et al., 2010). The loss of p53 activity ensures that cell survival and 
proliferation continues unabated (Lim et al., 2008).  
In a study observing how different cellular lineages perceived and interpreted cell-ECM 
signals, it was found that active FAK provided cells from different lineages with resistance to 
anoikis (Zouq et al., 2009). The mechanisms by which this resistance was achieved varied 
from one cell lineage to another (Zouq et al., 2009).  For example epithelial cells require 
Paxillin, its SH2 domain, in order to activate the Protein kinase B (Akt) and PI3K Pathway 
(Zouq et al., 2009). While in fibroblasts, FAK mediated anoikis resistance required the 
activation of p130Cas (Zouq et al., 2009). This in turn activated the Ras-Rac pathway via Crk 
and Nck (Zouq et al., 2009).  However possible mechanisms by which FAK, pro-survival 
based signalling can be activated ectopically has yet to be determined. 
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Figure 2. A schematic representation of FAK-regulated signal transduction 
cascades. 
Green FAK is representative of an active FAK. Red regions indicate the inhibition of 
p53 by FAK and the consequences for this inhibition on the p53-apoptosis pathway. 
The MAPK pathway is activated by FAK as seen by the uncoloured green circles 
whilst PTEN inhibits FAK activity. The PI3K pathway is also activated by FAK, 
indicated by uncoloured green squares, and the consequences for the activation of 
this pathway are highlighted. Abbreviations: mitogen activated protein kinase kinase 
(MEK), the extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinases 
(JNK), Mouse double minute 2 homolog (MDM2), matrix metallopeptidase 9 (MMP9), 
protein kinase B (Akt/PKB) and PTEN. The image was modified (Microsoft Paint ©) 
from papers published by Fu and colleagues, 2012. 
  
 
 
 
 
 
 
     Proliferation 
Migration 
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1.5. RSK, its activators, repressors and sublocalization within the cell 
The ribosomal S6 kinase (RSK) family is a group of Ser/Thr kinases that can be divided into 
2 categories namely the p70 Ribosomal S6 kinases (S6K) and p90 ribosomal S6 kinases 
(RSK) (Yntema et al., 1999; Frödin and Gammeltoft, 1999; Li et al., 2013). The p90 kDa 
ribosomal S6 kinases (RSK), also known as the MAPK-activated protein kinase-1 
(MAPKAP-K1), play a large role in multiple pathways (Anjum and Blenis, 2008; Gayanilo, 
et al., 2014). RSK is an unusual protein in that it contains two catalytic domains at the N- and 
C-terminus of the protein (Frödin and Gammeltoft, 1999; Gayanilo et al., 2014; Jones et al., 
1988). These kinase domains are known as NTKD and CTKD respectively (Frödin and 
Gammeltoft, 1999; Gayanilo et al., 2014).  
 
There are four isoforms of the p90 ribosomal S6 kinase (RSK, p90RSK, MAPKAP-K1) in 
mammals, RSK1 to 4 (Yntema et al., 1999; Jacquot et al., 1998). The isoforms, RSK1-3, are 
expressed in all cells, however, their individual abundance within cell lineages appears to be 
tissue specific (Yntema et al., 1999). The RSK isoforms all share a similar overall structure 
and appear to have overlapping roles in signal transduction cascades (Leighton et al., 1995; 
Carriere et al., 2008). They display a degree of functional redundancy and are activated in a 
similar way (all key residues are conserved amongst the isoforms) (Carriere et al., 2008).  
However, it is specifically known that RSK1 and RSK 2 have been implicated in cancer 
development and maintenance (Carriere et al., 2008). Due to the functional redundancy of 
these isoforms they will collectively be referred to as RSK in this paper. 
 
 RSK activation, canonically, requires the binding of the extracellular signal-regulated kinase 
(ERK) to its C-terminal docking site (RSK) (Roux et al., 2003). The C-terminal domain acts 
as a negative regulator for the activity of the RSK N-terminal kinase (Richards et al., 1999). 
As a result of this in the first stage of RSK activation ERK phosphorylates RSK at ser-573, in 
the activation loop of the COOH-terminal kinase (Ballif et al., 2005; Kuang et al., 2009). 
This triggers the phosphorylation of 2 other sites on the linker region by ERK (Thr-359/Ser-
363) and other kinases (Ballif et al., 2005; Kuang et al., 2009). The phosphorylation of the 
linker region is thought to assist in unfolding the protein thereby priming it for full activation 
(Ballif et al., 2005; Kuang et al., 2009).  Lastly the C-terminal kinase domain creates a 
binding site for 3-phosphoinositide-dependent kinase, PDK2, by phosphorylating Ser380 
(Ballif et al., 2005; Richards et al., 1999).  PDK2 in turn phosphorylates Ser-221 in the N-
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terminal kinase domain of RSK, activating its kinase activity (Ballif et al., 2005; Kuang et 
al., 2009; Richards et al., 1999). The final step of RSK activation involves the separation of 
the RSK-ERK complex (Ballif et al., 2005; Kuang et al., 2009). This is triggered by the 
autophosphorylation of RSK, by the N-terminal kinase domain, at serine 732 (Roux et al., 
2003; Ballif et al., 2005; Kuang et al., 2009).  
 
RSK is activated by ERK, a key member in the MAPK pathway, identifying this protein as a 
downstream signalling molecule that promotes cell survival based signalling (Figure 3) 
(Gayanilo et al., 2014).  RSK is also associated with the rapamycin-mTOR pathway and the 
PI3K pathway, see Figure 3 (Zeng and Kinsella, 2008; Gayanilo et al., 2014). As a 
downstream signalling molecule in a signal transduction cascade, RSK modulates the activity 
of a variety of proteins in order to elicit a cellular response (Zeng and Kinsella, 2008; 
Gayanilo et al., 2014).   The substrates that RSK act on can be found in any sublocation 
within the cell (Anjum and Blenis, 2008; Frödin and Gammeltoft, 1999; Qi et al., 2007).  
RSK substrates include CREB, Fascin-1, Hsp27, c-FOS, cAMP, Bad, Bim and c-Met (Kang 
et al., 2010; Li et al., 2013).  
 
One such substrate of RSK, the glycogen synthase kinase 3β (GSK3β), is known to play a 
fundamental role in several signal transduction pathways that regulate cell cycle progression, 
proliferation, differentiation and migration, see Figure 3 (Domoto et al., 2016; Jope and 
Johnson, 2004). GSK3β and its isoform GSK3α are ubiquitously expressed serine-threonine 
kinases (Hansen et al., 1997). The reported roles GSK3β plays in neoplasmic transformations 
are exceedingly conflicting.  Its been found to be overexpressed and activated, by 
phosphorylation at tyrosine 216, in several forms of cancer including epithelial ovarian 
tumours, pancreatic and colorectal cancers (Domoto et al., 2016; Rask et al., 2003; Shakoori 
et al., 2005; Shakoori et al., 2007; Mai et al., 2009; Ougolkov et al., 2005). The inhibition of 
GSK3β actually suppressed cancer proliferation and induced apoptosis (Ougolkov et al., 
2007; Ougolkov et al., 2005). GSK3β has also been found to promote migration through the 
activation of Rac 1, which promotes lamellipodia formation (Koivisto et al., 2003; Vaidya et 
al., 2006). 
Literature has shown that GSK3β acts as tumour suppressor that negatively regulates the 
activity of Wnt pathway (Waaler et al., 2011).  It does this by preventing β-catenin from 
activating the T-cell factor/lymphoid enhancer factor (TCF/ LEF), which transcribe several 
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genes that underpin the transformed state (c-Myc, cyclin D1, matrix metalloproteinase 7 
(MMP7) etc.) (Cook et al., 1996; Manoukian and Woodgett, 2002; Fuchs et al., 2005; Jope 
and Johnson, 2004). GSK3β, adenomatous polyposis coli (APC) and axin collectively bind 
to/phosphorylates β-catenin at Ser 33, Ser 37 and Thr 41 (Hinoi et al., 2000; Rask et al., 
2003; Waaler et al., 2011). This phosphorylation triggers the ubiquitination of β-catenin by β-
TrCP which ultimately results in the protein being degraded by the proteasome (Hinoi et al., 
2000; Fuchs et al., 2005). The constant activation of the Wnt-pathway upon the loss of 
GSK3β activity often leads to cancer and its inhibition is often associated a reduction in 
cancer cell growth (Kwong et al., 2002).  GSK3β has also been implicated in the PI3K-Akt 
pathway (Figure 3) and has several other substrates including c-jun, cyclic AMP response 
protein-1, heat shockfactor-1 and Myc (Sutherland et al., 1993; Grimes et al., 2001; Hinoi et 
al., 2000; Rask et al., 2003). RSK and Akt both inhibit GSK3β activity, by phosphorylating 
its inhibitory site (Serine 9), thereby regulating its function within the cell (Jope and Johnson, 
2004; Stambolic and Woodgett, 1994; Pap and Cooper, 1998). It is possible that RSK may 
elicit a specific cellular response via the inhibition of one of its substrates such as GSK3β. 
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                 Figure 3. A schematic representation of the canonical pathway of RSK. 
The MAPK-RSK pathway is commonly activated by growth factors; this pathway is 
indicated by the green uncoloured spheres. RSK requires the activity of both PDK1 
and ERK for its activation. Once activated RSK modulates the mTOR pathway by 
inhibiting TSC1/TSC2, as seen by the uncoloured hexagon. RSK also acts on other 
substrates such as GSK3β and promote gene expression. The activity of RSK within 
the cell often leads to cell motility. Abbreviations: mammalian target of rapamycin 
(mTOR), mTOR complex 1 (mTORC1), tuberous sclerosis complex (TSC), protein 
kinase B (Akt/PKB) and eukaryotic initiation factor 4E (elF4E). The image was 
produced (Microsoft Paint ©) by making use of the information provided from papers 
published by Brett and colleagues (2014) and Anjum and Blenis (2008).  
 
1.6. RSK, cell motility and pro-survival based signalling 
RSK has a diverse range of functions within the cell and may therefore play a vital role in cell 
survival based signalling (Xian et al., 2009). Recently it was found that RSK activity induced 
by high levels of fibroblast growth factor receptor 1, resulted in non-transformed mammary 
cells being able to survive and proliferate in suspension (loss of Cell-ECM interactions) 
(Xian et al., 2009). The role of RSK in anoikis resistance, cell survival and EMT was further 
solidified by the fact that these cells underwent apoptosis when RSK was inhibited (Xian et 
al., 2009). Other studies corroborated this discovery finding RSK activity necessary for the 
Substrate phosphorylation 
Cell motility 
mTORC1 
14 
 
weakening of cell-cell contacts and the increased cellular migration of cancer cells 
(Čáslavský, Klímová, and Vomastek, 2013). This is achieved by altering the cells gene 
expression profile (Doehn et al., 2009). RSK activates the expression of a variety of pro-
invasive proteins such as uPAR, whilst inhibiting the expression tumour suppressor proteins 
(Doehn et al., 2009). The response RSK elicits in epithelial cells can be linked to cell 
scattering, wound healing, cell multilayering and ECM invasion (Doehn et al., 2009). This 
implies that RSK mediates cell motility and invasion via gene regulation (Doehn et al., 
2009). Ultimately these findings indicate that RSK may well play a role in pro-survival based 
signalling and that ectopically RSK activation can lead to increased cell invasiveness.  
1.7. A link between RSK and the focal adhesion pathway  
With the knowledge that RSK plays such a varied role in cell signalling cascades, few studies 
have focused on the possible interactions RSK might mediate at the membrane level.  The 
sublocalisation of RSK has become increasingly important since the study conducted by Woo 
et al. (2004). In this study it was found that the need for ERK to activate RSK was 
circumvented in cells exposed to epidermal growth factors, EGF (Woo et al., 2004). In this 
case EGF caused the translocation of RSK to the plasma membrane where it was activated by 
phosphorylation, before being translocate into the nucleus (Woo et al., 2004).  Based on its 
subcellular locations within the cell, RSK may activate multiple proteins including Filamin 
A, which assists in cell motility by remodelling the actin cytoskeleton (Woo et al., 2004).  
 
RSK was in fact found to localise near focal adhesion complexes (Gawecka et al., 2012). 
Gawecka and colleagues found that RSK co-localised with talin, a protein that is thought to 
play a role in integrin activation. It was also found that RSK, at this position in the focal 
adhesion complex, may be able to modulate the activation of integrins (as RSK2 located near 
the cytoplasmic tails) (Gawecka et al., 2012). RSK may therefore play a role in initiating 
several focal adhesion based signalling processes, including those that regulate the 
cytoskeletal contacts at that point (Gawecka et al., 2012). Therefore RSK, outside of its 
canonical MAPK pathway, may play an active role in focal adhesion signalling by activating 
FAK, see Figure 4A (Gawecka et al., 2012). 
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1.8. Human oesophageal squamous cell carcinomas (HOSCC) 
Cells that show a high degree of dependency on cell-ECM, focal adhesion based signalling, 
for survival often adopt interesting mechanisms to circumvent these controls in cancer 
(Ohashi et al., 2010).  For example oesophageal squamous cells are highly substrate-
dependent before transforming into highly invasive cancer cells (Ohashi et al., 2010). 
The degree of metastasis seen in human oesophageal squamous cell carcinomas (HOSCC) 
made this form of cancer the sixth most deadliest form of cancer in the world (Ohashi et al., 
2010, Ferlay et al., 2012). In South Africa 1 in every 6250 individuals will be affected by this 
disease and only 10 % of all of these patients will survive longer than 5 years after the initial 
prognosis is given ( Hendricks and Parker, 2002; Ohashi et al., 2010).  Understanding the 
molecular mechanisms that allow this form of cancer to circumvent anoikis and promote cell 
survival/proliferation can only aid in the battle against this disease. Because the transition 
from the original state to the highly metastatic and invasive HOSCC cell lines is so drastic, it 
may involve multiple alterations to the intermediates, of the signal transduction pathways, 
that mediate cell anchorage dependent survival (Fanucchi and Veale, 2009). 
1.9. The effects of RSK on focal adhesion signalling through its interactions with key 
players within the focal adhesion pathway in HOSCC 
As a prominent player in focal adhesions, FAK plays an important role in detecting/ 
transducing signals that are generated by cell-ECM interactions (Mitra and Schlaepfer, 2006; 
Carragher and Frame, 2004; Zhong and Rescorla, 2012). Most of these signals promote cell 
survival which when, activated under atypical conditions, could explain how cancer cells 
circumvent anoikis and promote cell survival (Frisch and Jolla, 1996). In reality should FAK 
be activated non-canonically it would convey cell-ECM based signals regardless of whether it 
(cell-ECM interactions) were present or absent (Frisch and Jolla, 1996; Zouq et al., 2009). 
For this reason FAK is overexpressed in many different forms of cancer (colon, cervix and 
breast cancer) and  is thought to play a prominent role in maintaining the transformed state 
(Van Miltenburg et al., 2014).  
HOSCC have been shown to resist anoikis in suspension through the creation of multicellular 
aggregates that sustain FAK activity (Zhang et al., 2004). FAK promoted cell survival 
signalling and fibronectin deposition (Zhang et al., 2004). This coupled with the knowledge 
that FAK is overexpressed in other cancers suggests that the overexpression and activity of 
16 
 
FAK might play a fundamental role in the transformation of epithelial cells (Canel et al., 
2006; Frisch and Jolla, 1996). In fact FAK activation/overexpression has been associated 
with cancerous strains that are resistant to chemotherapeutics and the reduction of FAK 
activation in these cell lines rendered them susceptible to chemotherapeutic agents (Wilson et 
al., 2014; Eke et al., 2012). This indicates that FAK signalling plays a vital role in 
propagating a chemo resistant phenotype in SCC that its loss decreased cancer cell viability 
and its proliferative capacities (Golubovskaya et al., 2012; Eke et al., 2012).  
 
Therefore the mechanism by which this protein is activated, non-canonically, may be a good 
therapeutic target for anti-cancer therapeutics (Frisch and Francis, 1994; Carlson et al., 2004; 
Fanucchi and Veale, 2009; Lim et al., 2008; Ohashi et al., 2010). Understanding the 
mechanisms that regulate FAK activation may help to provide a more detailed image of 
cancer progression in HOSCC cancer cells (Carlson et al., 2004; Fanucchi and Veale, 2009; 
Lim et al., 2008; Ohashi et al., 2010).  
 
RSK has been said to play a role in several signal transduction pathways, such as the PI3K 
pathway and the MAP kinase pathway, however, its role in focal adhesion complex 
regulation has only recently been suggested by Gawecka and colleagues (2012). Based on the 
subcellular location of RSK and the pathways that are said to activate this protein, RSK may 
play a role in activating multiple proteins in focal adhesions, including FAK (Gawecka et al., 
2012; Woo et al., 2004). In its canonical pathway, RSK promotes cellular motility, EMT and 
metastasis in epithelial cells. With little information being known about the relationship 
between RSK and FAK, it is possible that RSK may directly activate this protein. 
 In previous years a link between RSK activity and the phosphorylation of FAK, Tyr861 was 
made in HNSCC cell lines (Kang et al., 2010). However, this study considered it unlikely 
that RSK would modulate the activation of FAK directly, instead suggesting that RSK may 
modulate FAK activity via one of its substrates (Kang et al., 2010). In 2014 the effect of RSK 
inhibition on the proliferation of oral squamous cell carcinomas was investigated. Here loss 
of RSK resulted in the inhibition of its downstream targets; it caused cell cycle arrest (via its 
modulation of p21 expression) and apoptosis (Chiu et al., 2014). It is possible that the role 
RSK plays in modulating p21 expression may be through its activation of FAK, see Figure 
4A (Chiu et al., 2014).  
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Therefore this investigation wishes to determine whether or not cross talk exists between the 
focal adhesion pathway and the MAPK-RSK pathway in HOSCC (Figure 4A). It is predicted 
that this study will elucidate novel mechanisms by which FAK is regulated ectopically and 
thereby provide scientists with a better understanding of how HOSCC modulates cell survival 
based signalling (Figure 4A and B).  This knowledge could not only be imperative for ones 
understanding of the molecular mechanisms that propagate this disease, but may also 
improve our mechanisms of combating this disease. 
1.9.1. The Aim of this investigation: 
The role RSK plays in modulating focal adhesion based signalling will be investigated by 
determining whether RSK activates the principle focal adhesion kinase (FAK) (either directly 
or indirectly) in HOSCC cell lines (Figure 4A and 4B). 
1.9.2. The Objectives 
 The basal levels of phospho-𝛽-catenin (Ser33, Ser37 & Thr41) (phosphorylation 
targets 𝛽-catenin for ubiquitination), active FAK (phospho-FAK (Tyr397)) and 
inactive GSK3β (phospho- GSK3β (Ser9)) will be semi-quantitatively determined for 
all the HOSCC cell lines including the control cell lines (the HT29 and A431 cell 
line). 
 To putatively determine whether RSK activates FAK directly, RSK will be 
specifically inhibited (by BI-D1870) within the HOSCC cell lines and the subsequent 
fluctuations in the level of active FAK monitored (Figure 5C and 5D).   
 To determine whether RSK is inhibited effectively within the HOSCC cell lines, RSK 
will be specifically inhibited and the levels of inactive GSK3β monitored (RSK 
phosphorylates GSK3β at Serine 9) (control).  
 To explore whether FAK activation is indirectly caused by RSK activity via the 
activation of its substrate the glycogen synthase kinase 3β (GSK3β); both RSK and 
GSK3β will be specifically inhibited (by BI-D1870 and AR-A014418) simultaneously 
and the levels of active FAK monitored (Figure 5E).  
 To determine the effect of GSK3β inhibition has on the levels of phospho-FAK 
(Tyr397), GSK3β will be specifically inhibited (AR-A014418) in each of the HOSCC 
cell lines and the subsequent levels of active FAK will be monitored (control). 
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 To determine whether GSK3β is effectively inhibited within the HOSCC cell lines, 
GSK3β will be specifically inhibited and the levels of phospho-𝛽-catenin (Ser33, 
Ser37 & Thr41) monitored (GSK3β targets 𝛽-catenin for ubiquitination) (control).  
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Figure 4 (A and B). A schematic representation of the proposed mechanisms 
by which focal adhesion-based signalling can be modulated by RSK in HOSCC.   
Green represents active proteins whilst red represents proteins that are inactive. Red 
lines represent inhibition. A. FAK is suggested to be ectopically activated by RSK, 
not the result of cell-ECM interactions, and this results in pro-survival signalling as 
illustrated by the inhibition of the p53-apoptosis pathway. The involvement of RSK in 
this pathway, as seen in purple, is being proposed in this article and has not yet been 
proven. B. Alternatively FAK may be ectopically activated by a protein that is 
ordinarily repressed be GSK3β activity, not the result of cell-ECM interactions, and 
this results in pro-survival signalling. The image was produced (Microsoft Paint ©) by 
making use of the information provided from papers published from Lim et al., 2008. 
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Figure 5 (C, D and E). The experimental mechanisms and predicted roles RSK might play in focal adhesion based 
signalling (activation of FAK) in HOSCC. 
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Figure 5 (C, D and E). A schematic 
representation of the experimental 
mechanisms and predicted roles RSK 
might play in focal adhesion based 
signalling (activation of FAK) in 
HOSCC.  
Green represents active proteins whilst 
red represents proteins that are inactive. 
Red lines represent inhibition. C. RSK 
inhibition (by BI-D1870), in the HOSCC 
cell lines, showed a reduction in active 
FAK within in the HOSCC cell lines. FAK 
is suggested to be ectopically activated 
by RSK. D. Alternatively RSK inhibition 
(by BI-D1870), in the HOSCC cell lines, 
showed a reduction in active FAK within 
in the HOSCC cell lines. FAK may be 
ectopically activated by a protein that is 
ordinarily repressed by GSK3β activity. 
E. Should FAK activation remain 
unaltered upon RSK inhibition (BI-
D1870) in conjunction with GSK3β 
inhibition (AR-A014418), then an 
unknown substrate of GSK3β may be 
responsible for the ectopic activation of 
FAK in HOSCC. 
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Chapter 2 
2. The basal levels of key phospho-intermediates involved in the focal 
adhesion and Wnt pathway within the HOSCC cells 
2.1. Introduction  
Several studies have focused on the overexpression of FAK in neoplasmic cells. The 
overexpression of this protein can have multiple effects on the diseased phenotype. Lyngeal 
squamous cell carcinoma cells that overexpress FAK have a distinctive survival advantage, 
increased proliferative capacities and a reduced susceptibility to apoptosis induction (Li et al., 
2012).  FAK overexpression also correlated with rectal cancer resurgence following multiple 
rounds of chemoradiation (del Pulgar et al., 2016). Thoracic oesphageal cancer was also 
found to overexpress FAK (Miyazaki et al., 2003). Only 38 % of patients with FAK 
overexpression survived longer than 5 years, significantly lower than patients that did not 
overexpress this protein. Characteristics of FAK overexpression were predominantly linked 
to lymph node metastasis and tumour invasiveness (Miyazaki et al., 2003). This would 
suggest that FAK overexpression is a marker for the transformed state but does this correlate 
with FAK activation?  
The high abundance of active FAK, phospho-FAK (Tyr397), has been associated with 
particularly invasive cancer strains suggesting that active FAK may promote lymph node 
metastasis and promote cell survival (Rodrigo et al., 2007; Aust et al., 2014). FAK activity 
also appears to be essential for anoikis resistance and promotes EMT in epithelial cells (Bolos 
et al., 2010; Halder et al., 2005). Circulating breast cancer cells that expressed activated 
signaling kinases (FAK and PI-3K) were found to be malignant/metastatic (Kallergi et al., 
2007).  Interestingly, osteosarcoma cells that overexpressed high levels of GKS3β, FAK and 
β5 integrin were found to be less responsive to neoadjuvant chemotherapeutics (Le Guellec et 
al., 2013). This suggests that high levels of FAK activation could be used as a marker for 
more virulent forms of cancer. This study therefore wishes to determine whether high levels 
of active FAK are a hallmark of human oesphageal squamous cell carcinomas. Provided that 
FAK activation is a common trait in HOSCC cells, the mechanisms by which this protein is 
activated ectopically will need to be elucidated. 
Key signal transduction intermediates that may provide insight into the ectopic mechanisms 
of FAK activation are proteins that associate with the Wnt pathway, GSK3β and β-catenin. 
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GSK3β has the capacity to both promote and inhibit cancer (Waaler et al., 2011; Ougolkov et 
al., 2007; Ougolkov et al., 2005). The role GSK3β plays in the transformed state appears to 
be dependent on the cell lineage. In oral cancers GSK3β acts as a tumour suppressor protein 
that regulates transcription, accelerated cell cycle progression and promotes epithelial cell 
homeostasis (Kim et al., 2007; Iamaroon et al., 2009).  
It does this in part, by inhibiting the Wnt pathway (MacDonald et al., 2009). GSK3β triggers 
the ubiquitination/degradation of β-catenin by phosphorylating it at Ser33, Ser37 and Thr41 
(Hinoi et al., 2000; Rask et al., 2003; Waaler et al., 2011). This halts the Wnt pathway 
thereby preventing inapt cell renewal/proliferation (MacDonald et al., 2009). Should GSK3β 
be inhibited continually it would lead to excessive Wnt signaling and a loss in phospho-β-
catenin (Ser33, Ser37 & Thr41) (MacDonald et al., 2009). Attaining the relative abundance 
of phospho-β-catenin within neoplasmic cells would provide scientists with an indicator of 
GSK3β activity. 
The inhibition of GSK3β itself, by phosphorylation at Ser9, is upregulated by the oncogenic 
activation of either p90 ribosomal S6 kinase (RSK), Protein kinase A(PKA), Akt and protein 
kinase C (PKC) (Fang et al.,2000; Kim et al.,2007; Jope and Johnson, 2004; Stambolic and 
Woodgett, 1994; Pap and Cooper, 1998). The activation of these proteins and subsequent 
inhibition of GSK3β, underpins the diseased state in oral squamous cell carcinomas 
(Iamaroon et al., 2009; Lim et al., 2005). Therefore it stands to reason that cancer cell lines 
with high to moderate levels of GSK3β inhibition, phospho-GSK3β (Ser9) contain equally 
high levels of its antagonists (actively inhibiting GSK3β). This study also wishes to 
determine whether GSK3β inhibition is prominent in HOSCC cells. Not only will this 
indirectly determine whether GSK3β antagonists (such as the p90 ribosomal S6 kinase) are 
active, it may also ascertain whether GSK3β acts in the capacity of a tumour suppressor or 
oncogene within these cells. GSK3β or one of its antagonists may play a large role in cancer 
cell progression by playing an active role in FAK activation.  
Lastly, the levels of phospho-β-catenin (Ser33, Ser37 & Thr41) will also be monitored to 
ascertain the level of GSK3β activity that underpins the transformed state in HOSCC cells. 
This will provide some indication as to whether GSK3β or one of its antagonists is more 
likely to play a role in FAK activation within these cells. 
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2.2. Methods and Materials 
2.2.1. Cell culture 
Five South African moderately differentiated human oesophageal squamous cell carcinoma 
cell lines were obtained from the Cell Biology Research Laboratory, the School of Molecular 
and Cell Biology, University of the Witwatersrand. The cell lines were denoted as the 
WHCO1, WHCO3, WHCO5, WHCO6 (Veale and Thornley, 1989) and the SNO (Bey et al., 
1976) cell lines. To date, there appears to be no archetypical oesophageal squamous cell lines 
that accurately represent the correct physiological profile of non-transformed oesophageal 
squamous cells in vivo (Jankowski et al., 1995; Underwood et al., 2010). Even the HET-1A 
cell line, the most commonly used model for organotypical oesophagus in vitro, was found to 
lack squamous differentiation (Underwood et al., 2010). This cell line failed to express the 
classic epithelial markers, E-cadherin and casein kinase 5/6, displaying mesenchymal 
markers such as vimentin and N-cadherin instead (Underwood et al., 2010). This suggests 
that the HET-1A cell line, or its equivalent, cannot act a representative model for ‘normal’ 
oesophageal squamous epithelium (Jankowski et al., 1995; Underwood et al., 2010). This 
makes the HET-1A cell line unsuitable as a comparative control in this investigation 
(Underwood et al., 2010). 
 
The HT29 cell line, derived from a human colon adenocarcinoma, and the A431 cell, 
originating from a human epidermoid carcinoma, were therefore used as comparative 
controls. The HT29 cell line contains constitutively high quantities of phospho-FAK 
(Tyr397), a truncated adenomatous polyposis coli (APC) and a mutant p53 (R273H) 
suggesting it would be an suitable comparative control (Golubovskaya et al., 2003; Bossi et 
al., 2006; Chandra et al., 2012). This cell line also acted as a negative control for phospho-β-
catenin (Ser33, Ser37 & Thr41) as the presence of a truncated APC results in the stabilization 
of β-catenin (preventing the phosphorylation of β-catenin at Ser 33, Ser37 & Thr41) within 
this cell line (Morin et al., 1996; Chandra et al., 2012). The A431 cell line overexpresses 
epidermal growth factor receptor (EGFR), FAK and integrin β1 (Lu et al., 2001; Kao et al., 
2008; Slack-Davis et al., 2007; Brockbank et al., 2005). The A431 cell line also contained 
high levels of phospho-GSK3β (Ser9) making it an appropriate comparative control (Saito et 
al., 1994).  
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All cells were maintained as monolayer cultures in Dulbecco’s modified eagles medium 
(DMEM/Hams F12 (3:1)) (Life Technologies) (Appendix A, Section 1.7.1., Section 1.7.2. 
and Section 1.7.3.) supplemented with 10 % foetal calf serum (FCS) in 5 % carbon dioxide, 
at 37°C (humidified environment).  FCS supplemented the media with growth factors, 
proteins or lipids whilst DMEM/Ham`s F12 contained essential amino acids, glucose and 
vitamins. It is important to note that the same batch of FCS was used concurrently for each 
experiment. 
2.2.2. Subculture  
Cell cultures were propagated in 10cm dishes. Once the cells reached an approximate 
confluency of 80 %, the media was aspirated and the cell monolayer washed twice with warm 
(37°C) sterile phosphate buffered saline (PBS), pH 7.3 ( Appendix A, Section 1.1.1.).  
A 2 ml solution containing ethylenediamineterta-acetic acid (EDTA) (BDH Laboratory 
reagents) and trypsin (Gibco BRL) (Appendix A, Section 1.6.4 and Section 1.6.5) was then 
added to the tissue culture dish. The dish was then placed in an incubator for 5 minutes at   
37°C to facilitate the disruption of cell-cell and cell-ECM based attachment/adhesion. A Leitz 
Watzlar inverted light microscope was used to verify cell-cell/cell-ECM detachment. A 
fraction of the detached cells, in the trypsin-EDTA solution (Appendix A, Section 1.6.6.), 
were seeded into a new tissue culture dish and 10 ml of fresh media (containing 10 % FCS) 
added. Cells were then maintained as described in Section 2.2.1. 
2.2.3. Whole cell protein extraction 
 Whole cell protein extractions were performed as outlined by Laemmli, 1970. A whole cell 
protein extraction was opted for, instead of a nuclear or cytoplasmic protein extraction, as the 
proteins of interest (FAK and β-catenin) are located within all subcellular locations within the 
cell (Fanucchi and Veale, 2009; Willert and Jones, 2006; Krieghoff et al., 2006).  
 
Cells were allowed to proliferate until a confluency of 80 % was reached. The cells were then 
washed twice with 1 ml of PBS. The cells were then exposed to 1 ml of PBS containing 
phenyl-methyl-sulphonyl fluoride (PMSF) (1 mM) (Trasylol ®, Bayer S.A.), sodium fluoride 
(NaF) (5 µl/ml) (Sigma-Aldrich ®) and sodium orthovanadate (Na3VO4) (100 µl/ml) (Sigma-
Aldrich ®) (Appendix A, Section 1.1.3,Section 1.1.4. and Section 1.1.5). PMSF, an 
irreversible serine protease inhibitor, was utilised to prevent protein degradation within the 
whole cell lysates (James, 1978; Powers et al., 2002). As the proteins were extracted for 
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phospho-antibody based experiments, phosphatase inhibitors ( NaF and Na3VO4) were 
incorporated in the extraction procedure in order to prevent the loss of certain  post 
translational modifications during the extraction procedure (Gordon, 1991; Di et al., 2013; 
Posner et al., 1994). The cells were then carefully mechanically harvested into this 
PMSF/PBS solution using a rubber policeman. The harvested cells were transferred into 
sterile Eppendorf® Safe-Lock microcentrifuge tubes and centrifuged in a TOMY HF-120 
(1145 xg), 1 min, to yield a highly concentrated mass of cells (pellet).  
The supernatant was then aspirated and the pellet resuspended in Laemmli double lysis buffer 
(Appendix A, Section 1.1.2.) (ratio of 1:2). The lysis buffer (Appendix A, Section 1.1.2.) 
contained β-mercaptoethanol (reduce disulphide bonds) and sodium dodecyl sulphate (SDS) 
which encouraged protein denaturation preparing the samples for SDS-PAGE analysis. The 
sample was then boiled for 5 minutes and the lysates spun down in a PRISM™ Refrigerated 
Microcentrifuge (12000 xg) for 15 minutes. Lastly, the samples, appropriate for SDS-PAGE 
analysis, were stored at -20°C. 
2.2.4. Protein determination  
A modified Bradford assay as proposed by Bramhall et al. (1969) was utilised to semi- 
quantitatively determine the concentration of protein within each of the whole cell protein 
extracts. This ensured that equimolar/equivalent quantities of protein were loaded during 
SDS-PAGE analyses for each of the HOSCC cell lysates (for comparative purposes). 
Whatman ® Filter paper was hydrated in distilled water, for 20 minutes, and dehydrated 
using a series of one, five minute incubations in 95 % ethanol, 100 % ethanol and 100 % 
acetone (applied sequentially) (Appendix A, Section 1.2.1). The dehydrated filter paper was 
then placed in a sterile fume hood to air dry. A known concentration of protein (1 µg/µl) was 
produced by solubilizing bovine serum albumin (BSA) (BDH Laboratory reagents) in 
Laemmli double lysis buffer (ratio of 1:1). The stock BSA solution (1 µg/µl) was then spotted 
onto the dry filter paper to generate standard concentrations of BSA (1 µg, 3 µg, 6 µg, 12 µg, 
16 µg and 20 µg of protein) which collectively formed a standard curve. Additionally, 2 µl of 
each of the HOSCC whole cell protein extracts were spotted onto the same filter paper. The 
filter paper was air-dried and exposed to trichloroacetic acid (TCA) (Appendix A, Section 
1.2.2.) for 45 minutes. TCA caused the proteins to precipitate onto the filter paper and 
removed any residual SDS that may have remained from the lysis buffer (safeguarded against 
SDS interference with regard to the spectrophotometer readings). The filter paper was placed 
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in 0.25 % Coomassie brilliant blue G-250 (CBB) (Appendix A, Section 1.2.3.) for 5 minutes 
(washed off residual TCA). The filter paper was exposed to fresh CBB stain for 1 hour, 
placed in a destain solution (Appendix A, Section 1.2.4) for 1 hour (to remove all background 
staining) and then allowed to air dry in a sterile fume hood. 
 
The resulting blue-stained circles, located on the filter paper, represented precipitated protein. 
Each of these circles were then cut out and individually placed into 5 ml of elution solution 
(Appendix A, Section 1.2.5.). The stains circles were then left in the dark overnight. The 
absorbance readings for each of these solutions were obtained using an Abbota SV1100 
spectrophotometer (set to a wavelength of 595 nm). Note that elution solution served as a 
blank for the spectrophotometer. CBB, upon protein dye binding, absorbed light in the  
595 nm range and this absorbance was equivalent  to the concentration of protein present 
(Bradford, 1976). A standard curve was then developed using the known protein 
concentrations of BSA (absorbance at 595 nm over protein concentration). The resulting 
absorbance readings, for the known BSA standards (eluents of known protein concentration), 
were then utilised to generate a standard curve of absorbance (at 595 nm) versus protein 
concentration (µg/µl) (Appendix B, Section 2.1) generated in Microsoft® Excel 2010 
(Version 14.0). This standard curve was then used to determine the protein concentration of 
each of the HOSCC cell lysates (of unknown protein concentration). Only standard curves 
with an R2 of greater than 0.98 was utilised (indicative of how well the standard curve fits the 
data). These concentrations were then used to standardize the amount of protein loaded per 
SDS-PAGE analysis. 
2.2.5. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) 
 A 10 % (w/v) discontinuous SDS-PAGE analysis, as described by Laemmli (1970) was used 
to obtain high resolution protein separations (on the basis of size). The proteins, present in 
each of the HOSCC whole cell lysates, were effectively separated using this technique. Ten 
percent discontinuous SDS-PAGE gels were generated using the Mighty Small™ SE245Dual 
Gel Caster set (Hoefer Scientific). A 10 % separating gel solution, containing SDS, 
(Appendix A, Section 1.3.2 and Section 1.3.3) was placed between 2 glass plates located 
within the Dual Gel Caster. Approximately 200 µl of a 0,2 % SDS overlay (Appendix A, 
Section 1.3.4) was added to prevent oxygen affecting the polymerization reaction and the gel 
was allowed to polymerise for approximately 25 minutes. The overlay was discarded before a 
5 % stacking gel solution (Appendix A, Section 1.3.3) was poured directly above the 
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separating gel (between the 2 glass plates). A comb, with the capacity to generate either 10 or 
20 µl wells, was then inserted into the stacking gel before it was allowed to polymerise (for 
approximately 25 minutes). The comb is used to generate wells, each able to accommodate 
up to10 or 20 µl of sample. 
 
The polymerised gel was then removed from the caster set and inserted into the Mighty 
Small™ Electrophoresis Unit (Hoefer ®), filled with electrophoresis tank buffer ( pH 8.3) 
(Appendix A, Section 1.3.1.). The comb was removed and 40 µg of protein, from each whole 
cell protein lysate, was loaded into each of the wells. Approximately 1 µl of PageRuler Plus 
Pre-stained Protein ladder (molecular weight marker) (Thermo Fisher Scientific ®) was 
loaded into the last well of each gel. The proteins, collectively forming the Pre-stained 
protein ladder, represented proteins with a mass of approximately 250, 130, 100, 70, 55, 35 
and 25 kDa (used to monitored protein migration in the gel and visualise protein transfer 
step). The gel was fully resolved using constant current, 21 mA (400 V) per gel (45 minutes). 
Once the molecular weight marker, 25 kDa, reached a set point on the separating gel (two 
centimetres from the end), the gel was removed from the Mighty Small™ Electrophoresis 
Unit.  The SDS-PAGE gel could then be utilised for western immunoblotting.  
Visualisation of the resolved protein pattern was attained by staining the SDS-PAGE gel with 
CBB stain (Appendix A, 1.3.5.) for 1 hour. The gel was destain solution (Appendix A, 
Section 1.3.6.) for 1 hour and left in distilled water overnight. The gel was scanned using a 
Hewlett Packard ScanJet G3110 scanner. 
2.2.6. Western immunoblotting 
 The western immunoblotting procedure is able to semi-quantitatively determine the 
abundance of a specific protein (or post translational modification located on a protein) 
within a whole cell protein lysate. Western immunoblotting does this, by capitalising on 
monoclonal/polyclonal antibodies ability to bind exclusively to a specific protein. It does this 
making use of a specific polyclonal/monoclonal antibody-antigen interaction, a secondary 
antibody system conjugated with a detector molecule and an effective detection system 
(Towbin, Staehelin, and Gordon, 1992). Western blots were performed as outlined by 
Towbin, and colleagues (1992).  
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A 10 % (v/w) discontinuous SDS-PAGE analysis was initially required in order to fully 
resolve the proteins located in the HOSCC lysates as described in Section 2.2.5. The SDS-
PAGE gels were cut, at a range around the molecular weight of the protein of interest as 
indicated by the PageRuler Plus Pre-stained Protein ladder. The proteins, resolved by SDS-
PAGE analysis, were transferred onto an  BioTrace™ PVDF nitrocellulose membrane (Pall) 
using a Bio-Rad Criterion™ Blotter containing transfer buffer (Appendix A, Section 1.4.1.), 
at constant current of 400 mA (4°C).The protein transfer took approximately 2 to 3 hours to 
complete (dependent on the molecular weight of the protein of interest). Each 
monoclonal/polyclonal antibody has specific protocol requirements that were utilised, 
following this step in order to obtain western blots with little to no non-specific antibody 
binding. 
2.2.6.1 Anti-phospho-FAK (Tyr397) 
The protein transfer step, described in Section 2.2.6., took 3 hours to complete. The 
membrane was washed in Tris-buffered saline (TBS) (Appendix A, Section 1.4.1.) and placed 
in a casein based-blocking solution (Appendix A, Section 1.4.1.5.) for 1 hour to prevent non-
specific antibody binding. The membrane was then washed in Tris-buffered saline-Tween 
(TBS-T)(Appendix A, Section 1.4.1) and placed in a primary polyclonal anti-phospho-FAK 
(Tyr397) polyclonal rabbit antibody solution, 1 % BSA in TBS-T (antibody dilution:1:1000), 
overnight at 4°C (Cell Signalling Technology ®). The membrane was washed in TBS-T 
several times to remove any unbound antibody (5 minutes per wash). The membrane was 
then incubated in a goat-anti-rabbit horseradish peroxidase (HRP)-conjugated secondary 
antibody solution, blocking solution (Appendix A, Section 1.4.1) (antibody dilution: 1:2000), 
for 1 hour at room temperature (in the dark) (Sigma-Aldrich ®). Several washes, in TBS-T, 
were performed to remove residual secondary antibody from the membrane (5 minutes per 
wash). The membrane then underwent a process outlined in 2.2.7 to 2.2.9. 
2.2.6.2. Anti-phospho-GSK3β (Ser9) 
 The protein transfer step, described in Section 2.2.6., took 2 hours to complete. The 
membrane was washed in TBS (Appendix A, Section 1.4.1.), to remove any residual transfer 
buffer. Next the membrane was placed in a casein based-blocking solution (Appendix A, 
Section 1.4.1.) for 1 hour to prevent non-specific antibody binding. Excess blocking solution 
was removed by washing the membrane with TBS-T (several 5 minute washes). The 
membrane was incubated in an anti-phospho-GSK3β (Ser9) polyclonal rabbit antibody 
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solution, 2.5 % BSA in TBS-T (antibody dilution: 1:1000), overnight at 4°C (Cell signalling 
technology ®). The membrane was washed in TBS-T several times to remove any unbound 
antibody (5 minutes per wash). The membrane was then incubated with a goat-anti-rabbit 
HRP-conjugated secondary antibody solution, 2, 5 % casein based-blocking solution 
(Appendix A, Section 1.4.1.) (antibody dilution: 1:3000), for 1 hour at room temperature (in 
the dark) (Sigma-Aldrich ®). Several washes, in TBS-T, were performed to remove residual 
secondary antibody from the membrane (5 minutes per wash). The membrane then underwent 
a process outlined in 2.2.7 to 2.2.9. 
2.2.6.3. Anti-phospho-β-catenin (Ser33, Ser37 & Thr41)  
The protein transfer step, described in Section 2.2.6., took approximately 3 hours to 
complete. The membrane was then washed in TBS-T (Appendix A, Section 1.4.1.) and 
placed in a primary polyclonal anti-phospho-β-catenin (Ser33, Ser37 & Thr41) polyclonal 
rabbit antibody solution, 2 % BSA in TBS-T (antibody dilution:1:1000), overnight at             
4°C (Cell signalling technology®). The membrane was washed in TBS-T several times to 
remove any unbound antibody (5 minutes per wash). The membrane was then incubated in a 
goat-anti-rabbit HRP-conjugated secondary antibody solution, 2.5 % TBS-for BLOTTO 
blocking solution (Appendix A, Section 1.4.1.) (antibody dilution: 1:2500), for 1 hour at 
room temperature (in the dark) (Sigma-Aldrich ®). Several washes in TBS-T were performed 
to remove excess secondary antibody from the membrane (5 min per wash). The membrane 
then underwent a process outlined in 2.2.7 to 2.2.9. 
2.2.6.4. Anti-β-actin 
 The protein transfer step described in Section 2.2.6 took 2 hours to complete. The membrane 
was washed in TBS (Appendix A, Section 1.4.1.) and placed in a casein based-blocking 
solution (Appendix A, Section 1.4.1.) for 1 hour. The membrane was then washed in TBS-T 
(Appendix A, Section 1.4.1.) and placed in a primary polyclonal anti-β-actin polyclonal 
rabbit antibody solution (2.5 % casein-based blocking solution in PBS (antibody dilution: 
1:2500)) overnight at 4°C (Cell signalling technology ®). The membrane was washed in 
TBS-T several times (5 minutes per wash). The membrane was incubated with a goat-anti-
rabbit HRP-conjugated secondary antibody solution, blocking solution (Appendix A, Section 
1.4.1.) (antibody dilution: 1:10000), for 1 hour (in the dark) (Sigma-Aldrich ®). Several 
washes, in TBS-T, were performed to remove residual secondary antibody from the 
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membrane (5 min per wash). The membrane then underwent a process outlined in 2.2.7 to 
2.2.9. 
2.2.7. Antibody detection 
The membrane was incubated in a luminol/hydrogen peroxide solution (1:1 ratio), 
SuperSignal ® West, for 5 minutes in the dark (Appendix A, Section 1.4.4.). The membrane 
was placed in Versafilm ® clear cling-wrap and exposed to CL-XPosure X-ray film (Pierce 
Chemical ©). The X-ray film was exposed to the membrane for 10 minutes (in the dark). A 
latent image was formed by deposits of free silver ions that are liberated when light photons 
strike the silver bromide crystals found on the X-ray film. Next, the X-ray film was placed in 
developer solution (Thermo Fisher Scientific ®) (Appendix A, Section 1.4.2.). The film was 
washed in water and then placed in fixer solution (Appendix A, Section 1.4.3.). Finally the 
film was rinsed in water before it was allowed to air dry. A Hewlett Packard ScanJet G3110 
scanner was then used to obtain digital images of the X-ray film. 
2.2.8. Densitometry 
All densitometric analyses were performed using MATLAB® R2013a image acquisition and 
analysis software. MATLAB semi quantitatively determined the relative abundance of a 
specific phospho-protein as determined by western blotting. The band intensities/integrated 
optical densities (IOD) represent the magnitude of the HRP-dependant chemiluminescent 
signal generated during the western blotting technique. This provided an estimation of the 
relative abundance of key phospho-proteins within each of the HOSCC cell lines (described 
in more detail below). All densitometric data generated was compared to the optical density 
of the A431 or WHCO6 cell lines (Appendix B, Section 2.2.). To generate accurate and 
comparable data, the computed IOD, determined by MATLAB, were normalised for all 
western blot replicates as described in Appendix B, Section 2.6 (Degasperi et al., 2014) 
2.2.9. Data analysis 
 All experiments were performed in triplicate, unless otherwise stated. Results were 
represented by the mean plus/minus the standard error of the mean. The statistical 
significance of the densitometric data obtained by western immunoblot analysis, was 
determined by performing a standard Student’s t-test (Appendix B, Section 2.2.) using 
GraphPad Prism®, Version 7.0 (GraphPad Software, Inc., La Jolla, USA) (p<0.05 indicated 
statistical significance).  
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2.3. Results section 
2.3.1 Efficacy of the whole cell protein extraction and protein determination technique 
The separation of proteins into descreet polypeptide bands, by SDS-PAGE analysis indicated 
that the whole cell protein extraction procedure is an effective mechanism of extracting 
cellular proteins from HOSCC cell lysates (Figure 6 ). Upon staining the polypeptides with 
Coomassie Brilliant Blue stain a reasonably uniform banding pattern, across all of the lanes 
of the SDS-PAGE gel, was made apparent (Figure 6). This uniform banding pattern, present 
across all of the HOSCC cell lines, provided proof of the accuracy and reliablilty of the 
protein estimation technique (approximately 20 µg of protein was loaded into each lane, see 
Appendix B, Section 2.1., Figure 6). The molecular weight marker (MWM), located in lane 
1, was fully resolved. This was noted by the fact that the MWM split into a range of 
distinctive bands (each a representative of a polypeptide with a set molecular weight) upon 
SDS-PAGE analysis. This indicates that the blue-stained polypeptides, located in lanes 2 to 8, 
were fully separated on the basis of size and had goo d resolution at the regions of interest, 
indicated by arrows on Figure 6. As there are polypeptides present at the molecular weight 
regions of the proteins of interest, it is likely that these key signal transduction intermediates 
(FAK, GSK3β and β-catenin) are present and were effectively extracted from the HOSCC 
cell lysates. This warranted further investigation into the presence of key signal transduction 
intermediates at set molecular weight marker regions. Western immunoblot analyses were 
then preformed to confirm that these proteins are present within the HOSCC cell lines and 
verify that the post translational modifications, made to each of these key intermediates, 
remained intact (further validating the effectivity of the protein extraction procedure). Lastly 
the western blot analyses were used to determine the relative abundance of key phospho-
proteins (indicative of the activation/inhibition state of each protein) within each of the 
HOSCC cell lines at a specific point in time.   
All of the key signal transduction intermediates, mentioned in Figure 7, were present within 
the HOSCC cell lines. The western immunoblotting technique physically verified that key 
post translational modifications located on cellular proteins were retained (through the use of 
phosphatase inhibitors, Section 2.2.4. of the methods and materials) in the HOSCC cell 
lysates. As the major phospho-intermediates pertaining to this study were readily detectable 
by western immunoblotting, the protein extraction procedure was considered successful 
(Figure 7). This ensured that the activation/ inhibition state of each protein could be studied 
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by western immunoblotting thus providing the physical surety needed to continue the current 
study. Lastly, the western immunoblotting procedure yielded little to no non-specific 
antibody binding indicating that the western blotting technique is capable of  producing 
reliable and repeatable western blots. As western immunoblotting (for phospho-FAK 
(Tyr397)) is known to produce reliable results (Fanucchi and Veale, 2009), smaller western 
blots were employed, dimensions that adequately cover a range around the molecular weight 
of the protein of interest (Figure 7). This was done to conserve reagents. 
 
 
 
 
 
 
 
 
 
 
 
Figure 6. High resolution separation of the cellular proteins that were 
extracted from the HOSCC cell lines, A431 and HT29 cells. 
A 10 % (w/v) discontinuous SDS PAGE analysis revealed that the protein 
determination and extraction procedure was successful. This can be seen by 
uniform banding pattern of the blue-stained protein polypeptides noted across 
all seven of the lanes. A molecular weight marker was fully resolved in the 
first lane of the gel. The gel was stained, with Coomassie brilliant blue. The 
suggested positions of phospho-β-catenin (Ser33, Ser37 &Thr41) (92kDa), 
phospho-FAK (Tyr397) (125kDa) and phospho-GSK3β (Ser9) (46kDa), 
relative to the molecular weight marker (MWM), are indicated by arrows. 
(CO1:WHCO1; CO3: WHCO3; CO5: WHCO5 and CO6: WHCO6) 
 
 
 
    MWM                   A431    HT29     CO1      SNO     CO3      CO5     CO6 
100kDa 
25 kDa 
35 kDa 
70 kDa 
55 kDa 
130 kDa 
250 kDa 
IB: pFAK 
(Tyr397) 
IB:  
pGSK3β (Ser9) 
IB: 
pβ-catenin (Ser 
33, Ser37 and 
Thr41):   
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2. 3.2. The relative abundance of key phospho-intermediates differ greatly amongst the 
HOSCC cell lines 
 
Phospho-FAK (Tyr397) (125kDa), phospho-GSK3β (Ser9) (46kDa) and phospho-β-catenin 
(Ser33, Ser37 & Thr41) (92kDa) were all detected in the HOSCC cell lines under standard 
tissue culture conditions (Figure 7). The β-actin western blots provided physical evidence to 
support the success of the protein estimation technique. Equal protein loading across all of 
the HOSCC cell lines was confirmed by β-actin immunoblots that sported a uniform banding 
pattern (Figure 7). As archetypical oesophageal squamous cell lines are currently unavailable 
(Section 2.2.1, method and materials), the HT29 cell line and A431 cell line were used as 
comparative controls to determine the relative abundance of phospho-FAK (Tyr397) within 
the HOSCC cell lines (Section 2.2.1, method and materials). Both of these cell lines are 
known to have a high abundance of phospho-FAK (Tyr397) and this was confirmed in the 
current study (Figure 7 and Figure 8) (Golubovskaya et al., 2003). With the exception of 
phospho-β-catenin (Ser33, Ser37 & Thr41), in the HT29 cell line (Section 2.2.1, method and 
materials), all of the key phospho-proteins were detected within these two comparative 
controls (HT29 and A431 cell lines) (Figure 7). The WHCO6 cell line acted as an internal 
control for the western blotting technique ensuring that the protein levels detected on one 
immunoblot was comparable to another. All densitometric data was made relative to the IOD 
of the A431/WHCO6 cell line (Section 2.2.8, method and materials) 
The relative abundance of phospho-FAK (Tyr397), phospho-GSK3β (Ser9) and phospho-β-
catenin (Ser33, Ser37 & Thr41) differed greatly amongst the HOSCC cell lines, relative to 
the IOD of the A431 cell line (Figure 8). This suggests that the mechanisms by which the 
transform state is propagated/ maintained within one WHCO cell line may not be universally 
applicable to all HOSCC cells. It should therefore be noted that the high/low abundance of a 
specific phospho-protein may or may not be a hallmark of the transformed state of HOSCC 
cells (a commonality between all HOSCC cells) (Figure 8).  This resulted in the WHCO cell 
lines being segregated, based on the relative abundance of key phospho-intermediates, in 
order to develop a more holistic view of the phospho-protein profile located within HOSCC 
cells. The overall trends, with regard to the relative abundance of the key phospho-
intermediates, have been summarised Table 1. 
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Most HOSCC cell lines, excluding the WHCO1 cells, contained an equivalent/greater level of 
phospho-FAK (Tyr397) than that which was found within the HT29 cell line (Figure 8 and 
Table 1). This indicates that the majority of HOSCC cell lines contain endogenously high 
levels of this phospho-protein, as the HT29 cells are known to contain high levels of 
phospho-FAK (Try397) (Golubovskaya et al., 2003). The WHCO6 cell line contained 
exceedingly high levels of phospho-FAK (Tyr397) and was second only to the A431 cell line 
(contained greatest relative abundance of phospho-FAK (Try397)). The endogenous levels of 
phospho-FAK (Tyr397), noted for all HOSCC cell lines, was significantly different to levels 
of this protein found within the A431 cells (Appendix B, Section 2.2.). Three of the five 
HOSCC cell lines were found to contain moderate to high levels of phospho-GSK3β (Ser9). 
This suggests that, in general, HOSCC cells are likely to maintain moderate to high levels of 
phospho-GSK3β (Ser9). The WHCO3 and WHCO1 cell lines were the exception to the rule, 
as these cells contained a relatively low abundance of phospho-GSK3β (Ser9). When 
comparing the levels of phospho-GSK3β (Ser9) found within the A431 cell line to that of the 
HOSCC cells, only levels of phospho-GSK3β (Ser9) located within the SNO cell line were 
not considered statistically significant (Appendix B, Section 2.2.). As most of the WHCO cell 
lines contained moderate to high levels of phospho-β-catenin (Ser33, Ser37 & Thr41) when 
compared to the A431 cell line, the HOSCC cells generally contain moderate/high levels of 
this phospho-protein (Figure 8). The levels of phospho-β-catenin (Ser33, Ser37 & Thr41) 
differed significantly in the WHCO1, WHCO5 and WHCO6 cells when compared to the 
A431 cell line (Appendix B, Section 2.2.).  
 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
                        
 
 
  
Figure 7. Representative western immunoblots used to detect the basal levels 
of phospho-GSK3β (Ser9), phospho-FAK (Tyr397) and phospho-β-catenin 
(Ser33, Ser37 & Thr41) in HOSCC cell lines. 
The levels phospho-GSK3β (Ser9), phospho-FAK (Tyr397) and phospho-β-catenin 
(Ser33, Ser37 & Thr41) were detected in the WHCO cells, as well as the 2 control 
cell lines, HT29 and A431 cells. The relative abundance of the phospho-proteins 
were detected under standard tissue culture conditions using polyclonal (anti-
phospho-FAK (Tyr397), anti-phospho-GSK3β (Ser9), anti-phospho-β-catenin (Ser33, 
Ser37 & Thr41) and anti-β actin) antibodies. Three biological replicates were 
performed. The HOSCC cell lines, in general, appeared to contain high to moderate 
levels of phospho-FAK (Tyr397) and phospho-GSK3β (Ser9). The HT29 cell line 
acted as a negative control for phospho-β-catenin (Ser33, Ser37 & Thr41) 
abundance. The western blot analyses, for the detection of β-actin, acted as a 
loading control, indicate equal protein loading, for the western blotting technique.  
 
 
 
 
 
 
125kDa 
92kDa 
42kDa 
46kDa 
IB: Phospho-FAK (Tyr 397):     
IB: Phospho-GSK3𝜷 (Ser 9):  
IB: Phospho-𝜷𝐜𝐚𝐭𝐞𝐧𝐢𝐧 (Ser33, Ser37 & 
Thr41):   
 
IB: β-actin:     
          A431      HT29    WHCO1   WHCO3 WHCO5  SNO   WHCO6       
                
36 
 
 
Figure 8. The relative abundance of certain phospho-intermediates appeared to 
be HOSCC cell line specific under standard tissue culture conditions. 
The relative abundance of each phospho-protein was obtained by normalising semi-
quantitatively determined densitometric analyses relative to the A431 cell line 
(Appendix B, Section 2.2.). The level of each phospho-protein appeared to vary 
greatly from one HOSCC cell line to the next. Phospho-FAK (Tyr397) is highly 
abundant within most of the HOSCC cell lines (equivalent/greater levels of phospho-
FAK (Tyr397) than the HT29 cell line). Secondly, most of the HOSCC cell lines 
contained high to moderate levels of phospho-GSK3β (Ser9) and phospho-β-catenin 
(Ser33, Ser37 & Thr41) when compared to the A431 cell line. Only the WHCO3 and 
WHCO1 cell lines had low levels of phospho-GSK3β (Ser9). A star (*) represents any 
statistical difference, when compared to the A431 cell line (*p <0 .05, **p < 0.01, ***p 
< 0.001) (Appendix B, Section 2.2.). 
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Table 1. The relative abundance of key phospho-intermediates in the HOSCC 
cells under standard tissue culture conditions and the resulting phospho-
protein trends. 
The level of each phospho-protein, within the WHCO cells, was characterised as 
high, medium and low. This was done by comparing the relative abundance of each 
protein with the endogenous levels of set-protein in the A431 and HT29 cell lines 
(Section 2.2.1, methods and materials). A star (*) graphically represented any 
statistical difference, when compared to the A431 cell line using a standard Student’s 
t-test (*p <0 .05, **p < 0.01, ***p < 0.001) (Appendix B, Section 2.2.). 
Protein Cell line 
 A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
 ( mean) (mean)  (mean)   (mean) (mean )  (mean) (mean) 
Phospho-
FAK 
(Tyr397) 
(Active 
protein) 
 
Extremely 
high 
      (1) 
 
High 
 
(0.41) 
 
Moderate 
/Low** 
    (0.25) 
 
Very high** 
(0.65) 
 
Very 
high** 
(0.65) 
 
High** 
(0.41) 
 
Extremely 
high**** 
   (0.86) 
Phospho-
GSK3β 
(Ser9) 
(Inactive 
protein) 
 
High 
(1) 
 
Moderate
**  
(0.55) 
 
Low** 
(0.4) 
 
Low** 
   (0.36) 
 
Moderate* 
(0.65) 
 
High 
(0.78) 
 
High**** 
(1.05) 
Phospho-β-
catenin 
(Ser33, 
Ser37 & 
Thr41) 
(Target for 
ubiquitinatio
n) 
     High 
(1) 
    None 
      (0) 
High* 
(0.99) 
Moderate 
(0.72) 
Moderate*
(0.77) 
High* 
(1.14) 
Low* 
(0.24) 
 
 
2.4. Discussion: 
Human oesophageal squamous cell carcinoma cells are extremely resilient and adaptive. 
Single HOSCC cells are capable of forming a tumour and appear to be highly resistant to 
anti-cancer therapeutics (Tripathi, 2016; Van Miltenburg et al., 2014; Ge et al., 2015; Li et 
al., 2014; Hasan et al., 2016). Some have even suggested that there may be regenerative 
pockets of ҅stem cell like cells҅ that assist in maintaining the diseased state (Ge et al., 2015; 
Xia et al.,2016; Zhao et al., 2013). Even though HOSCC development has been associated 
with several risk factors such as the use of tobacco, hot beverages and poor oral hygiene, the 
disease is still prevalent in our communities (Castellsague et al., 2000; Abnet et al., 2005; 
Wei et al., 2005). It is imperative that scientists identify accurate biomarkers for this 
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debilitating disease. Cancer biomarkers identify key molecular pathways that maintain the 
cancerous state in the hopes that these pathways may be targeted by anti-cancer therapeutics 
(Li et al., 2014; Hasan et al., 2016).  However, biomarkers need to be accurate in order for 
the anticancer therapeutics to be effective at treating the disease (Li et al., 2014; Hasan et al., 
2016). Biomarkers should also be found to identify patients that are at risk of cancer 
resurgence (Li et al., 2014; Hasan et al., 2016).  With the HOSCC cells heterogeneity, 
identifying universal biomarkers that underpin the diseased state is challenging to identify 
and harder to capitalise on.  
2.4.1. High levels of active FAK may be a biomarker for the transformed state in 
HOSCC cells 
Phospho-FAK (Tyr397), active FAK, was detected in all of the HOSCC cell lines under 
standard tissue culture conditions. Previous studies could only detect phospho-FAK (Tyr397), 
via western immunoblot analyses, in SNO and WHCO6 cell lines, at 80 µg of protein 
(Fanucchi and Veale, 2009).  This discrepancy may have been due to the use of different 
primary antibodies during the western blotting technique. An anti-phospho-FAK (Tyr397) 
monoclonal mouse antibody was used previously as opposed to an anti-phospho-FAK 
(Tyr397) polyclonal rabbit antibody that was used in the current study. The level of active 
FAK within the two control cell lines (the HT29 and A431 cell lines) were also detected by 
western immunoblotting. The A431 cell line had the highest level of active FAK of all of the 
cell lines that were used in the current study. The levels of FAK activation within the A431 
cell line was found to be statistically different, at a p-value ҅ 0.01, when compared to the 
HOSCC cell lines used in the current study. This suggests that the A431 cell line maintains 
extremely high levels of active FAK higher than that of the HT29 cell line (a cell line that is 
known to contain high levels of active FAK) (Golubovskaya et al., 2003).  
With the exception of the WHCO1 cells, all HOSCC cell lines had greater or equivalent 
levels of active FAK than that of the HT29 cell line. This suggests that WHCO cell lines 
generally contain high levels of active FAK, phospho-FAK (Tyr397). It can therefore be said 
that high levels of this phospho-protein may act as a hallmark/biomarker for moderately 
differentiated HOSCC cells (Fanucchi and Veale, 2009). This may in part explain why this 
disease is so virulent. Based on the literature, high levels of this active protein is associated 
with highly invasive cancers such as ovarian, breast and colon cancers (Golubovskaya et al., 
2009; Wang et al., 2008). The over expression and activity of FAK was associated with 
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increased cell survival, EMT and migration (within ovarian, breast and colon cancers) 
(Golubovskaya et al., 2009; Wang et al., 2008). FAK activation was indispensable for the 
metastasis and invasion of mesenchymal triple negative breast cancer cells, one of the most 
invasive and virulent forms of breast cancer (Taliaferro-Smith et al., 2015). The WHCO6, 
WHCO5 and WHCO3 cell lines maintain exceptionally high levels of active FAK suggesting 
that these cell lines may also be more predisposed to anoikis resistance, EMT and metastasis. 
However, although FAK activation plays a prominent role in propagating migratory/pro-
survival based signalling in differently differentiated cells the mechanisms by which FAK 
does this may be different. Likewise the mechanisms by which this protein is activated within 
cancerous cells may also be cell lineage specific.  
Nevertheless, based on the role FAK plays in the transformed state, this protein may be a 
good molecular target for anti-cancer therapeutics (Taliaferro-Smith et al., 2015; Tripathi, 
2016). However, with FAK playing a role in normal cell functioning, as a key member of the 
focal adhesion pathway, inhibiting this protein may prove ineffective (Fanucchi and Veale, 
2009; Mitra and Schlaepfer, 2006; Parsons, 2003). With the knowledge that high levels of 
FAK activation is common within the HOSCC cells, the mechanisms by which this protein is 
activated will be explored further in Chapter 3. 
2.4.2. GSK3β inhibition, an indicator of its antagonists activity within the HOSCC cells? 
The inhibition of GSK3β by phosphorylation at Ser9 is upregulated by the oncogenic 
activation of either p90 ribosomal S6 kinase (RSK), Protein kinase A (PKA), Akt or protein 
kinase C (PKC) (Fang et al., 2000; Kim et al., 2007; Jope and Johnson, 2004; Stambolic and 
Woodgett, 1994; Pap and Cooper, 1998). Therefore should any of the above mentioned 
proteins be active within the HOSCC cell lines, GSK3β will be phosphorylated at serine 9. 
Anyone of the above mentioned antagonists may play a role in FAK activation. This makes   
the verification of the activity of these proteins within the HOSCC cells imperative.  
The GSK3β inhibition was detected in all of the HOSCC cell lines and the two comparative 
controls under standard tissue culture conditions. This suggests that all of the WHCO cell 
lines maintained sufficient levels of phospho-GSK3β (Ser9) for it to be detectable, using the 
western immunoblotting technique. The level of GSK3β inhibition appeared to be the greatest 
in the WHCO6, SNO and WHCO5 cell lines. The other two cell lines contained low levels of 
GSK3β inhibition. This would suggest that there are two subgroups of WHCO cells, 
containing either low or high/moderate abundance of GSK3β inhibition. This finding was 
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corroborated by a previous study conducted by Nicolene Shaw, a previous colleague of the 
Cell Biology laboratory (Shaw, 2012). In the previous study, the levels of GSK3β inhibition 
were also found to be low within the WHCO3/WHCO1 cell lines, whilst being high to 
moderate within the other three WHCO cell lines. It is likely, based on the relative abundance 
of phospho-GSK3β (Ser9), that the GSK3β antagonists are active within the HOSCC cell 
lines. The degree to which the antagonists are active within the HOSCC cells appears to vary, 
as the levels of GSK3β targeted for ubiquitination differ from cell line to cell line. Lastly, the 
exact antagonist or combination of antagonists (p90RSK, Akt, PKC and/or PKA) that are 
responsible for GSK3β inhibition, by phosphorylation at Serine 9, within the HOSCC cells 
are currently unknown. Previous knowledge, obtained by Shaw and colleagues, detected high 
levels of Akt/PKB within the WHCO6/SNO cell lines, suggesting that PKB may, in part, play 
a role in the inhibition of GSK3β within these cell lines (2012). 
Interestingly β-catenin has been found to be overexpressed in HOSCC cell lines in which 
GSK3β activity is lost (Deng et al., 2015). As GSK3β triggers the ubiquitination and eventual 
degradation of β-catenin, by phosphorylating it at Ser33, Ser37 and Thr41, cancer cells with 
high levels of GSK3β inhibition should contain higher levels of cytoplasmic β-catenin (Hinoi 
et al., 2000; Rask et al., 2003; Waaler et al., 2011). A study conducted by Hasan and 
colleagues found that the Wnt pathway played a key role in HOSCC progression (Hasan et 
al., 2016). A high level of cytoplasmic β-catenin was noted in the early stages of oesphageal 
dysplasia (Hasan et al., 2016).  This suggests that GSK3β inhibition also affects other pro-
proliferative pathways which may impact FAK activation. 
Interestingly, the levels of phospho-β-catenin (Ser33, Ser37 & Thr41) were detected in all of 
the HOSCC cell lines and the A431 cell line under standard tissue culture conditions. All of 
the HOSCC cell lines had high to moderate levels of β-catenin, targeted for ubiquitination, 
except the WHCO6 cells. This suggests that GSK3β may not be the only protein that targets 
β-catenin for ubiquitination within the HOSCC cells. Cell lines with high levels of GSK3β 
inhibition, still contained high levels of phospho-β-catenin (Ser33, Ser37 & Thr41). It is 
possible that PKC, a protein that also phosphorylates β-catenin at Serine33, Serine37 and 
Threonine41, activity may be responsible for this discrepancy within the SNO cells (Goode et 
al., 1992). Overall, high levels of phospho-β-catenin (Ser33, Ser37 & Thr41) suggest that the 
Wnt pathway is still effectively inhibited within most of the HOSCC cells. The WHCO6 cells 
had very low levels of phospho-β-catenin (Ser33, Ser37 & Thr41), and high levels of GSK3β 
inhibition, suggesting that the Wnt pathway may play a more prominent role in maintaining 
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the transformed state of within these cells. This is interesting as the WHCO6 cells also 
contain the highest levels of active FAK when compared to all of the other WHCO cells.  
In recent years there is an exceeding large amount of evidence to suggest that both FAK and 
the Wnt signal transduction pathways play a crucial role in promoting cancer (Fonar and 
Frank, 2011). The overactivation of either of these pathways is often associated with several 
forms of cancer. However, the interplay between the 2 pathways is complex and appears to 
be cell line dependent (Fonar and Frank, 2011; Santos et al., 2010; Rangaswami et al., 2012).  
Interestingly, FAK activation seemed to promote the stabilization of β-catenin and the 
activation of the Wnt pathway during embryonic development (Santos et al., 2010; 
Rangaswami et al., 2012; Fonar et al., 2011). These to pathways may therefore work 
synergistically to maintain the transformed state (Santos et al., 2010; Rangaswami et al., 
2012). The link between these two pathways may be more prominent within the WHCO6 cell 
line. This indicates that FAK activation may involve multiple signalling intermediates from 
several intrinsic pro-survival/migratory pathways (Chapter 1). 
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Chapter 3 
3. p90RSK, a regulator of FAK activation within the HOSCC cell lines? 
3.1. Introduction: 
Another key signal transduction intermediate that is known to play a prominent role in 
neoplastic transformations is the p90 ribosomal S6 kinase (RSK) (Kang et al., 2010).  
The MAPK/RSK signal transduction pathway is an iconic/well studied signal transduction 
cascade that regulates cell proliferation, differentiation, cell survival, proliferation, 
metabolism and motility (Mendoza et al., 2011; Redman et al., 2013; Clement et al., 2013). 
RSK, when activated indirectly by EGFR, efficiently activates the Y-box binding protein-1 
(YB-1) (Stratford et al., 2008). The YB-1 protein is a notorious oncogenic transcription factor 
that plays a role in cell proliferation, migration and EMT (Syed et al., 2014). The activation 
of RSK and therefore its substrates, such as YB-1, promoted chemo-resistance, invasion and 
an EMT phenotype in malignant melanoma cells. The inhibition of RSK sensitised these cells 
to chemotherapeutics highlighting the role this protein plays in maintaining the cancerous 
state (Syed et al., 2014). Interestingly, when RSK activity is dysregulated within cancerous 
cells, these cells often display three key features: cell motility, metastasis and increased 
invasive capacities. For this reason RSK activity is likely to be associated with more virulent 
forms of cancer (melanomas, ovarian cancer, prostate, head and neck squamous cell 
carcinomas (HNSCC) etc.) not unlike the HOSCC cells (Kang et al., 2010; Syed et al., 2014; 
Torchiaro et al.,2016; Chen et al., 2013).  
 
A gene-based pathway analysis of prostate cancer found that the MAPK/RSK pathway 
played a prominent role in the diseased state particularly when combined with gene mutations 
in PTK2/FAK and EGFR (Chen et al., 2013).  The MAPK/RSK pathway is known to be 
activated by FAK (Yurdagul et al., 2016). Therefore should RSK ectopically activate FAK it 
would create a positive feedback loop that promotes sustained RSK signalling (Yurdagul et 
al., 2016). This feedback loop could explain why certain cancer strains are more malignant 
than others (Torchiaro et al., 2016).  
 
FAK activation appears to be highly abundant within the HOSCC cells (Chapter 1), which 
could in part be due to the activity of RSK. FAK itself is known to play a significant role in 
tumour cell migration, propagating a chemo resistant phenotype and anchorage independent 
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proliferation in SCC (Serrels et al., 2012; Eke et al., 2012). However, the mechanisms by 
which FAK activation occur, within these cells, is unknown. As FAK function is imperative 
for normal cellular functioning, it may be difficult to target this protein in the treatment of 
cancer (Serrels et al., 2012). As focal adhesions are dependent on FAK activity for normal 
cell functioning, the mechanisms by which this protein is activated, ectopically, may provide 
scientists with a viable alternative for anti-cancer therapeutics (Carlson et al., 2004; Fanucchi 
and Veale, 2009; Lim et al., 2008; Ohashi et al., 2010). 
 
This study therefore aims to determine whether RSK plays a role in FAK activation within 
the HOSCC cells. In an attempt to elucidate whether RSK activates FAK, RSK will be 
specifically inhibited, within the HOSCC cell lines, and fluctuations in the levels of active 
FAK monitored. Should FAK activation be RSK-dependent (there is a significant decrease in 
FAK activation post RSK inhibition) it may provide a new target for anti-cancer therapeutics.  
3.2. Methods and Materials 
3.2.1. Cell culture 
Described previously (Chapter 2, Section 2.2.1). 
3.2.2. Subculture 
Described previously (Chapter 2, Section 2.2.2) 
3.2.3. RSK inhibition assay 
Cells were seeded into 6 cm dishes and allowed to proliferate, until a confluency of 80 % was 
reached. The media was discarded and the cell culture washed twice with warm PBS (37°C).  
Subsequently, three millilitres of fresh culture media, containing 10 % FCS, was dispensed 
into the tissue culture plate. The media contained a concentration of 10 µM BI-D1870 (stock 
diluted in dimethyl sulfoxide (DMSO) (Appendix A, Section 1.5.1. and Section 1.5.2.  
(Millipore) as described by Sapkota et al. (2007) . BI-D1870 was used because it is a highly 
specific ATP competitive inhibitor for RSK function, it inhibits the N-terminal domain kinase 
(Sapkota et al., 2007). This inhibitor is selective for all isoforms of RSK (Sapkota et al., 
2007). Simultaneously, controls for each cell line were prepared containing 0.1 % DMSO. 
The cell monolayers were then incubated, for 30 minutes, at 37°C in a humid incubator with 
5 % carbon dioxide.   
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3.2.4. Whole cell protein extraction 
Described previously (Chapter 2, Section 2.2.3.). 
3.2.5. Protein determination  
 Described previously (Chapter 2, Section 2.2.4.). 
3.2.6. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) 
 
 Described previously (Chapter 2, Section 2.2.5.). 
3.2.7. Western immunoblotting 
Described previously (Chapter 2, Section 2.2.6). 
3.2.8. Antibody detection 
 Described previously (Chapter 2, Section 2.2.7). 
3.2.9. Densitometry 
 MATLAB® R2013a image acquisition and analysis software was used for all densitometric 
analyses as described previously (Chapter 2, Section 2.2.8). This provided an estimation of 
the relative abundance of key phospho-proteins within each of the HOSCC cell lines 
(described in more detail below). All densitometric data generated was compared to the 
optical density of A431 or WHCO6 cell lines (Appendix B, Section 2.3.). To generate 
accurate and comparable data, the IOD, determined by MATLAB, were normalised for all 
western blot replicates as described in Appendix B, Section 2.6. (Degasperi et al., 2014) 
3.2.10. Data analysis 
All experiments were performed in triplicate. Results were represented described previously 
(Chapter 2, Section 2.2.9). The statistical significance of the densitometric data was 
determined by performing a standard Student’s t-test (Appendix B, Section 2.3.) using 
GraphPad Prism®, Version 7.0 (GraphPad Software, Inc., La Jolla, USA) (where p<0.05 
indicated statistical significance).  
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3.3. Results section 
3.3.1. The efficacy of the RSK inhibitor, BI-D1870, under standard tissue culture 
conditions: 
Phospho-GSK3β (Ser9) and phospho-FAK (Tyr397) were successfully detected in all of the 
HOSCC cell lines, post RSK inhibition (Figure 9). Fluctuations in these key phospho-
intermediates were visualised via the western immunoblotting technique. All normalised 
densitometric data was made relative to IOD of the A431/WHCO6 cell line (Methods and 
materials, Section 3.3.9) and the WHCO6 cell line acted as an internal control. β-actin 
western blots were obtained to confirm equal protein loading and had a fairly uniform 
banding pattern (Figure 9). Comparative studies were then performed assessing the difference 
between the relative abundance of a set phospho-protein in a HOSCC cell lines exposed to 
BI-D1870 as opposed to the DMSO control. The net change (Appendix B, Section 2.5.) in the 
cellular levels of these key phospho-intermediates, post RSK inhibition, has been summarised 
in the Table 2 below. 
Decreased levels of cellular phospho-GSK3β (Ser9) post RSK inhibition, verified the activity 
of the RSK inhibitor (BI-D1870) within the HT29 cell line (Figure 9). RSK phosphorylates 
GSK3β at Serine 9 (substrate of RSK), therefore a loss of phospho-GSK3β (Ser9) is 
indicative of a loss in RSK activity (Stambolic et al., 1994; Sutherland et al., 1993). Effective 
RSK inhibitors hamper this proteins ability to phosphorylate its substrates hence resulting in 
a decrease in the phosphorylation of GSK3β at Serine 9. The activity of BI-D1970 was 
verified within three of the Five HOSCC cell lines, by decreased levels of endogenous 
phospho-GSK3β (Ser9) (post RSK inhibition) (Figure 9 and Figure 10). The levels of 
phospho-GSK3β (Ser9) appeared to increase in WHCO5 and WHCO3 cell lines, post RSK 
inhibition (Figure 10 and Table 2). However the degree to which the levels of phospho-
GSK3β (Ser9) fluctuated appeared to vary from one WHCO cell line to the next. The 
WHCO1 and SNO cells suffered the greatest losses in phospho-GSK3β (Ser9), post RSK 
inhibition (Table 2). The decreased levels of phospho-GSK3β (Ser9) noted within the SNO 
cells following RSK inhibition, were considered statistically significant, at a p-value ҅ 0.01. 
Therefore, in general, RSK inhibition by BI-D1870 was successfully verified within the 
HOSCC cell lines. Interestingly, the level of phospho-GSK3β (Ser9) remained relatively 
unaltered within the A431 cell line regardless of whether the cells were exposed to BI-D1870 
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or not (Figure 10 and Table 2). This suggests that the RSK inhibitor may or may not be active 
within this cell line. 
3.3.2. The cellular levels of phospho-FAK (Tyr397) within the HOSCC cell lines were 
variably affected by the loss of RSK 
The cellular levels of phospho-FAK (Tyr397) appeared to decrease in the SNO and WHCO6 
cells, upon the loss of RSK (Figure 10 and Table 2).  The relative abundance of this phospho-
protein increased in WHCO3 and WHCO5 cells that were exposed to the RSK inhibitor 
(Figure 10). This indicates that RSK inhibition within the HOSCC cells variably affected the 
endogenous levels of phospho-FAK (Tyr397). RSK inhibition decreased the levels of cellular 
phospho-FAK (Tyr397) within the HT29 cell line (Figure 10). However, the relative 
abundance of this phospho-protein remained relatively unaltered within the A431 and 
WHCO1 cell lines regardless of whether the cells were exposed to BI-D1870 or not (Figure 
10 and Table 2). 
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Figure 9. Representative immunoblots for the detection of phospho-FAK (Tyr397) 
and Phospho-GSK3β (Ser9) within the HOSCC cell lines post RSK inhibition (BI-
D1870). 
The levels phospho-GSK3β (Ser9) and phospho-FAK (Tyr397) were detected in the 
WHCO cells as well as the 2 control cell lines, HT29 and A431 cells. The relative 
abundance of phospho-FAK (Tyr397), within the HOSCC cell lines appeared to be 
variably affected by the loss of RSK. Cells were exposed to the RSK inhibitor for 30 
minutes and control was added to the experiment (cells exposed to 0.1 % DMSO). The 
western blot analyses for the detection of β-actin acted as a loading control for the 
western blotting technique (indicating equal protein loading). Three biological replicates 
were performed. (BI-D+: with 10 µM BI-D1870; BI-D-: without 10 µM BI-
D1870/containing 0.1 % DMSO; WC: whole cell protein extract under standard tissue 
culture conditions) 
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Figure 10. The relative abundance of certain phospho-intermediates within the 
HOSCC cell lines appears to be variably affected by the loss of RSK activity (10 
µM BI-D1870). 
The relative abundance of each phospho-protein was obtained by normalising semi-
quantitatively determined densitometric analyses relative to the A431 cell line 
(Appendix B, Section 2.6.). A star (*) represents any statistical difference when 
compared to the control (exposed to 0.1 % DMSO) for each cell line (*p <0.05) 
(Appendix B, Section 2.3.). A. The specific inhibition of RSK by BI-D1870, decreased 
the cellular levels of phospho-FAK (Tyr397) within the WHCO6 and SNO cell lines. 
B. The cellular levels of phospho-GSK3β (Serine 9) decreased in most of the 
HOSCC cell lines post RSK inhibition. As RSK is responsible for the phosphorylation 
of GSK3β at serine 9, monitoring the loss of this particular phosphorylation verified 
the activity of the inhibitor within these cell lines. Unfortunately as the net change in 
phospho-GSK3β was found to be positive in the WHCO3 and WHCO5, BI-D1870 
activity could not be verified within these 2 cell lines. (BI-D+: with 10 µM BI-D1870; 
BI-D-: without 10 µM BI-D1870/containing 0.1 % DMSO). 
 
 
 
 
 
 
 
 
 
A. 
B. 
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Table 2. Net change in the relative abundance of a few key phospho-
intermediates within the HOSCC cell lines post RSK inhibition (10 µM BI-
D1870). 
Net changes in the cellular levels of each phospho-protein, within the WHCO cells post RSK 
inhibition, were determined as outlined in Appendix B, Section 2.5. A star (*) graphically 
represented any statistical difference, when compared to the control (exposed to 0.1 % 
DMSO) for each cell line using a standard Student’s t-test (*p <0 .05;**p < 0.01) (Appendix 
B, Section 2.3.)(↑: Net increase in the cellular levels of a phospho-protein; ↓: Net decrease in 
the cellular levels of a phospho-protein; ≡: Equivalent net change in the cellular levels of a 
phospho-protein). 
 
  Cell line 
 A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
Phospho-
Protein 
↑/↓/≡    ( 
% 
change) 
↑/↓/≡    
( % 
change) 
↑/↓/=    
(% 
change) 
↑/↓/≡ 
( % 
change) 
↑/↓/≡ 
(% 
change ) 
↑/↓/≡ 
(% 
change) 
↑/↓ /≡ 
(% 
change) 
Phospho-
FAK 
(Tyr397) 
(Active 
protein) 
 
≡ 
(-2) 
 
↓* 
(-47) 
 
≡ 
(6) 
 
↑ 
(25) 
 
↑ 
(88) 
 
↓ 
(-10) 
 
↓ 
(-36) 
Phospho-
GSK3β 
(Ser9) 
(Inactive 
protein) 
 
≡ 
(-7) 
 
↓ 
(-21) 
 
↓ 
(-54) 
 
↑ 
(22) 
 
↑ 
(22) 
 
↓** 
(-43) 
 
↓ 
(-21) 
 
3.4. Discussion: 
Only about 30 % of cellular proteins have the capacity to be phosphorylated (Ubersax and 
Ferrel, 2007; Tichy et al., 2011). Observing the levels of a specific phosphorylated protein 
involves monitoring infinitesimally small alterations in the phospho-proteome (Ubersax and 
Ferrel, 2007; Tichy et al., 2011). This would suggest that any fluctuations in the levels of a 
specific phospho-protein, that are detectable, may likely indicate a substantial change in the 
regulation/activation of this phospho-intermediate within the cells (Ubersax and Ferrel, 2007; 
Tichy et al., 2011). Although not all of the observed changes in the levels of key phospho-
proteins post RSK inhibition were found to be statistically significant, the alterations in the 
phospho-proteome did indicate the general trends HOSCC cells embody under certain 
cellular conditions.   
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Cells rely on complex signaling systems to ҅sense ҅ changes in the external environment in 
which they are found (Nakakuki et al., 2010; Kholodenko et al., 1997). To prevent 
inappropriate/disproportionate cellular responses from occurring, due to the ectopic 
activation/repression of individual signal transduction cascades, cells must detect and 
integrate signals from several sources of external stimulation (Arkun, 2016). Signal 
transduction cascades therefore regulate one another at points of cross talk (Nakakuki et al., 
2010; Kholodenko et al., 1997). These pathways, when activated in unison can either up or 
down regulate a signal (Arkun, 2016; Nakakuki et al., 2010). Therefore, cross talk between 
pathways may actually act as an additional layer of cellular control. When one signal 
transduction pathway is dysregulated, several other cascades (salvage pathways) may be 
activated in an attempt to salvage the activity of the dysregulated pathway, and maintain a 
specific cellular response (Nakakuki et al., 2010; Kholodenko et al., 1997). The salvage 
pathways may modulate signal transduction intermediates at points of cross talk between the 
two pathways or alter the expression/activity of regulators of the dysfunctional pathway.  
3.4.1. RSK inhibition (BI-D1870) within the human epidermoid carcinoma cell line and 
the possible salvage pathways that tempered the effects of the inhibitor 
The specific inhibition of RSK (BI-D1870) appeared to have little to no effect on the 
endogenous levels of active FAK and GSK3β inhibition within the A431 cells (Figure 9 and 
Figure 10). The lack of any significant difference in GSK3β inhibition within these cells post 
RSK inhibition may suggest that BI-D1870 is not functional within this cell line (Chapter 3, 
Section 3.3.1). Although this is probable it is more likely that the effects of the inhibitor, BI-
D1870, are being offset by a salvage pathway within this cell line. In reality any signal 
transduction cascade that promotes the activation of either protein kinase A (PKA), PKB/Akt 
or protein kinase C (PKC) within the A431 cells could act as a possible salvage pathway for 
the loss of RSK (Fang et al., 2000; Kim et al., 2007; Jope and Johnson, 2004; Stambolic and 
Woodgett, 1994; Pap and Cooper, 1998).  All three of these proteins when activated, 
promotes the inhibition of GSK3β by phosphorylation at serine 9, mimicking the activity of 
RSK within these cells (Fang et al., 2000; Kim et al., 2007; Jope and Johnson, 2004; 
Stambolic and Woodgett, 1994; Pap and Cooper, 1998). Therefore should any of these 
proteins be activated, within the A431 cells upon the loss of RSK it may explain why the 
cellular levels of GSK3β inhibition remained unaltered (Table 2). 
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Interestingly, the A431 cells are known to contain high levels of the EGF receptor (EGFR) 
(Wu et al., 2013). Cancer cells which express high levels of EGFR or contain EGF receptors 
with activating mutations exhibit higher levels of EGF signalling (Faber et al., 2009). EGF 
signalling promotes cell proliferation, migration, adhesion, cell survival and metastasis (Wu 
et al., 2013). EGFR signalling does this by promoting the activation of the Janus kinase 
(JAK)/signal transducer and activator of transcription (STAT), PI3K/Akt and MAPK/RSK 
signal transduction cascades (see Figure 11 ) (Faber et al., 2009; Wu et al., 2013; Uribe et al., 
2011). Interestingly, the loss of both PI3K/Akt and MAPK/RSK signalling was necessary to 
promote apoptosis in non-small lung cancers with mutant EGF receptors (promote activation) 
(Faber et al., 2009). This suggests that there is synergy between these two pathways and that 
the loss of one pathway was not sufficient at curbing the aberrant growth of non-small lung 
cancer (Faber et al., 2009). Interestingly, the inhibition of the PI3K/Akt pathway by 
metformin, inhibited the proliferation of the A431 cells (Liu et al., 2015). This indicated that 
the PI3K/Akt pathway plays a prominent role in maintaining the transformed state within this 
cell line (Liu et al., 2015). It is therefore likely that the activation of Akt/PKB, possibly via 
an EGFR-dependent signalling pathway, may compensate for the loss of RSK activity (BI-
D1870) within the A431 cells.  Several growth factors located within FCS were introduced 
concurrently with BI-D1870 as fresh culture media (containing 10 % FCS and BI-D1870) 
was exposed to the A431 cells at the beginning of the inhibitory assay (Methods and 
Materials, Section 3.2.3). Serum stimulation may therefore be responsible in part for the 
variable nature or noise noted in the experimental data, as the activation of several signal 
transduction cascades within the HOSCC cell lines may mask the overall effects of the RSK 
inhibitor, and even this may be context dependent. Therefore the role fresh culture media and 
FCS plays in promoting spatiotemporal responses, within the A431 cell line post RSK 
inhibition, was explored further in Chapter 4.  
The loss of RSK had little to no effect on FAK activation within these cells, suggesting that 
RSK may not play a prominent role in FAK activation within the A431 cell line. Salvage 
pathways may compensate for the loss of RSK; however, it is also probable that RSK may 
mediate FAK activation via the inhibition of GSK3β. Here the activation of this protein, 
FAK, may be modulated by a substrate of GSK3β. FAK may be ectopically activated by a 
protein that is ordinarily repressed by GSK3β activity. The loss of GSK3β activity, by RSK, 
could promote this substrates ability to activate FAK. Should this be the case FAK activation 
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would have remained relatively the same within this cell line, due to the activity of Akt 
(maintaining the inhibition of GSK3β) (Table 2). This was explored further in Chapter 4. 
3.4.2. The relative abundance of active FAK within the WHCO cells appears to be 
variably affected by the inhibition of RSK (10 µM BI-D1870). 
The WHCO cell lines can be separated into 2 subgroups, with the exception of the WHCO1 
cell line, based on the net change in FAK activation, post RSK inhibition. The levels of FAK 
activation appeared to increase in one subgroup whilst decreasing in the other, post RSK 
inhibition. This may indicate that there is variability amongst the carcinomas given the same 
physiological grading, moderately differentiated carcinomas (Fanucchi and Veale, 2009).  
The WHCO1 cell line deviated from the common trends noted for the other four HOSCC cell 
lines. The levels of FAK activation within the WHCO1 cell line appeared to be unaffected by 
the specific inhibition of RSK (BI-D1870) (Figure 10 and Table 2). Interestingly, the 
inhibition of RSK also had little to no impact on FAK activation within the A431 cell line.  
This may suggest that the signal transduction pathways that maintain and propagate the 
transformed state within the A431 cells may also play a role in the WHCO1 cells. However, a 
decrease in GSK3β inhibition, upon the loss of RSK, was noted for the WHCO1 cell line, but 
not the A431 cells. This verified the activity of the RSK inhibitor within this cell line.  
Diminished GSK3β inhibition within the WHCO1 cells may suggest that the salvage 
pathways mentioned previously for the A431 cells may not be as present or effective enough 
to offset the effects of the loss of RSK (By BI-D1870) within this cell line. Interestingly, 
Nicolene Shaw and colleagues found that the WHCO1 cell line had extremely low levels of 
active PKB/Akt (phospho-PKB (Ser473)) (around 10 % of the active PKB found in the 
WHCO6 cell line) (2012).  The low levels of active PKB within the WHCO1 cell line 
suggests that this cell line is unable to use the PI3K/Akt pathway to compensate for the loss 
of RSK (as hypothesized for the A431 cells) resulting in the loss of GSK3β phosphorylation. 
This was further confirmed by the fact that the WHCO1 cell line contains very high levels of 
Phosphatase and tensin homolog (PTEN), as determined by Glen Driver and Robin Veale 
(2006) ( Appendix B, Section 2.4.). In fact the WHCO1 cell line had the highest levels of the 
negative regulator, of the PI3K/Akt pathway (PTEN), of all of the HOSCC cells.  
Despite the loss of GSK3β inhibition, the active form of GSK3β did not impact the levels of 
active FAK within this cell line. This may suggest that FAK activation is being propagated by 
growth factor mediated signal transduction pathways or integrin heterodimers. These 
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canonical mechanisms of FAK activation may be masking the impact RSK inhibition has on 
FAK activity within this cell line (Figure 11). Chapter 4 will explore whether the results 
obtained from the RSK inhibition studies are in fact the result of a spatiotemporal response (a 
consequence of cells being exposed to multiple forms of external stimulation 
simultaineously). However, it is important to note that should this not be a spatiotemporal 
response, it is likely that RSK activity plays no role in FAK activation within the WHCO1 
cells, when grown as monolayer (attached to a substrate).  
The cellular levels of both active FAK and inactive GSK3β decreased within the HT29, SNO 
and WHCO6 cells, post RSK inhibition (BI-D1870), (Figure 10 and Table 2). The activity of 
the RSK inhibitor was verified within these cell lines as the relative abundance of phospho-
GSK3β (Ser9), inhibited GSK3β, decreased post RSK inhibition. It is therefore likely that 
RSK promotes FAK activation decreased within these cell lines post RSK inhibition. 
Interestingly the net change in the cellular levels of active FAK post RSK inhibition was only 
found to be statistically significant for the HT29 cell line (Appendix B, Section 2.3.). The 
other two cell lines showed a clear decrease in the cellular levels of active FAK, upon the loss 
of RSK (BI-D1870), and this depression may yet be statistically significant provided that 
more biological replicates be performed.  
The net change in the cellular levels of active FAK/inactive GSK3β, post RSK inhibition, 
within the HT29 and WHCO6 cells is almost identical. This may suggest that the signal 
transduction pathways that maintain the transformed state within these two cell lines may be 
similar. It is interesting that the two cell lines that contain mutant p53, hotspot mutation 
R175H (SNO) and R273H (HT29), were found to have RSK-dependent FAK activation 
(Fanucchi and Veale, 2009; Bossi et al., 2006).  In a previous study conducted by Fanucchi 
and Veale, the mutant p53 located within the SNO cells rendered FAK resistant to caspase 3 
mediated cleavage, upon apoptosis induction and staurosporine mediated cell detachment 
(Fanucchi and Veale, 2009).  In this study the induction of staurosporine mediated apoptosis 
resulted in the activation and translocation of FAK into the nucleus of SNO/WHCO6 cells 
(Fanucchi and Veale, 2009). In the nucleus, FAK acted in its capacity as a scaffolding protein 
promoting the degradation of p53 and hence promoting pro-survival based signalling 
(Fanucchi and Veale, 2009). It is unlikely that RSK caused the activation of FAK under these 
conditions as RSK is inhibited by staurosporine, a nonspecific ATP-competitive kinase 
inhibitor (Fischer et al., 2010; Nguyen, 2008; Belmokhtar et al., 2001).  However, it is 
possible that RSK may play a role in activating FAK, promoting cell survival based 
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signalling, in WHCO cells that are grown in suspension, inducing anoikis ҅naturally ҅. It is 
important to note however that RSK-dependent FAK activation may be context dependent (a 
spatiotemporal response).  
The endogenous levels of active FAK and inhibited GSK3β increased in the WHCO3 and 
WHCO5 cell lines post RSK inhibition.  This was surprising finding as it suggests that RSK 
inhibition inhibits FAK activity within these cell lines. It also suggests that the loss of RSK 
promoted the phosphorylation of its own substrate, GSK3β at serine 9. It is possible that the 
WHCO3 and WHCO5 cell lines have alternative salvage pathways that result in the 
activation of FAK. Serum stimulation may have promoted the activation of FAK and the 
inhibition of GSK3β, via either integrin or growth factor dependent pathways (Sieg et al., 
2000). This may have masked the effects of the RSK inhibitor (BI-D1870) within these cell 
lines. Although the exact components of serum are nebulous, it is known that serum, FCS, 
contains a vast array of growth factors including the platelet derived growth factor (Childs et 
al., 1982; Brindley et al., 2012). As serum stimulation, involving growth factor receptor 
signalling, occurred concurrently with RSK inhibition, it`s possible that any fluctuations in 
the relative abundance of key phospho-proteins may be the accumulation/amalgamation of all 
of these signalling ques combined.  This would suggest that the responses noted in reaction to 
the inhibition of RSK may be context dependent. This was explored further in Chapter 4.   
Recent studies have found that the exact role RSK plays in signal transduction pathways 
appears to be context specific and therefore cannot be generalised (Aronchik et al., 2014). 
This study found that cells may only be reliant on RSK activity for cell survival under 
conditions of anchorage independence (Aronchik et al., 2014). Aronchik and colleagues also 
found that RSK activity appeared to be cell lineage dependent (Aronchik et al., 2014). This 
suggests that the activity of RSK within the HOSCC cell lines may be variable and context 
specific. To determine whether this is indeed the case further studies were performed in 
Chapter 4.  
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Figure 11. A schematic overview of epidermal growth factor (EGF) mediated 
signal transduction cascades. 
The activation of the EGFR receptor triggers the activation of the PI3K/Akt pathway, 
the MAPK/ERK pathway and the JAK/STAT pathway. (ERK: Extracellular signal 
regulated kinase; PI3K: phosphatidylinositol 3-kinase; Janus Kinase: JAK; STAT: 
Signal transducer and activator; GSK3β: Glycogen synthase kinase 3β; T-cell 
factor/lymphoid enhancer factor: TCF/ LEF). The image was produced (Microsoft 
Paint ©) by making use papers published by Jope and Johnson (2004), Zheng et al. 
(2007) and information provided by C. Hooper (Abcam © 2016).  
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 Chapter 4  
4. 4. GSK3β, RSK and serum stimulation: the link to FAK activation 
within HOSCC cells? 
4.1. Introduction: 
4.1.1. GSK3β, RSK and FAK activation? 
 GSK3β is distinctive in that it is ubiquitously expressed and perpetually active within the cell 
(Woodgett, 1990). This protein`s activity is regulated by inhibition (Fang et al., 2000; Kim et 
al., 2007; Jope and Johnson, 2004; Stambolic and Woodgett, 1994; Pap and Cooper, 1998).  
Several proteins including RSK, PKB and PKC play a role in modulating the activity of 
GSK3β by inhibition (Fang et al., 2000; Kim et al., 2007; Jope and Johnson, 2004; Stambolic 
and Woodgett, 1994; Pap and Cooper, 1998).  However, GSK3β activity is also interesting in 
that GSK3β preferentially phosphorylates pre-primed substrates (Fiol et al., 1987; Frame et 
al., 2001; Dajani et al., 2001; ter Haar et al., 2001). Substrates with a consensus sequence of 
Ser/ThrXXXSer/Thr (pre-primed phosphorylation) are often phosphorylated by GSK3β at the 
initial Ser/Thr residue 4 amino acid residues (X) from the pre-primed phosphorylation (Fiol 
et al., 1987; Frame et al., 2001; Dajani et al., 2001; ter Haar et al., 2001). The N terminal 
phosphorylation of GSK3β at Ser9 inhibits GSK3β activity by acting as a pseudo-substrate 
that outcompetes pre-primed substrates for the phosphate binding site (Frame et al., 2001). 
GSK3β, when activated, plays a role in inflammation, cell survival based signalling, 
apoptosis and glycogen biosynthesis (Embi et al., 1980; Doble and Woodgett, 2003; Sun et 
al., 2009).  
GSK3β activity also plays a prominent role in embryonic development, regulating cell 
polarity and migration and is thought to play a large role in regulating actin cytoskeletal 
dynamics/cell-ECM interactions spatiotemporally (Sun et al., 2009). Embryonic stem cells 
were found to undergo differentiation when exposed to a particular substrate-specific level of 
elasticity provided that the MAPK pathway and GSK3β remained active (Shimizu et al., 
2012). However, when the MAP kinase, GSK3β and Src were inhibited, the embryonic stem 
cells retained their pluripotency, encouraging self-renewal, independent of substrate elasticity 
(Shimizu et al., 2012). This indicates that Src, GSK3β and the MAPK pathway play a 
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prominent role in promoting mechanically triggered cell differentiation (Shimizu et al., 
2012).  This suggests that GSK3β activity plays a fundamental role in regulating several 
signal transduction pathways.  
Although the part GSK3β plays in cancer progression is not fully understood (Chapter 1, 
Section 1.5), it appears as though the role this protein plays in neoplasmic transformations is 
very much cell lineage dependent. In pancreatic cancer cells GSK3β activity played a 
fundamental role in promoting cancer cell invasion and chemo-resistance (Kitano et al., 
2013).  The loss of GSK3β activity reduced cell proliferation and rendered the cells 
susceptible to certain chemotherapeutics (Kitano et al., 2013). GSK3β was also found to 
enhance p53 mediated DNA transcription, thereby repressing cancer cell growth, in some 
cancer cells whilst promoting the MDM2 mediated degradation of p53 in others (Turenne and 
Price, 2001; Kulikov et al., 2005). Interestingly GSK3β appeared to be localised at focal 
adhesions within melanoma cells suggesting that GSK3β plays a prominent role in promoting 
more motile melanoma cells. It’s interesting to note that majority of GSK3β was inhibited 
within these cells (Kitano et al., 2013). Only a small subset of GSK3β remained active within 
these cells (Kitano et al., 2013). The complete inhibition of GSK3β resulted in a decrease in 
FAK activation, increasing the size of the focal adhesions (John et al., 2012).  This suggests 
that GSK3β may play a role in FAK activation within the HOSCC cell lines. 
Interestingly previous studies have suggested that GSK3β, a substrate of RSK, may inhibit 
FAK activity by phosphorylating it at serine 722 (Kobayashi et al., 2006; Bianchi et al., 
2005; Sutherland, 2011). This suggests that the role GSK3β plays in FAK activation appears 
to be inconsistent with some studies suggesting GSK3β may inhibit FAK activation whilst 
other suggest it may promote FAK activity (Kobayashi et al., 2006; Bianchi et al.,2005).  The 
role GSK3β played in FAK activation, by triggering the auto phosphorylation of FAK at 
Tyrosine 397, is highly contested. Whether GSK3β ectopically activates/inhibits FAK within 
the HOSCC cell lines still remains unclear.  
It is also possible that RSK may indirectly effect FAK activation by inhibiting GSK3β 
(Chapter 3, Section 3.4.1; Chapter 1, Section 1.9.2). GSK3β phosphorylates several 
substrates causing the inhibition of these proteins activity. Should GSK3β be inactivated, by 
RSK, it would promote the activity of these substrates. One such substrate of GSK3β is the 
phosphatase and tensin homolog deleted in chromosome 10 (PTEN). Active GSK3β has been 
found to de-stabilise PTEN, a cellular inhibitor of FAK activation, by phosphorylating it at 
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Thr366 (Maccario et al., 2007; Sapkota et al., 2007). This post translational modification has 
been known to hinder PTEN activity promoting FAK activation. Therefore RSK may 
promote FAK inactivation via the inhibition of GSK3β and subsequent stabilisation of PTEN 
within HOSCC cells. 
Interestingly, a study conducted on human placental cells, derived from trophoblasts, found 
that Kisspeptin inhibited cell growth via an interesting p90RSK- GSK3β pathway. In these 
cells Kisspeptin-10 promoted RSK activation which in turn phosphorylated GSK3β at serine 
9. However this study found that this promoted β-catenin stabilization and FAK activation 
via a feedback loop. However the exact mechanism by which FAK activation was promoted 
is unclear (Roseweir et al., 2012).  
Therefore the role RSK and GSK3β play in FAK activation will be determined by performing 
dual inhibition studies. It is hoped that these studies will provide more clarity as to whether 
RSK activates or inhibits FAK activation, either directly or indirectly, within the HOSCC cell 
lines.   
4.1.2. Serum stimulation: a spatiotemporal response? 
Cells, originating from multicellular organisms, are continually being exposed to an array of 
external stimuli (Wang et al., 1998; Kholodenko et al., 1997; Nakakuki et al., 2010). How 
cells integrate these externally-derived signals, promoting a specific cellular response, is 
largely context dependent (Kholodenko et al., 1997; Nakakuki et al., 2010). This makes 
studying complex diseases challenging. It`s imperative, in the study of complex disorders, not 
to underestimate the role the micro-environment, in which these cells are found, plays in 
maintaining the transformed state (Kholodenko et al., 1997; Nakakuki et al., 2010). Serum 
stimulation could play a role in promoting specific signal transduction cascades, within 
established cell lines, particularly because its constituents are unknown (Childs et al., 1982; 
Brindley et al., 2012). However FCS is a necessary complication as moderately differentiated 
human squamous cell carcinoma cells are challenging to maintain in vitro.   The opposite is 
also true; serum deprivation is equally unnatural (Yamada and Geiger, 1997; Zhu et al., 2006; 
Li et al., 2008; Leong et al., 2003). It places cells under extreme stress resulting in several 
cell survival pathways being favoured in an attempt to inhibit apoptosis and promote cell 
survival (Zhu et al., 2006; Li et al., 2008; Leong et al., 2003). Serum deprivation also causes 
morphological changes in established cell lines (Qi et al., 1997; Han et al., 2006).  
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Serum stimulation initially flooded the cell monolayer with growth factors, amino acids and 
other essential nutrients. This initial influx of signaling may have masked the impact of the 
RSK inhibitor within the HOSCC cells, particularly as the incubation period for BI-D1870 is 
30 minutes. The initial serum stimulation, concomitantly with BI-D1870, may have promoted 
a specific spatiotemporal response within the HOSCC cell lines.  However serum deprivation 
could produce an equally definitive spatiotemporal response. To ascertain the effects RSK 
inhibition has on the phospho-proteome profile of the HOSCC cells under conditions that 
most closely mimic the natural environment, these cells will be pre-exposed to serum 23 
hours and 30 minutes prior to being exposed to the RSK inhibitor. This will be done in order 
to determine whether the results obtained in Chapter 3 can be reproduced under slightly 
different environmental conditions.  
4.2. Methods and Materials 
4.2.1. Cell culture 
Described previously (Chapter 2, Section 2.2.1). 
4.2.2. Subculture 
 Described previously (Chapter 2, Section 2.2.2). 
4.2.3. RSK and GSK3β inhibition assay 
Due to the vastly different incubation periods of BI-D1870 and AR-A014481 (Appendix A, 
Section 1.5.2 and Section 1.6.2.) the cell cultures were not exposed to both inhibitors 
simultaneously. Instead the cell monolayer was exposed to AR-A014481 prior to BI-D1870 
in such a way that both inhibitors reach optimal activity within the cells at the same time. 
This split-inhibition incubation period ensured that both inhibitors reached optimal activity 
simultaneously within the cells (a likely representation of the inhibition of both RSK and 
GSK3β).  
Cell cultures were propagated in 6 cm plates. Once the cell monolayer reached a confluency 
of 65 %, the cells were washed twice in warm sterile PBS (37°C). Subsequently, three 
millilitres of fresh culture media, containing 10 % FCS and a final concentration of 10 µM 
AR-A014481 (Sigma-Aldrich ®) (Appendix A, Section 1.6.1 and Section 1.6.2), was added 
to the cell culture as described by Kitano et al. (2013) (Bhat et al., 2003). AR-A014418  was 
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selected as it is a highly specific ATP competitive inhibitior for GSK3β which does not 
inhibit closely related kinases (cdk2 and cdk5) (Bhat et al., 2003). Simultaneously, controls 
for each cell line were prepared containing 0.187 % DMSO. Next, the cells were incubated 
for 23 hours and 30 minutes at 37°C, in a humid incubator with 5 % carbon dioxide. 
Following this incubation period, a concentration of 10 µM BI-D1870 was inserted into the 
tissue culture plate (previously exposed to AR-A011481), as described by Sapkota et al. 
(2007). A further 0.1 % DMSO was added to the controls, previously exposed to 0.187 % 
DMSO. The cell cultures were then re-incubated for 30 minutes, at 37°C in an incubator with 
5 % carbon dioxide.  
A second control for GSK3β inhibition was performed as described by Kitano et al. (2013). 
Cell cultures were propagated in 6 cm plates. Once the cell monolayer reached a confluency 
of 65 % the cells were washed twice in warm sterile PBS (37°C). Subsequently, three 
millilitres of fresh culture media, containing 10 % FCS and a final concentration of 10 µM 
AR-A014481 (Sigma-Aldrich ®) (Appendix A, Section 1.6.1 and Section 1.6.2), was added 
to the cell culture as described by Kitano et al. (2013) (Bhat et al., 2003). Simultaneously, 
controls for each cell line were prepared containing 0.187 % DMSO. The cells were 
incubated for 24 hours at 37°C, in a humid incubator with 5 % carbon dioxide.  
A third control was prepared for RSK inhibition as described by Sapkota et al. (2007). Cell 
cultures were propagated in 6 cm plates. Once the cell monolayer reached a confluency of   
65 % the cells were washed twice in warm sterile PBS (37°C). Subsequently, three millilitres 
of fresh culture media containing 10 % FCS, was added to the cell culture. The cells were 
incubated for 23 hours and 30 minutes, at 37°C, in a humid incubator with 5 % carbon 
dioxide. Following this incubation period, a concentration of 10 µM BI-D1870 was inserted 
into the tissue culture plate (previously exposed to fresh culture media, 10 % FCS), as 
described by Sapkota et al. (2007). Simultaneously, controls for each cell line were prepared 
and 0.1 % DMSO added. The cell cultures were then incubated for 30 minutes at 37°C, in an 
incubator with 5 % carbon dioxide.  
4.2.4. Whole cell protein extraction 
Described previously (Chapter 2, Section 2.2.3). 
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4.2.5. Protein determination  
Described previously (Chapter 2, Section 2.2.4). 
4.2.6. Sodium dodecyl sulphate polyacrylamide electrophoresis (SDS-PAGE) 
  Described previously (Chapter 2, Section 2.2.5). 
4.2.7. Western immunoblotting 
Described previously (Chapter 2, Section 2.2.6). 
4.2.8. Antibody detection 
Described previously (Chapter 2, Section 2.2.7). 
4.2.9. Densitometry 
MATLAB® R2013a image acquisition and analysis software was used for all densitometric 
analyses as described previously (Chapter 2, Section 2.2.8). This provided an estimation of 
the relative abundance of key phospho-proteins within each of the HOSCC cell lines 
(described in more detail below). All densitometric data generated was compared to the 
optical density of A431 or WHCO6 cell lines (Appendix B, Section 2.4.). To generate 
accurate and comparable data, the computed optical densities (IOD) determined by 
MATLAB, were normalised for all western blot replicates as described in Appendix B, 
Section 2.6. (Degasperi et al., 2014) 
4.2.10. Data analysis 
All experiments were performed in triplicate unless otherwise stated. Results were 
represented as described previously (Chapter 2, Section 2.2.9). The statistical significance of 
the densitometric data was determined by performing a standard Student’s t-test (Appendix 
B, Section 2.4.) using GraphPad Prism®, Version 7.0 (GraphPad Software, Inc., La Jolla, 
USA) (where p <0.05 indicated statistical significance).  
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4.3. Results section 
The levels of Phospho-GSK3β (Ser9), phospho-β-catenin (Ser33, Ser37 & Thr41) and 
phospho-FAK (Tyr397) were successfully detected in all of the HOSCC cell lines, post 
inhibition (RSK, GSK3β or RSK/GSK3β inhibition) (Figure 12). Comparative studies were 
then performed by relating the difference between the relative abundance of a phospho-
protein within an HOSCC cell line, exposed to an inhibitor (or set of inhibitors), as opposed 
to its DMSO control. Overall the net changes in the phospho-protein profile (Table 3) 
indicated that none of the HOSCC cell lines are identical. The net change in the cellular 
levels of all of the key phospho-proteins, following the inhibition of GSK3β, RSK or the dual 
inhibition of both proteins (GSK3β/RSK) varied from cell line to cell line. Even the 
comparative controls had distinct responses to all three of the inhibitor combinations noted 
above.  
4.3.1 RSK inhibition variably affected the relative abundance of a few key phospho-
proteins within the HOSCC cell lines, 24 hours after the introduction of serum 
(control). 
The exact degree to which the levels of these phospho-proteins fluctuated post RSK 
inhibition appeared to vary from one WHCO cell line to the next. The WHCO1, HT29 and 
A431 cells behaved in a similar fashion when exposed to a specific RSK inhibitor (24 hours 
after the introduction of FCS).  The cellular levels of phospho-FAK (Tyr397) increased in 
these three cell lines post RSK inhibition (Figure 13 and Table 3).  Interestingly, the relative 
abundance of phospho-GSK3β (Ser9) decreased in all of these cell lines upon the loss of RSK 
(BI-D1870) thereby verifying the activity of the RSK inhibitor within these cells (Figure 13). 
The net changes in the levels of phospho-FAK (Tyr397)  and phospho-GSK3β (Ser9), within 
the HT29 cell line post RSK inhibition, were found to be statistically significant (Figure 13 
and Table 3). Lastly the decreased levels of phospho-β-catenin (Ser33, Ser37 & Thr41) noted 
within the WHCO1 cell line upon the loss of RSK (BI-D1870), was also found to be 
statistically significant (Appendix B, Section 2.4.).   
The relative abundance of all of the key phospho-proteins decreased within the WHCO3 and 
SNO cell lines, post RSK inhibition (24 hours after the introduction of serum, FCS). Lastly 
the levels of phospho-FAK (Tyr397) and phospho-GSK3β (Ser9) increased in the WHCO5 
and WHCO6 cell lines (Figure 13). The increased levels of phospho-β-catenin (Ser33, Ser37 
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& Thr41) and phospho-FAK (Tyr397) within the WHCO6 cell line upon the loss of RSK (BI-
D1870) were found to be statistically significant. The fluctuations noted in the endogenous 
levels of phospho-GSK3β (Ser9), within the WHCO5 and SNO cells post RSK inhibition 
were also found to be statistically significant.  
4.3.2. The specific inhibition of GSK3β (AR-A014481) variably affected the cellular 
levels of a few key phospho-proteins within the HOSCC cell lines (control). 
Decreased levels of phospho-β-catenin (Ser33, Ser37 & Thr41), post GSK3β inhibition, 
verified the activity of the GSK3β inhibitor (AR-A014481) within the WHCO5, WHCO6 and 
SNO cell lines (Figure 13 and Table 3). GSK3β phosphorylates β-catenin at Ser33, Ser37 and 
Thr41, therefore a loss of phospho-β-catenin (Ser33, Ser37 & Thr41) is indicative of a loss in 
GSK3β activity (Hinoi et al., 2000; Rask et al., 2003; Waaler et al., 2011). However, the 
activity of the inhibitor could not be verified within the WHCO1, WHCO3 and A431 cell 
line. 
The inhibition of GSK3β (AR-A014481) decreased the cellular level of phospho-FAK 
(Tyr397) within A431, HT29, WHCO5 and SNO cell lines (Figure13). The cellular levels of 
this phospho-protein increased in the remaining three cell lines, following the inhibition of 
GSK3β.  Interestingly, the cellular levels of phospho-GSK3β (Ser9) appeared to decrease in 
all of the cell lines, except the WHCO5 and WHCO1 cells, upon the loss of GSK3β (AR-
A014481) (Figure 13 and Table 3).   
4.3.3. The dual inhibition, of GSK3β and RSK, generally resulted in decreased cellular 
levels of phospho-FAK (Tyr397) within the HOSCC cell lines. 
Dual inhibition, AR-A014481and BI-D1870, studies found that most of the HOSCC cell lines 
had diminished levels of phospho-GSK3β (Ser9) and phospho-FAK (Tyr397) when both 
RSK and GSK3β were inhibited simultaneously (Figure 13).  Only the A431 cell line had 
elevated levels of GSK3β (Ser9) post RSK/GSK3β inhibition (Table 3). This suggests that 
the effectivity of the RSK inhibitor was verified in all of the HOSCC cell lines and one of the 
control cell lines.  The loss of both GSK3β and RSK activity (AR-A014481and BI-D1870), 
within the HT29 and WHCO1 cells, appeared to have no effect on the cellular levels of 
phospho-FAK (Tyr397). The effectivity of the GSK3β inhibitor was verified within all of the 
HOSCC cell lines, except SNO and WHCO6 cells (Figure 13 and Table 3). The levels of 
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phospho-β-catenin (Ser33, Ser37 & Thr41) increased in these two cell lines, post 
GSK3β/RSK inhibition (Figure 13).  
Fluctuations in the levels of phospho-GSK3β (Ser9), within the WHCO5 and SNO cells, post 
RSK/GSK3β inhibition were found to be statistically significant. The net change in the levels 
of phospho-FAK (Tyr397), within the WHCO3 and SNO cells, was also found to be 
statistically significant. The decreased cellular levels of phospho-β-catenin (Ser33, Ser37 & 
Thr41) within the A431 and WHCO5 cell line, upon the loss of RSK and GSK3β activity, 
were also found to be significantly different from their respective controls (Figure 13).   
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Figure 12. Representative immunoblots for the detection of a few key phospho-
proteins within the HOSCC cell lines, post GSK3β inhibition (10 µM AR-
A014481), RSK inhibition (10 µM BI-D1870, 24 hours after serum 
introduction) and post RSK-GSK3β inhibition. 
Figure 12. Representative immunoblots for the detection of a few key phospho-
proteins within the HOSCC cell lines post GSK3β inhibition (10 µM AR-
A014481), RSK inhibition (10 µM BI-D1870, 24 hours after serum introduction) 
and post RSK-GSK3β inhibition (10 µM BI-D1870 and 10 µM AR-A014418). The 
levels of phospho-FAK (Tyr397), phospho-GSK3𝛽 (Ser9) and phospho-β-catenin 
(Ser33, Ser37 & Thr41) were detected in the WHCO cells as well as the 2 control cell 
lines, HT29 and A431 cells. The relative abundance of phospho-FAK (Tyr397) within 
the HOSCC cell lines appeared to be variably affected by the loss of RSK and/or 
GSK3β. The western blot analyses, for the detection of β-actin, acted as a loading 
control, indicate equal protein loading, for the western blotting technique. Cells were 
exposed to the GSK3β inhibitor for 24 hours, the RSK inhibitor for 30 minutes and a 
control was added for each experiment (RSK inhibition: cells exposed to 0.1 % 
DMSO; GSK3β inhibition: cells exposed to 0.187 % DMSO). Three biological repeats 
were obtained. (BI-D+: with 10 µM BI-D1870; BI-D-: without 10 µM BI-
D1870/containing 0.1 % DMSO; AR+: with 10 µM AR-A014418; AR-: without 10 µM 
AR-A014418/containing 0.187 % DMSO; BI-D+/AR+: with 10 µM BI-D1870/AR-
A014418; BI-D-/AR-: without 10 µM BI-D1870/AR-A014418 (containing 0.287 % 
DMSO); WC: whole cell protein extract under standard tissue culture conditions)  
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Figure 13. The relative abundance of a few key phospho-intermediates, within the HOSCC cell lines post RSK inhibition (10 
µM BI-D1870, 24 hours after serum introduction), GSK3β inhibition (10 µM AR-A014481) and post dual inhibition (AR-A014481 
and  BI-D1870). 
The relative abundance of phospho-FAK (Tyr397), phospho-GSK3𝛽 (Ser9) and phospho-β-catenin (Ser33, Ser37 & Thr41) were 
obtained by normalising semi-quantitatively determined densitometric analyses, relative to the A431 cell line (Appendix B, Section 2.6.). 
Net changes in the cellular levels of each phospho-protein, within the WHCO cells post RSK and/or GSK3β inhibition, were determined 
as outlined in Appendix B, Section 2.5. A star (*) represents any statistical difference, when compared to the control (*p <0 .05; **p < 
0.01). A. The cellular levels of phospho-FAK (Tyr397) were variably affected by the inhibition RSK (24hours after serum introduction), 
the inhibition of GSK3β and the inhibition of RSK/GSK3β within the HOSCC cell lines. B. The relative abundance of phospho-GSK3β 
(Ser9) decreased within the HT29, A431, WHCO3 and SNO cells, post RSK inhibition and post GSK3β inhibition. C. Fluctuations in the 
levels of phospho-β-catenin (Ser33, Ser37 & Thr41) seem to vary from cell line to cell line, post RSK inhibition (24hours after serum 
introduction), GSK3β inhibition and post RSK/GSK3β inhibition. (BI-D+: with 10 µM BI-D1870; BI-D-: without 10 µM BI-D1870/containing 
0.1 % DMSO; AR+: with 10 µM AR-A014418; AR-: without 10 µM AR-A014418/containing 0.187 % DMSO; BI-D+/AR+: with 10 µM BI-
D1870/AR-A014418; BI-D-/AR-: without 10 µM BI-D1870/AR-A014418 (containing 0.287 % DMSO); WC: whole cell protein extract 
under standard tissue culture conditions)  
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Table 3. Net changes in the relative abundance of a few key 
phospho-intermediates, within the HOSCC cell lines, post 
RSK inhibition (10 µM BI-D1870, 24 hours after serum 
introduction), GSK3β inhibition (10 µM AR-A014481) and 
post dual inhibition. 
 
 
 
Table 3. Net changes in the relative abundance of a few key phospho-intermediates 
within the HOSCC cell lines post RSK inhibition (10 µM BI-D1870, 24 hours after 
serum introduction), GSK3β inhibition (10 µM AR-A014481) and post dual inhibition 
(AR-A014481 and  BI-D1870).  
Net changes in the cellular levels of each phospho-protein, within the WHCO cells post RSK 
inhibition, were determined as outlined in Appendix B, Section 2.5. A star (*) graphically 
represented any statistical difference, when compared to the control (exposed to 0.1 % DMSO) for 
each cell line using a standard Student’s t-test (*p <0 .05;**p < 0.01) (Appendix B, Section 2.4).(↑: 
Net increase in the cellular levels of a phospho-protein; ↓: Net decrease in the cellular levels of a 
phospho-protein; ≡: Equivalent net change in the cellular levels of a phospho-protein).  
 
 Protein Cell line 
  A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
  ↑/↓/≡    ( 
% 
change) 
↑/↓/≡    ( 
% 
change) 
↑/↓/=    
(% 
change) 
↑/↓/≡ 
    ( % 
change) 
↑/↓/≡ 
 (% 
change )  
↑/↓/≡ 
(% 
change) 
↑/↓ /≡ 
(% change) 
RSK 
inhibition 
24 hrs after 
FCS 
introduced 
Phospho-FAK 
(Tyr397) 
(Active protein) 
↑ 
(51) 
↑* 
(31) 
↑  
(47) 
↓*  
(-33) 
↑ 
(70) 
↓ 
(-9) 
↑** 
(63) 
Phospho-
GSK3β (Ser9) 
(Inactive 
protein) 
↓ 
(-41) 
↓** 
(-63) 
↓ 
(-62) 
↓  
(-42) 
↑* 
(73) 
↓* 
(-94) 
↑ 
(38) 
phospho-β-
catenin (Ser33, 
Ser37 & Thr41) 
↑ 
(48) 
0 ↓* 
(-68) 
↓ 
(-25) 
↓ 
 (-21) 
↓ 
  (-40) 
↑**  
(36) 
GSK3β 
inhibition  
Phospho-FAK 
(Tyr397) 
(Active protein) 
↓  
(-18) 
↓  
(-51) 
↑* 
 (185) 
↑ 
(99) 
↓** 
(-13) 
↓ 
(-31) 
↑ 
(74) 
Phospho-
GSK3β (Ser9) 
(Inactive 
protein) 
↓ 
 (-36) 
↓* 
(-56) 
↑ 
(45) 
↓ 
 (-10) 
↑* 
 (150) 
↓ 
 (-42) 
↓ 
 (-27) 
phospho-β-
catenin (Ser33, 
Ser37 & Thr41) 
↑ 
(17) 
0 ↑ 
(143) 
↑** 
(128) 
↓* 
 (-65) 
↓ 
  (-25) 
↓  
(-58) 
RSK/GSK
3β 
inhibition 
Phospho-FAK 
(Tyr397) 
(Active protein) 
↓  
(-14) 
≡ 
(6) 
≡  
(-6) 
↓*  
(-17) 
↓ 
(-18) 
↓** 
(-36) 
↓ 
 (-55) 
Phospho-
GSK3β (Ser9) 
(Inactive 
protein) 
↑ 
(17) 
↓* 
(-10) 
↓ 
(-34) 
↓ 
 (-20) 
↓** 
(-83) 
↓** 
(-70) 
↓ 
(-93) 
phospho-β-
catenin (Ser33, 
Ser37 & Thr41) 
↓*  
(-23) 
0 ↓ 
(-27) 
↓ 
(-2) 
↓** 
 (-54) 
↑ * 
 (21) 
≡ 
(4) 
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4.4. Discussion: 
It is becoming increasingly apparent that certain signalling molecules may have a context 
dependent role in cancer progression and that this heterogeneity ultimately impacts the 
effectivity of targeted therapeutics (Languino et al., 2016; Kholodenko et al., 1997; Nakakuki 
et al., 2010; Aronchik et al., 2014; Rahman et al., 2016).   The mechanisms that underlie 
heterogeneity within neoplastic transformations and drug resistance are still being explored 
today. One study found that TGF-β signalling promoted heterogeneity in squamous cell 
carcinoma (SCC) stem cells that were poised to metastasize, located near vascular systems 
(Oshimori et al., 2015). Oshimori and colleagues found that TGF-β signalling, alone, could 
encourage the activation of alternative molecular pathways, increased drug resistance and 
altered tumour characteristics, without ever altering the DNA profile of the SCC cells 
(Oshimori et al., 2015). This indicates the importance of studying the impact of the 
microenvironment on outside-in signalling and its effects of the transformed state (Oshimori 
et al., 2015). Indeed molecular heterogeneity appears to be particularly prevalent within 
human squamous cell carcinomas.  
Oral squamous cell carcinomas (OSCC) for example often exhibit erratic behaviour and 
molecular heterogeneity creating fundamental challenges for targeted based chemotherapy 
(Severino et al., 2008).  Other studies conducted on HOSCC cell lines have found that there 
are vast differences in the pathways cancerous cells can take in order to maintain and 
propagate the cancerous state (Fanucchi and Veale, 2009; Kang et al., 2010). Previous studies 
have shown that due to the nature of cancer, the step-wise accumulation of genetic defects, 
each cell line may be a case study in and of itself (Kang et al., 2010). HOSCC cell lines are 
moderately differentiated carcinomas, however, the variability in the results seen in this 
experiment and in literature shows that there is a vast difference in the differentiation patterns 
of cell lines given the same grading (Fanucchi and Veale, 2009; Kang et al., 2010).  This 
diversity is further amplified by that fact that RSK activity, within cells, is context and cell 
lineage dependent (Aronchik et al., 2014). This in part explains why HOSCC cells have such 
high heterogeneity. In the current study not one of the HOSCC cell lines responded 
identically to all three inhibition studies, despite all being considered moderately 
differentiated carcinomas. This would suggest that an improved grading system be put in 
place to further subdivide moderately differentiated carcinomas.  This also in part explains 
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the poor prognosis cancer patients have when they contract this form of cancer (Hendricks 
and Parker, 2002; Ohashi et al., 2010). The dysregulated molecular pathways that 
underlie/maintain the cancerous state within one patient may be vastly different to another, 
even though both forms of cancer appear phenotypically similar. The high level of 
heterogeneity from patient to patient impacts the effectivity of the selected chemotherapeutics 
used to combat this disease (Hendricks and Parker, 2002; Ohashi et al., 2010; Languino et al., 
2016). In fact the heterogeneity, across HOSCC cancer cells, may be a marker for human 
oesophageal squamous cell carcinomas, not unlike the other forms of SCC. The different 
molecular mechanisms, that encourage molecular heterogeneity within HOSCC cells, needs 
to be fully defined in order to improve the grading system of moderately differentiated 
carcinomas and the drug targets used to treat HOSCC.  
Also the combination of both RSK inhibition and serum stimulation produced a different 
spatiotemporal response within each of the HOSCC cells than the introduction of serum 24 
hours prior to the inhibition of RSK. It is interesting the general phospho-protein trends noted 
in Chapter 3, were not reproduced in all of the HOSCC cell lines post RSK inhibition (24 
hours after serum stimulation). Serum contains platelet derived growth factors that appear to 
act similarly to transforming growth factors (Childs et al., 1982). The presence of these 
growth factors, after long periods of deprivation, may trigger the MAPK pathway and the PI-
3K pathway to name a few) (Clement et al., 2013; Chen et al., 2015). This may explain some 
of the slight discrepancies that were noted post RSK inhibition (under 2 different 
environmental conditions) (Clement et al., 2013; Chen et al., 2015). This did, however, 
confirm that the activity of RSK, within the HOSCC cells may be variable and context 
specific (Aronchik et al., 2014). Also although not all of the observed changes, in the levels 
of key phospho-proteins, post RSK/GSK3β inhibition were found to be statistically 
significant, the alterations in the phospho-proteome did indicate the general trends HOSCC 
cells embody under certain cellular conditions.  
4.4.1. RSK impedes FAK activation, via its inhibition of GSK3β, within a human 
epidermoid squamous cell carcinoma cell line. 
The inhibition of RSK, when combined with serum stimulation, had a nominal/insignificant 
impact on the endogenous levels of FAK activation within the human epidermoid squamous 
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carcinoma cells. This is likely due to the activation of the PI3K/Akt salvage pathway within 
the A431 cells (Liu et al., 2015). However the loss of RSK activity, under different 
environmental conditions (24 hours after serum stimulation), promoted the activation of FAK 
(by 51 %) within the A431 cells. This suggests that RSK inhibits FAK activation, either 
directly or indirectly, within these cells. However the cellular levels of GSK3β activation also 
increased upon the loss of RSK activity (RSK-dependent GSK3β inhibition (phospho-GSK3β 
(Ser9) decreased 24 hours after serum/RSK inhibitor stimulation). The higher levels of 
GSK3β activity, post RSK inhibition, was confirmed by the increased cellular levels of β-
catenin being targeted for ubiquitination (levels of phospho-β-catenin (Ser33, Ser37 & 
Thr41) increased by 41 %). Perhaps GSK3β may activate FAK. This was confirmed in part 
by the inhibition of GSK3β, within the A431 cells.  
The loss of GSK3β activity decreased the cellular levels of active FAK (by 18 %). Although 
the levels of FAK activation were only slightly reduced, upon the loss of GSK3β, the RSK 
inhibition studies showed that GSK3β activation could promote increased levels of active 
FAK if left dysregulated. This corroborated earlier findings that suggested that the loss of 
GSK3β activity resulted in reduced levels of FAK activation within melanoma cells (John et 
al., 2012). However, it contradicted other studies that suggest that GSK3β directly inhibits 
FAK activation (Domoto et al., 2016; Kobayashi et al., 2006; Bianchi et al., 2005; 
Sutherland, 2011).  This would suggest that GSK3β may indirectly promote FAK activation 
by modulating the activity of one of its substrates (Maccario et al., 2007; Sapkota et al., 
2007). The activation of GSK3β promotes the destabilization/inhibition of PTEN, substrate of 
GSK3β, thereby promoting the inhibition of PTEN (Maccario et al., 2007; Sapkota et al., 
2007). The loss in PTEN activity, an antagonist of FAK based signalling, may promote FAK 
activation within the A431 cells (Maccario et al., 2007; Sapkota et al., 2007). The inhibition 
of both RSK and GSK3β showed a similar decrease in the levels of FAK activation to that 
which was noted when GSK3β was solely inhibited, within the A431 cells.  
This suggests that RSK promotes FAK inhibition by negatively regulating GSK3β activity 
within this cell line. It should also be noted that the role the RSK/GSK3β pathway plays in 
sustaining FAK activation, within this cell line, is fairly minimal, which could explain why it 
is not statistically significant. GSK3β-dependent FAK activation only accounted for about 
14-18 % of the cellular levels of active FAK within these cells. This suggests that alternative 
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cellular pathways are the main driving force behind the sustained activation of FAK noted 
within the A431 cells. It is likely that EGF-dependent signalling may play a prominent role in 
FAK activation, as EGF is highly abundant within these cells and is known to promote FAK 
activity (Wu et al., 2013).  
 Lastly the levels of phospho-β-catenin increased in the A431 cells despite the loss of GSK3β 
activity (GSK3β inhibition). This could have been due to the activation of the protein kinase 
C (PKC) within the A431 cells (Raab et al., 2009). Even though GSK3β is generally known 
to phosphorylate β-catenin, recent studies have found that PKC also inhibits the activation of 
β-catenin, promoting its degradation by phosphorylating it at serine 33 and serine 37 (Raab et 
al., 2009) (Figure 14). This may explain why the levels of phospho-β-catenin increase upon 
the loss of GSK3β within the A431 cells. 
4.4.2. RSK-dependent FAK activation: context dependent pathway that is not a 
commonality amongst HOSCC cells  
The HOSCC cell lines can be classified into 3 different categories with regard to RSK-
dependent FAK activation. RSK impeded FAK activation within the WHCO5, WHCO1 and 
HT29 cells, in part through its inhibition of GSK3β. This subgroup acted similarly to the 
A431 cells. RSK inhibition, promoted FAK activation within the WHCO5 cells, by 88 and 70 
% respectively (under both environmental conditions although the extent to which this occurs 
varies). The effectivity of the inhibitor could not be confirmed within this cell, however, as 
the cellular levels of inhibited GSK3β increased post RSK inhibition. Salvage pathways, such 
as the Akt/PI3K pathway, may have again play a role in promoting GSK3β inhibition, in the 
absence of RSK, as seen in the A431 cells (BI-D1870) (Liu et al., 2015). Interestingly, 
GSK3β inhibition indicated that GSK3β promotes FAK activation (by 13 %), within these 
cell lines. The levels of β-catenin, targeted for ubiquitination, decreased upon the loss of 
GSK3β activity, confirming the effectivity of the inhibitor. Fascinatingly, the loss of both 
GSK3β and RSK activity within the WHCO5 cells displayed similar results to that which was 
obtained when GSK3β was solely inhibited (statistically significant) (Appendix B, Section 
2.4.). This indicates that GSK3β plays a role in FAK activation within the HOSCC cell lines. 
RSK regulates FAK activation negatively by negatively regulating the activity of its activator 
(GSK3β) within the WHCO5 cell line (Figure 14).  
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The HT29 cell line and WHCO1 cell line are more complex, in that the loss of GSK3β and 
RSK activity simultaneously had little to no effect on FAK activation. This indicates that any 
role RSK or GSK3β may have on FAK activation within these cells, is likely to be the result 
of a substrate of either one or both of these proteins. In the HT29 cells the levels of FAK 
activation increased significantly, post RSK inhibition (24 hours after serum stimulation) 
confirming that RSK inhibits FAK activation, indirectly. As the levels of phospho-GSK3β 
(Ser9) decreased by 63 percent, post RSK inhibition, the active levels of this protein 
increased by an equivalent scale factor within the HT29 cells. This indicates that RSK may 
promote the inhibition of FAK indirectly by inhibiting the activity of GSK3β, within the 
HT29 cells.  Interestingly, as with the A431 cells, GSK3β inhibition indicated that GSK3β 
activates FAK. This was seen by the fact that increasing levels of GSK3β inhibition resulted 
in decreasing levels of FAK activation, a 51 % decrease. However, the cellular levels of FAK 
increased only marginally within this cell line, post dual inhibition. This indicates that RSK is 
likely to inhibit FAK activation via the inhibition of GSK3β (an activator of FAK). RSK is 
also unlikely to inhibit FAK activity directly within these cell lines. GSK3β inhibition is 
likely to promote the activation of one of its substrates thereby encouraging FAK activation 
(Figure 14).   
The WHCO1 cell line behaved similarly to the A431 cells, in that RSK appears to inhibit 
FAK activation. However in contrast to the A431 cells, the WHCO1 cell line found that 
GSK3β inhibited FAK activation as well. The levels of phospho-β-catenin decreased upon 
the loss of GSK3β activity, as seen in the A431 cells. PKC may have acted as a salvage 
pathway for the loss of GSK3β activity, increasing the levels of phospho-β-catenin in its 
absence (Raab et al., 2009). PKC is thought to promote FAK activation under certain 
circumstances (Lewis et al., 1996). It is possible that PKC may have been responsible; in part 
for the significant increase in FAK (by 185 %) activation noted upon the loss of GSK3β, 
within the WHCO1 cells. This activation of PKC may have masked the effects GSK3β 
inhibition had on FAK activation (Figure 14). It does appear as though GSK3β inhibits FAK 
activation within these cells. In future PKC activity should be inhibited in this cell line, in 
combination with GSK3β inhibition to ascertain whether this is indeed the case or not. It is 
possible that GSK3β may directly inhibit FAK activation, as previous studies have implied 
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that GSK3β may inhibit FAK activity by phosphorylation (Domoto et al., 2016; Kobayashi et 
al., 2006; Bianchi et al., 2005; Sutherland, 2011).  
The loss of both RSK and GSK3β activity appeared to have no impact on FAK activation, as 
with the HT29 cells. This indicated that both proteins when inhibited individually caused a 
reduction in the levels of FAK activation but had no impact on FAK activity when inhibited 
simultaneously. In the same way as the HT29 cells, a substrate of either RSK or GSK3β may 
activate FAK within the WHCO1 cell line (Figure 14). 
The loss in GSK3β activity caused by AR-A014418 variably affected phospho-GSK3β 
(Ser9), phosphorylation event that naturally inhibits this protein. The levels of phospho-
GSK3β (Ser9) decreased in most of the HOSCC cell lines and the two comparative controls 
upon the loss of GSK3β activity (AR-A014418). As cells develop mechanisms to maintain 
homeostasis, a shift/imposed loss in GSK3β activity would naturally result in a decrease in its 
inhibition, phosphorylation at Ser 9, in an attempt to restore GSK3β activity within the cells 
(Yamada and Geiger, 1997; Fu et al., 2012). It is likely that the stabilisation of PTEN, upon 
the loss of GSK3β activity, may suppress the activation/ activity of two of the pathways that 
result in its inhibition, namely the MAPK/RSK and PI3K/Akt pathways (Gu et al., 1999; Li 
et al., 2010; Zhang et al., 2014). This could explain why the levels of phospho-GSK3β (Ser9) 
decrease, post GSK3β inhibition. The levels of phospho-GSK3β (Ser9) increased in the 
WHCO1 and WHCO5 cell lines, post GSK3β inhibition. This was unexpected and the exact 
reasons for this occurring are not completely understood, but it may be due to the activation 
of other salvage pathways that inhibit GSK3β activity. Pathways that promote the activation 
of PKA, PKB and PKC may promote the phosphorylation of GSK3β, post GSK3β inhibition 
(Fang et al., 2000; Kim et al., 2007; Jope and Johnson, 2004; Stambolic and Woodgett, 1994; 
Pap and Cooper, 1998).   
In the second subgroup, RSK activity promoted FAK activation within the SNO and WHCO3 
cell lines (Figure 14). The SNO cell line was fascinating in that the levels of FAK activation 
decreased post RSK inhibition (under both environmental conditions) (by ±10 %), post 
GSK3β inhibition (by 31 %) and post RSK/GSK3β inhibition (by 36 %, statistically 
significant) within the SNO cell line. The cellular levels of naturally inhibited GSK3β 
(phospho-GSK3β (Ser9)) also decreased throughout all of the inhibition studies, indicating 
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that the RSK inhibitor was active within this cell line (Appendix B, Section 2.4.). The levels 
of β-catenin, targeted for ubiquitination decreased in SNO cells exposed to either a RSK 
inhibitor or a GSK3β inhibitor. When both proteins were inhibited the levels of β-catenin, 
targeted for ubiquitination, increased within the SNO cells. This was unexpected as the loss 
of GSK3β, responsible for the phosphorylation of β-catenin should result in a decrease in 
phospho-β-catenin (Ser33, Ser37 & Thr41). This may be due to the activation of PKC within 
this cell line, as discussed previously (A431 cells) (Raab et al., 2009).  
However it appears as though GSK3β activity plays a more prominent role in FAK 
activation, within this cell line, than RSK. The loss of GSK3β promoted a 31 % decrease in 
the cellular levels of active FAK. The inhibition of both RSK and GSK3β resulted in a 36 % 
decrease in the levels of active FAK. It appears as though the majority of the losses in FAK 
activation were incurred due to the loss of GSK3β activity and not due to the loss of RSK 
(BI-D1870). Nevertheless as the levels of FAK activation did decrease slightly more upon the 
loss of both proteins, it is possible that RSK promotes FAK activation, via an alternative 
pathway or directly, within the SNO cells. This mechanism of FAK activation only accounted 
for 10 % of the active levels of FAK within this cell line. However, perhaps this pathway has 
a more prominent role in FAK activation when the HOSCC cells are placed under different 
environmental conditions. It would be interesting to see whether this RSK-dependent FAK 
activation pathway plays a more prominent role in maintaining FAK activation within SNO 
cells that are placed under conditions of anchorage independence or oxidative stress 
(spatiotemporal response).  Therefore it appears as though RSK activates FAK within the 
SNO cell line, using a mechanism that is independent of its regulation of GSK3β. It is also 
important to note that GSK3β appears to play a prominent role in activating FAK within this 
cell line. This activation may in part be due to the destabilization of PTEN but as this cell line 
contains very low levels of this tumour suppressor, perhaps GSK3β modulates FAK 
activation directly (Figure 14) (John et al., 2012; Maccario et al., 2007; Sapkota et al., 2007; 
Gu et al., 1999; Li et al., 2010; Zhang et al., 2014). 
RSK appears to activate FAK within the WHCO3 cells. The inhibition of RSK, 24 hours after 
serum stimulation, resulted in diminished cellular levels of active FAK and inhibited GSK3β, 
by 33 and 42 % respectively. The loss in FAK activation appears to be statistically 
significant. This suggests that RSK promoted FAK activation within the WHCO3 cells 
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possibly through its inhibition of GSK3β.  It is possible that GSK3β inhibits FAK activation 
within these cells. This theory was substantiated by the increased levels of FAK activation 
noted when GSK3β activity was further suppressed, post RSK inhibition (serum stimulation). 
The activation of PKC, activated by G-protein coupled receptors, or PKA, activated via c-
AMP/PKA pathways, may have been responsible for the sustained levels of GSK3β 
inhibition noted when the WHCO3 cells were stimulated with both serum and the RSK 
inhibitor (Chapter 3, Section 3.3.4.) (Fang et al., 2000; Kim et al.,2007; Jope and Johnson, 
2004; Stambolic and Woodgett, 1994; Pap and Cooper, 1998).  Akt is unlikely to play a role 
in FAK activation as the activity of this protein is minimal within the WHCO3 cells (Shaw 
and Veale, 2012). 
 Interestingly, the inhibition of GSK3β, by AR-A014481, resulted in higher levels of FAK 
activation being noted within the WHCO3 cells. Again the levels of phospho-β-catenin 
decreased upon the loss of GSK3β activity, as seen in the A431 cells. PKC may have 
compensated for the loss of GSK3β activity by targeting β-catenin for degradation in its 
absence (Raab et al., 2009). Should PKC be active within this cell line, as it may be within 
the WHCO1 cells, it could be  responsible, in part for the extreme increase in FAK (by 99 %) 
activation, noted upon the loss of GSK3β activity (Lewis et al., 1996). This activation of 
PKC may have masked the effects GSK3β inhibition had on FAK activation. However, it 
does appear as though GSK3β inhibits FAK activation within these cells. It is possible that 
GSK3β may directly inhibit FAK activation, as previous studies have implied that GSK3β 
may inhibit FAK activity by phosphorylation (Domoto et al., 2016; Kobayashi et al., 2006; 
Bianchi et al., 2005; Sutherland, 2011). 
The loss of both RSK and GSK3β activity, by dual inhibition, resulted in a significant 
decrease in the endogenous levels of active FAK, by 17 %. This suggests that the 
RSK/GSK3β pathway promoted FAK activation within this cell line, however the ectopic 
activation of FAK, via this mechanism, was only partly responsible for the activation of FAK 
within these cells (naturally). Here cell-ECM based signalling, EGFR based signalling and 
the signalling of other growth factor receptor pathways, such as the vascular endothelial 
growth factor, may be responsible for the remaining levels of FAK activation, within the 
HOSCC cell lines (Hwang et al., 2011; Takahashi et al., 1999; Yamada and Geiger, 1997; 
Park et al., 2016). Whether RSK activates FAK directly or promotes FAK activation solely 
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through the inhibition of GSK3β is unknown. In the future, co-immunoprecipitations should 
be performed to determine whether FAK directly associates with RSK or not. This will 
provide more insight into the mechanisms by which RSK regulates FAK activation (direct 
activation of FAK by RSK).  
Lastly the role RSK plays in FAK activation, within the WHCO6 cell line, is not clearly 
defined but it is possible that RSK may act in both capacities, inhibitor/activator, within this 
cell line. Upon the inhibition of RSK the levels of inactive GSK3β and active FAK, 
significantly, increased within the WHCO6 cell line (24 hours after serum stimulation). It 
therefore appears as though RSK inhibits FAK activation. The loss of RSK promoted the 
activation of salvage pathways within the WHCO6 cells. It is likely that PI3K/Akt pathway is 
responsible for maintaining/upregulating the levels of GSK3β inhibition within these cells, 
mimicking the activity of RSK and masking the effect of the inhibitor on RSK-dependent 
GSK3β inhibition (Zouq et al., 2009). The PI3K/Akt pathway is highly active within this cell 
line, containing the highest levels of active Akt/PKB of all of the HOSCC cell lines (Shaw 
and Veale, 2012). As GSK3β inhibition was upregulated, by 38 %, within these cell lines, it 
is possible that the loss of GSK3β activity may have been responsible for the increase in the 
cellular levels of active FAK. GSK3β may promote FAK inhibition and its loss resulted in 
the activation of FAK. This was corroborated by the fact that increasing levels of active 
GSK3β resulted in decreased levels of active FAK within the WHCO6 cells, post RSK 
inhibition (with Serum stimulation). This was further confirmed by the inhibition of GSK3β, 
by AR-A014481 within these cells. The loss of GSK3β activity resulted in large increases in 
FAK activation within this cell line. Therefore GSK3β inhibits FAK activity within this cell 
line. It appears as though RSK promotes FAK activation by inhibiting GSK3β activity.  
It would appear as though both proteins inhibit FAK activation, as the levels of active FAK 
will increase upon the loss of either protein. The loss of both RSK and GSK3β resulted in a 
55 % decrease in the endogenous levels of active FAK. This implies that a combination of 
both proteins activity is essential for the activation of 55 % of the endogenous levels of active 
FAK within these cells. Had RSK promoted FAK activation solely through the inhibition of 
GSK3β, the loss of GSK3β/RSK (dual inhibitions studies) should have resulted in the levels 
of active FAK increasing in an almost identical fashion to that which was noted for the levels 
of FAK, post GSK3β inhibition. However, this was not the case suggesting that to a degree 
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both GSK3β and RSK may promote FAK activation individualy. How RSK and GSK3β 
regulate FAK activation within this cell line is largely unknown. It is possible that RSK may 
salvage FAK activation upon the loss of GSK3β and that GSK3β may salvage FAK 
activation upon the loss of RSK. Alternatively both of these proteins may impact the activity 
of other proteins that play a role in FAK activation. This would suggest that one protein may 
promote the activation of FAK in the absence of the other protein and vice versa, 
compensating for each other semi-redundantly under certain environmental conditions.  
It is possible that both RSK and GSK3β activate and inhibit FAK within this cell line. RSK 
may promote FAK activation via its regulation of Liver kinase B1 (LKB1), which is known 
to inhibit FAK activity, whilst GSK3β may promote FAK activation via the 
inhibition/destabilisation of PTEN (Maccario et al., 2007; Sapkota et al., 2007; Martin et al., 
2009; Sapkota et al., 2001; Kline et al., 2013; Yoneda et al., 2010) (Figure 14).  Although 
this cell line has low levels of PTEN, suggesting that GSK3β activity may employ alternative 
pathways to activate FAK within the WHCO6 cell line (Driver and Veale, 2006). It is 
important to note that the role GSK3β plays in tumorigenesis appears to be two sided, as this 
protein appears to promote and inhibit FAK activation depending on the environmental 
stimuli the cells are exposed to  (Grassilli et al., 2013; Zheng et al., 2007; Guturi et al., 
2012). This duplicity may also in part explain the unusual effects the inhibition studies had on 
FAK activation within this cell line.   
The HOSCC cell lines were therefore broadly classified into 3 different categories. The 
WHCO5, WHCO1 and HT29 cell lines appear to act similarly in that RSK appears to inhibit 
FAK activation within these cell lines, in part through its inhibition of GSK3β. RSK appeared 
to activate FAK within the SNO and WHCO3 cell lines. Lastly the role the WHCO6 cell line 
had on FAK activation is not clearly defined, but it is thought that RSK may act in both 
capacities, inhibitor/activator, within this cell line. However none of the above mentioned 
pathways resulted in vast decreases in the cellular levels of active FAK. This would suggest 
that these cell lines employ alternative mechanisms to promote FAK activation ectopically, 
over and above RSK-dependent FAK activation. Interestingly the Aurora kinase A (AURKA) 
is thought to promote cell migration and invasion in HNSCC by activating FAK and Akt (Wu 
et al., 2016). Perhaps the ectopic activation of FAK, within the HOSCC cells, may be caused 
by the activity of AURKA instead of RSK (Wu et al., 2016). 
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Lastly the role RSK plays in FAK activation appears to be context dependent. In a study 
conducted by Torchiaro and colleagues, RSK promoted the secretion of fibronectin, in 
ovarian cancer cells via the activation of the YB-1 protein and transforming growth factor-β1 
(TGF-β1) (Torchiaro et al., 2016). The synthesis and secretion of fibronectin is known to 
promote cell metastasis and allow cells to survive under conditions of anchorage 
independence (Torchiaro et al., 2016). Fibronectin secretion assists in promoting cell survival 
in suspension by promoting the activation of α5β6 integrins (essential for cell adhesion and 
cell spreading) (Duperret et al., 2015; Torcharo et al., 2016). Fascinatingly, the activation of 
α5β6 integrins, by fibronectin, could result in the activation of FAK acting as an alternative 
mechanism by which RSK-dependent FAK activation may be achieved within neoplasmic 
cells grown in suspension.  
Indeed, human oral squamous cell carcinomas cells (SCC), when placed under conditions of 
anchorage independence, formed multicellular aggregates that promoted Fibronectin 
deposition, probably via the same RSK activated pathway noted in ovarian cancer cells 
(Zhang et al., 2004; Torchiaro et al., 2016). These cell aggregates had high levels of FAK 
activation likely due to the RSK-dependent secretion of fibronectin and the subsequent 
activation of the α5β6 integrin. This indicated that RSK may indirectly activate FAK by 
promoting the transformation of the microenviroment in which the HOSCC cells are found 
(Zhang et al., 2004; Duperret et al., 2015). This pathway appears to play a more prominant 
role in sustaining the anoikis resistant phenotype of cancerous cells placed under conditions 
of anchorage independence (Zhang et al., 2004; Duperret et al., 2015). It is therefore possible 
that RSK may indirectly activate FAK within these multicellular aggregates in order to 
promote cell survival in suspension. This may also explain, in part, why RSK-dependent 
FAK activation is context dependent (a spatio-temperal response) (Zhang et al., 2004; 
Duperret et al., 2015). 
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 Figure 14. (A, B, C and D). A schematic representation of the possible 
mechanisms by which RSK regulates FAK activation within the HOSCC cell 
lines. 
Green represents active proteins whilst red represents proteins that are inactive 
(images produced using Microsoft Paint ©). Red lines represent inhibition. The direct 
activation of FAK by RSK or GSK3β is indicated by a purple arrow. A. RSK impedes 
FAK activation, indirectly, by inhibiting GSK3β (which activates FAK). (Heading 
continues on the following page) 
A. 
B. 
C. 
D. 
Cell  
survival  Cell  
survival  
Cell  
survival  
Cell  
survival  
82 
  
 
 
 B. PKC may promote FAK activation in the absence of GSK3β activity. RSK still 
hinders FAK activation by inhibiting GSK3β, thus allowing PTEN to remain active (a 
known antagonist of FAK). C. GSK3β activity promotes FAK activation by 
destabilising PTEN, a known inhibitor of FAK. D. RSK regulates LKB1 activity and 
may therefore either hinder or promote FAK activation via this protein. The image 
was produced by making use of the information provided from papers published from 
Maccario et al., 2007; Sapkota et al., 2007; Martin et al., 2009; Sapkota et al., 2001; 
Kline et al., 2013; Yoneda et al.,2010; Raab et al., 2009 Lewis et al., 1996. (LKB1: 
Liver kinase B1; PKC: Protein kinase C; PTEN: Phosphatase and tensin homolog 
deleted in chromosome 10 FAK: Focal adhesion kinase; RSK: p90 Ribosomal S6 
kinase; PI-3K: Phosphatidylinositol-3 kinase) 
 
 
4.4.3. Link to therapeutics and future prospects: 
FAK activity is associated with EMT, cancer stem cells, metastasis, invasion, cell motility, 
anoikis resistance and cell survival based signalling (Infusino and Jacobson, 2012; 
Golubovskaya, 2014; Ho et al., 2009) . In HOSCC cells the reduction of FAK activation and 
Rac1, by introducing microRNA-92b-3p, decreased lymph node metastases by supressing 
cell motility (Ma et al., 2016). Cancer cells that have high levels of EGFR, like the HOSCC 
cell lines and the non-small cell lung cancers, are known to become resistant to 
chemotherapeutics that target this receptor by undergoing an EMT transition (Wilson et al., 
2014; Fanucchi and Veale, 2009; Veale and Thornley, 1989). The FAK/Src pathway is 
thought to promote this EMT-associated resistance to chemotherapeutics (Wilson et al., 
2014). Therefore the inhibition of FAK may also render cells susceptible to anti-cancer 
agents (Wilson et al., 2014). In fact the inhibition of FAK in 3D human and neck squamous 
cell carcinoma cells rendered them susceptible to radiotherapy indicating that FAK activation 
also promotes chemo-resistance (Hehlgans et al., 2009). There is a large body of evidence to 
support the notion that FAK is a promising drug target for anti-cancer therapeutics (Kurio et 
al., 2012). The loss of this protein, by use of inhibitors such as TAE226, inhibited cell 
proliferation, invasion and anchorage independent growth in oral squamous cell carcinomas 
(Kurio et al., 2012). However FAK is a challenging protein to target. Predominantly as FAK 
acts as both a scaffolding protein and non-receptor tyrosine kinase. In its scaffolding capacity 
it is known to mediate the degradation of p53 and is even known to mediate endophilin A2 
phosphorylation, which promotes invasion, in mammary tumours (Fan et al., 2013; Lim et 
al., 2008). FAK inhibitors have already began clinical trials however the efficacy of these 
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inhibitors are underwhelming, with acquired resistance to the inhibitor being responsible for 
the poor inhibitor responses (Marlowe et al., 2016). It is interesting that some have found that 
receptor tyrosine kinases can by-pass the inhibition by promoting the direct phosphorylation 
of Tyr397. This would suggest that receptor tyrosine kinases may impact patient responses to 
FAK inhibitors (Marlowe et al., 2016).  As FAK inhibition is challenging, and yields 
undesirable side effects, scientists have looked at the inhibition of its activator, β1 integrin, as 
a possible alternative to blocking the protein directly (Li et al., 2015).  
 
For this reason the role RSK plays in the FAK activation pathway was explored. RSK 
promotes metastasis, EMT and invasion making it a promising target for anti-cancer 
therapeutics (Sulzmaier and Ramos, 2013). In breast cancer cells the inhibition of RSK, and 
hence the inhibition of YB-1, sensitised breast cancer cells to chemotherapy (Davies et al., 
2015). This suggests that RSK activity promotes cancer relapses and ultimately links to poor 
prognoses (Davis et al., 2015).  p90RSK is a more attractive target for anticancer therapeutic, 
than FAK, as it is thought that the inhibition of this protein may have less harmful side effects 
(Neise et al., 2013). RSK is a promising target for anti-cancer therapeutics, despite only 
promoting FAK activation within 2 of the 5 HOSCC cell lines. However, as its role in the 
HOSCC cells also appears to be context specific, it may be more appropriate for RSK 
inhibitors to be used in combination with other targeted chemotherapeutics in an attempt to 
ward of cancer resurgence. Also since RSK inhibits FAK activation in most of the HOSCC 
cell lines, it would appear that the inhibition of GSK3β may be a more promising therapeutic 
target for the inhibition of FAK activity within the HOSCC cell lines.  
GSK3β is a mysterious protein in that it appears to be both anti-tumorigenic and pro-
tumorigenic. Cancers with inhibited GSK3β and active EGFR are thought to correlate with 
higher mortality rates as the suppression of GSK3β promotes the Wnt/β-catenin pathway 
(Zheng et al., 2007). Interestingly a further link between GSK3β inhibition, EGFR 
overexpression and β-catenin was made. In a study conducted by Guturi and colleagues, cross 
talk between β-catenin and EGFR was found in GSK3β inactivated prostate cancer (Guturi et 
al., 2012). It is suggested that the loss of GSK3β promotes β-catenin activity. β-catenin was 
found to transcribe EGFR leading to increased cell survival and proliferation (Guturi et al., 
2012). In contrast the inhibition of GSK3B in pancreatic cancer cells promoted apoptosis and 
84 
  
 
 
forced the cells into senescence (Zhou et al., 2012).  Globally the inhibition of GSK3B also 
reduced tumour growth size and angiogenesis (Zhou et al., 2012) 
In the current study FAK activation appears to be promoted in part, by the activation of 
GSK3β in some of the HOSCC cells. Fascinatingly, GSK3β promotes that activation of 
MDM2, by phosphorylation in the central kinase domain of MDM2 (Kulikov et al., 2005). 
The phosphorylation, of MDM2 by GSK3β, promoted its activity resulting in MDM2-
mediated p53 degradation (Kulikove et al., 2005). It is interesting that the same protein that 
activates MDM2 also promotes the activation of FAK, a scaffolding protein that assist in 
MDM2-mediated p53 degradation (Kulikove et al., 2005; Lim et al., 2008). Therefore 
GSK3β promoted cell survival based signalling by targeting p53 for degradation (Kulikove et 
al., 2005; Lim et al., 2008).  This was corroborated by a study that found that GK3β 
sustained chemo-resistance by promoting the loss of p53 (Grassilli et al., 2013). The 
inhibition of this protein sensitized cancer to chemotherapeutics such as 5-fluorouracil. 
Fascinatingly the FAK/MEK/ERK pathway has also been linked 5-fluorouracil resistance 
(Yang et al., 2016). This would suggest that GSK3β may play a prominent role in chemo 
resistance through the activation of FAK.  
As GSK3β activity acts more as a master switch that either promotes or inhibits neoplasmic 
transformations depending on the environment in which it is found, the inhibition of this 
protein as a target for anti-cancer therapeutic may be challenging. There is no doubt that the 
inhibition of this protein may impede cancer growth and improve overall patient prognoses 
by inhibiting FAK activation and p53-mediated degradation (Grassilli et al., 2013). However 
this may only occur in cancers with a specific proteome profile. Cancer cells that are more 
reliant on the Wnt/β-catenin pathway are unlikely to benefit from the loss of GSK3β, within 
these cells, as that would further promote Wnt pathway based signalling (Zheng et al., 2007). 
Therefore although GSK3β activates FAK, within some of the HOSCC cell lines, the 
inhibition of this protein may be too hazardous to capitalize on. Perhaps GSK3β may act in 
combination with other chemotherapeutics such as 5-flourouracil to improve its efficacy 
under specific circumstances.  
The combination of GSK3β and RSK inhibition resulted in reduced levels of FAK 
inactivation in most of the HOSCC cell lines. This suggests that the combination of these 
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inhibitors could be used to inhibit FAK activation within most of the HOSCC cells. However, 
as predicted above, the loss of GSK3β did promote β-catenin stabilization in some of the 
HOSCC cells.  This may counteract anti-proliferative effects the dual inhibition is likely to 
have on the HOSCC cells. Experiments should be performed to determine whether the dual 
inhibition of RSK/GSK3β results in reduced cell viability, reduced invasion or promotes 
anoikis susceptibility within the HOSCC cell lines. If this were indeed the case then the dual 
inhibition of both of these proteins may be a promising anti-cancer therapeutic for the 
treatment of most HOSCC cell lines.   
Future work may also involve looking at the role RSK and GSK3β play in anchorage 
independent growth. This is particularly interesting as RSK is thought to play a more 
prominent role in pro-survival based signalling under conditions of anchorage independence 
(Aronchik et al., 2014). Therefore the loss of cell-ECM based attachment could result in 
RSK- dependent FAK activation. In an attempt to ascertain the exact effects serum plays in 
promoting spatiotemporal responses, further research will have to be performed to determine 
how/if growth factors rescue the effects of the GSK3β and RSK inhibitors within HOSCC 
cell lines. Lastly as RSK-mediated fibronectin secretion is thought to promote sustained FAK 
activation in cells placed in suspension; it would be interesting to see if supressing 
RSK/fibronectin secretion would diminish the HOSCC cells ability to survive in suspension 
(Duperret et al., 2015; Torchiaro et al., 2016; Meng et al., 2009). Lastly the role PKC 
pathway plays in the HOSCC cells should be elucidated.  
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5. Conclusion 
 
p90RSK does not appear to activate or inhibit FAK directly, in most of the HOSCC cells, but 
rather modulates FAK activation through the inhibition of GSK3β. The role RSK, or GSK3β, 
plays in FAK activation, within HOSCC cells, cannot be generalised as it appears to be 
context dependent. The dysregulation of certain molecular pathways which underlie the 
diseased state within HOSCC cell lines appears to be variable. Here the effects the 
RSK/GSK3β pathway had on FAK activation was partially dependent on the HOSCC cells 
containing active levels of PTEN. It appears as though the inhibition of both GSK3β and 
RSK reduced the levels of active FAK in 3 of the 5 HOSCC cell lines, suggesting that this 
might be a good anti-cancer therapeutic. The general trends in the current paper suggest that 
the grading system for moderately differentiated carcinomas needs to be improved. RSK 
appears to play a context specific role in FAK activation and this adds an additional layer of 
complexity that will challenge scientists that are searching for targeted anti-cancer 
therapeutics. This paper also highlights the importance of studying the effects the 
microenvironment has on neoplasmic transformations.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
87 
  
 
 
Reference list: 
 
Abnet, C. C., Qiao, Y. L., Dawsey, S. M., Dong, Z. W., Taylor, P. R. and Mark, S. D. (2005). Tooth 
loss is associated with increased risk of total death and death from upper gastrointestinal cancer, heart 
disease, and stroke in a Chinese population-based cohort. International Journal of 
Epidemiology, 34(2): 467-474. 
Aguirre, G. J. (2002). Inhibition of FAK signalling activated by urokinase receptor induces dormancy 
in human carcinoma cells in vivo. Oncogene, 21(16): 2513-2524. 
Aksamitiene, E., Kiyatkin, A. and Kholodenko, B. N. (2012). Cross-talk between mitogenic 
Ras/MAPK and survival PI3K/Akt pathways: a fine balance. Biochemical Society 
Transactions, 40(1): 139-146. 
Anjum, R. and Blenis, J. (2008). The RSK family of kinases: emerging roles in cellular signalling. 
Nature Reviews. Molecular Cell Biology, 9(10): 747-758. doi:10.1038/nrm2509. 
Arkun, Y. (2016). Dynamic Modeling and Analysis of the Cross-Talk between Insulin/AKT and 
MAPK/ERK Signaling Pathways. PloS One, 11(3): e0149684. 
Aronchik, I., Appleton, B. A., Basham, S. E., Crawford, K., Del Rosario, M., Doyle, L. V., Estacio, 
W. F., Lan, J., Lindvall, M. K., Luu, C. A. and Ornelas, E. (2014). Novel potent and selective 
inhibitors of p90 ribosomal S6 kinase reveal the heterogeneity of RSK function in MAPK-driven 
cancers. Molecular Cancer Research, 12(5): 803-812. 
Aust, S., Auer, K., Bachmayr-Heyda, A., Denkert, C., Sehouli, J., Braicu, I., Mahner, S., Lambrechts, 
S., Vergote, I., Grimm, C. and Horvat, R. (2014). Ambivalent role of pFAK-Y397 in serous ovarian 
cancer-a study of the OVCAD consortium. Molecular Cancer, 13(1): 1. 
Ballif, B. A., Roux, P. P., Gerber, S. A., MacKeigan, J. P., Blenis, J. and Gygi, S. P. (2005). 
Quantitative phosphorylation profiling of the ERK/p90 ribosomal S6 kinase-signaling cassette and its 
targets, the tuberous sclerosis tumor suppressors. Proceedings of the National Academy of Sciences of 
the United States of America, 102(3): 667-672. 
 
Belmokhtar, C. A., Hillion, J., and Ségal-Bendirdjian, E. (2001). Staurosporine induces apoptosis 
through both caspase-dependent and caspase-independent mechanisms. Oncogene, 20(26): 3354-
3362. 
Bershadsky, A. D., Ballestrem, C., Carramusa, L., Zilberman, Y., Gilquin, B., Khochbin, S., 
Alexandrova, A. Y., Verkhovsky, A. B., Shemesh, T. and Kozlov, M. M. (2006). Assembly and 
mechanosensory function of focal adhesions: experiments and models. European Journal of Cell 
Biology, 85(3-4): 165-173. doi:10.1016/j.ejcb.2005.11.001. 
Bey, E., Alexander, J., Whitcutt, J. N., Hunt, J. A. and Gear, J. H. S. (1976). Carcinoma of the 
oesophagus in Africans: establishment of a continuously growing cell line from a tumour specimen. In 
Vitro, 12: 107-114. 
88 
  
 
 
Bhat, R., Xue, Y., Berg, S., Hellberg, S., Ormö, M., Nilsson, Y., Radesäter, A-C., Jerning, E., 
Markgren, P-O., Borgegård, T., Nylöf, M., Giménez-Cassina, A., Hernández, F., Lucas, J. J., Diaz-
Nido, J. and Avila, J. (2003). Structural insights and biological effects of glycogen synthase kinase 3-
specific inhibitor AR-A014418. Journal of Biological Chemistry, 278(46): 45937-45945. 
Bianchi, M., De Lucchini, S., Marin, O., Turner, D. L., Hanks, S. K. and Villa-Moruzzi, E. (2005). 
Regulation of FAK Ser-722 phosphorylation and kinase activity by GSK3 and PP1 during cell 
spreading and migration. Biochemical Journal, 391(2): 359-370. 
Bolos, V., Gasent, J. M., Lopez-Tarruella, S. and Grande, E. (2010). The dual kinase complex FAK-
Src as a promising therapeutic target in cancer. OncoTargets and Therapy, 3: 83-97. 
Bossi, G., Lapi, E., Strano, S., Rinaldo, C., Blandino, G. and Sacchi, A. (2006). Mutant p53 gain of 
function: reduction of tumor malignancy of human cancer cell lines through abrogation of mutant p53 
expression. Oncogene, 25: 304-309. 
Bradford, M. M. (1976). A rapid and sensitive method for the quantitation of microgram quantities of 
protein utilizing the principle of protein-dye binding. Analytical Biochemistry, 72: 248-254. 
Bramhall, S., Novack, N., Wu, M. and Loewenberg, J. R. (1969). A Simple Colorimetric Method for 
the Determination of Protein. Analytical Biochemistry, 31: 146-148. 
Brami-Cherrier, K., Gervasi, N., Arsenieva, D., Walkiewicz, K., Boutterin, M. C., Ortega, A., 
Leinard, P. G., Seantier, B., Gasmi, L., Bouceba, T., Kadar, G., Girault, J-A. and Arold, S. T. (2014). 
FAK dimerization controls its kinase-dependent functions at focal adhesions. The EMBO 
Journal, 33(4): 356-370. 
Brett, K. E., Ferraro, Z. M., Yockell-Lelievre, J., Gruslin, A., and Adamo, K. B. (2014). Maternal–
Fetal Nutrient Transport in Pregnancy Pathologies: The Role of the Placenta. International Journal of 
Molecular Sciences, 15(9): 16153-16185. 
Brindley, D. A., Davie, N. L., Culme-Seymour, E. J., Mason, C., Smith, D. W. and Rowley, J. A. 
(2012). Peak serum: implications of serum supply for cell therapy manufacturing. Regenerative 
Medicine, 7(1): 7-13. 
Brockbank, E. C., Bridges, J., Marshall, C. J. and Sahai, E. (2005). Integrin β1 is required for the 
invasive behaviour but not proliferation of squamous cell carcinoma cells in vivo. British Journal of 
Cancer, 92(1): 102-112. 
Calalb, M. B. and Polte, T. R. (1995). Tyrosine phosphorylation of focal adhesion kinase at sites in 
the catalytic domain regulates kinase activity҅: a role for Src family kinases . These include҅: 
Tyrosine Phosphorylation of Focal Adhesion Kinase at Sites in the Catalytic Domain Regulates Kin. 
Molecular and Cellular Biology, 15(2): 954-963. 
Canel, M., Secades, P., Rodrigo, J. and Suarez, C. (2006). Human Cancer Biology Overexpression of 
Focal Adhesion Kinase in Head and Neck Squamous Cell Carcinoma Is Independent of fak Gene 
Copy Number. Clinical Cancer Research, 12(11): 3272-3280. 
89 
  
 
 
Carlson, M. A., Longaker, M. T. and Thompson, J. S. (2004). Modulation of FAK, Akt , and p53 by 
Stress Release of the Fibroblast-Populated Collagen Matrix 1 , 2. Journal of Surgical Research, 120: 
171-177. 
Caron-Lormier, G. and Berry, H. (2005). Amplification and oscillations in the FAK/Src kinase system 
during integrin signalling. Journal of Theoretical Biology, 232(2): 235-248. 
Carpenter, G. and Cohen, S. (1990). Epidermal growth factor. Journal of Biological Chemistry, 
265(14): 7709-7712. 
Carragher, N. O. and Frame, M. C. (2004). Focal adhesion and actin dynamics: a place where kinases 
and proteases meet to promote invasion. Trends Cell Biology, 14: 241-249. 
Carriere, A., Ray, H., Blenis, J. and Roux, P. P. (2008). The RSK factors of activating the Ras/MAPK 
signaling cascade. Frontiers in Bioscience, 13(10): 4258-4275. 
Čáslavský, J., Klímová, Z. and Vomastek, T. (2013). ERK and RSK regulate distinct steps of a 
cellular program that induces transition from multicellular epithelium to single cell phenotype. 
Cellular Signalling, 25: 2743-2751. 
Castellsague, X., Munoz, N., De Stefani, E., Victora, C. G., Castelletto, R. and Rolon, P. A. (2000). 
Influence of mate drinking, hot beverages and diet on esophageal cancer risk in South 
America. International Journal of Cancer, 88: 658-664. 
Chandra, S. H. V., Wacker, I., Appelt, U. K., Behrens, J., and Schneikert, J. (2012). A common role 
for various human truncated adenomatous polyposis coli isoforms in the control of beta-catenin 
activity and cell proliferation. PloS One, 7(4): e34479. 
Chen, J., Lan, T., Zhang, W., Dong, L., Kang, N., Zhang, S., Fu, M., Liu, B., Liu, K., Zhang, C. and 
Hou, J., (2015). Platelet-activating factor receptor-mediated PI3K/AKT activation contributes to the 
malignant development of esophageal squamous cell carcinoma. Oncogene, 34(40): 5114-5127. 
Chen, Y., Xin, X., Li, J., Xu, J., Yu, X., Li, T., Mo, Z. and Hu, Y. (2013). RTK/ERK pathway under 
natural selection associated with prostate cancer. PloS One, 8(11): 78254. 
 
Childs, C. B., Proper, J. A., Tucker, R. F. and Moses, H. L. (1982). Serum contains a platelet-derived 
transforming growth factor. Proceedings of the National Academy of Sciences, 79(17): 5312-5316. 
Chiu, C. F., Bai, L. Y., Kapuriya, N., Peng, S. Y., Wu, C. Y., Sargeant, A. M., Chen, M. Y. and 
Weng, J. R. (2014). Antitumor effects of BI-D1870 on human oral squamous cell carcinoma. Cancer 
Chemotherapy and Pharmacology, 73(2): 237-247. 
 
Clement, D. L., Mally, S., Stock, C., Lethan, M., Satir, P., Schwab, A., Pedersen, S. F. and 
Christensen, S. T. (2013). PDGFRα signaling in the primary cilium regulates NHE1-dependent 
fibroblast migration via coordinated differential activity of MEK1/2–ERK1/2–p90RSK and AKT 
signaling pathways. Journal of Cell Science, 126(4): 953-965. 
 
90 
  
 
 
Cook, D., Fry, M. J., Hughes, K., Sumathipala, R., Woodgett, J. R. and Dale, T. C. (1996).Wingless 
inactivates glycogen synthase kinase-3 via an intracellular signalling pathway which involves a 
protein kinase C. EMBO Journal, 15(1): 4526-4536.ISSN: 0261-4189. 
Cooper, H. (2016). Epidermal growth factors and cancer. Available at: 
http://www.abcam.com/index.html?pageconfig=resource&rid=10723 (Accessed: 19 January 2017). 
Cram, E. J. and Schwarzbauer, J. E. (2004). The talin wags the dog: new insights into integrin 
activation. Trends in Cell Biology, 14(2): 55-57. 
Dajani, R., Fraser, E., Roe, S.M., Young, N., Good, V., Dale, T.C. and Pearl, L.H. (2001). Crystal 
structure of glycogen synthase kinase 3β: structural basis for phosphate-primed substrate specificity 
and autoinhibition. Cell, 105(6): 721-732. 
Davies, A. H., Reipas, K., Hu, K., Berns, R., Firmino, N., Stratford, A. L. and Dunn, S. E. (2015). 
Inhibition of RSK with the novel small-molecule inhibitor LJI308 overcomes chemoresistance by 
eliminating cancer stem cells. Oncotarget, 6(24): 20570. 
 
Davies, A. H., Reipas, K., Hu, K. and Dunn, S. E. (2015). YB-1 enhances ABCG2 expression in 
breast cancer to elicit chemoresistance that can be circumvented using RSK 
inhibitors. Oncotarget, 6(24): 20570-20577. 
Degasperi, A., Birtwistle, M. R., Volinsky, N., Rauch, J., Kolch, W. and Kholodenko, B. N. (2014). 
Evaluating strategies to normalise biological replicates of Western blot data. PloS One, 9(1): e87293. 
del Pulgar, T. G., Cebrián, A., Fernández-Aceñero, M. J., Borrero‐ Palacios, A., del Puerto-Nevado, 
L., Martínez-Useros, J., Marín-Arango, J. P., Caramés, C., Vega-Bravo, R., Rodríguez-Remírez, M. 
and Cruz-Ramos, M. (2016). Focal adhesion kinase: predictor of tumour response and risk factor for 
recurrence after neoadjuvant chemoradiation in rectal cancer. Journal of Cellular and Molecular 
Medicine, 20(9): 1729. 
Deng, F., Zhou, K., Cui, W., Liu, D. and Ma, Y. (2015). Clinicopathological significance of Wnt/beta-
catenin signaling pathway in esophageal squamous cell carcinoma. International Journal of Clinical 
and Experimental Pathology, 8(3): 3045-3053. 
Di, F., Giorgio, P., Soste, M., Feng, Y. and Picotti, P. (2013). ScienceDirect Reproducibility of 
combinatorial peptide ligand libraries for proteome capture evaluated by selected reaction monitoring. 
Journal of Proteomics, 89: 215-226. doi:10.1016/j.jprot.2013.05.037. 
Doble, B. W. and Woodgett, J. R. (2003). GSK-3: tricks of the trade for a multi-tasking 
kinase. Journal of Cell Science, 116(7): 1175-1186. 
Doehn, U., Hauge, C., Frank, S. R., Jensen, C. J., Duda, K., Nielsen, J. V, Cohen, M.S., Johansen, 
J.V., Winther, R.B., Lund, L.R., Winther, O., Taunton, J., Hansen, S.H. and Frödin, M. (2009). RSK 
Is a Principal Effector of the RAS-ERK Pathway for Eliciting a Coordinate Promotile/Invasive Gene 
Program and Phenotype in Epithelial Cells. Molecular Cell, 35(4): 511-522. 
91 
  
 
 
Domoto, T., Pyko, I.V., Furuta, T., Miyashita, K., Uehara, M., Shimasaki, T., Nakada, M. and 
Minamoto, T. (2016). Glycogen synthase kinase-3β is a pivotal mediator of cancer invasion and 
resistance to therapy. Cancer Science. 
Driver, G. A. (2007). Integrin-linked Kinase (ILK) Expression in Moderately Differentiated Human 
Oesophageal Squamous Carcinoma Cell Lines-Growth Factor Modulation, Activity and Link to 
Adhesion (Doctoral dissertation, Faculty of Science, University of the Witwatersrand). 
Driver, G. A. and Veale, R. B. (2006). Modulation of integrin-linked kinase (ILK) expression in 
human oesophageal squamous cell carcinoma cell lines by the EGF and TGF beta1 growth factors. 
Cancer Cell International, 6: 12. 
Dunty, J. M., Gabarra-niecko, V., King, M. L., Ceccarelli, D. F. J., Eck, M. J., Michael, D. and 
Schaller, M. D. (2004). FERM Domain Interaction Promotes FAK Signaling. Molecular and Cellular 
Biology, 24: 5353-5368. 
Duperret, E. K., Dahal, A. and Ridky, T. W. (2015). Focal-adhesion-independent integrin-αv 
regulation of FAK and c-Myc is necessary for 3D skin formation and tumor invasion. Journal of Cell 
Science, 128(21): 3997-4013. 
 
Eke, I., Deuse, Y., Hehlgans, S., Gurtner, K., Krause, M., Baumann, M., Shevchenko, A., Sandfort, V. 
and Cordes, N. (2012). β1 Integrin/FAK/cortactin signaling is essential for human head and neck 
cancer resistance to radiotherapy. The Journal of Clinical Investigation, 122(4): 1529. 
Embi, N., Rylatt, D. B. and Cohen, P. (1980). Glycogen synthase kinase-3 from rabbit skeletal 
muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. European 
Journal Biochemistry, 107: 519-527. 
Faber, A. C., Li, D., Song, Y., Liang, M. C., Yeap, B. Y., Bronson, R. T., Lifshits, E., Chen, Z., 
Maira, S. M., García-Echeverría, C. and Wong, K. K. (2009). Differential induction of apoptosis in 
HER2 and EGFR addicted cancers following PI3K inhibition. Proceedings of the National Academy 
of Sciences, 106(46): 19503-19508. 
Fan, H., Zhao, X., Sun, S., Luo, M. and Guan, J. L. (2013). Function of focal adhesion kinase 
scaffolding to mediate endophilin A2 phosphorylation promotes epithelial-mesenchymal transition 
and mammary cancer stem cell activities in vivo. Journal of Biological Chemistry, 288(5): 3322-
3333. 
 
Fang, X., Yu, S. X., Lu, Y., Bast, R. C., Woodgett, J. R. and Mills, G. B. (2000). Phosphorylation and 
inactivation of glycogen synthase kinase 3 by protein kinase A. Proceedings of the National Academy 
of Science, 97: 11960-11965. 10.1073/pnas.220413597. 
Fanucchi, S. and Veale, R. B. (2009). Role of p53/FAK association and p53Ser46 phosphorylation in 
staurosporine-mediated apoptosis: wild type versus mutant p53-R175H. FEBS Letter, 583: 3557-
3562. 
Ferlay, J., Soerjomataram, I., Ervik, M., Dikshit, R., Eser, S., Mathers, C., Rebelo, M., Parkin, D. M., 
Forman, D. and Bray, F. (2013). GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality 
92 
  
 
 
Worldwide: IARC CancerBase No. 11 [Internet].Lyon, France: International Agency for Research on 
Cancer; 2013. Available from: http://globocan.iarc.fr, accessed on day/month/year. 
Fiol, C. J., Mahrenholz, A. M., Wang, Y., Roeske, R. W. and Roach, P. J. (1987). Formation of 
protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for 
the synergistic action of casein kinase II and glycogen synthase kinase 3. Journal of Biological 
Chemistry, 262(29): 14042-14048. 
Fischer, J. J., Graebner, O. Y., Dalhoff, C., Michaelis, S., Schrey, A. K., Ungewiss, J., Andrich, K., 
Jeske, D., Kroll, F., Glinski, M. and Sefkow, M. (2010). Comprehensive identification of 
staurosporine-binding kinases in the hepatocyte cell line HepG2 using Capture Compound Mass 
Spectrometry (CCMS). Journal of Proteome Research, 9(2): 806-817. 
Fonar, Y. and Frank, D. (2011). FAK and Wnt signaling: the meeting of two pathways in cancer and 
development. Anti-Cancer Agents in Medicinal Chemistry (Formerly Current Medicinal Chemistry-
Anti-Cancer Agents), 11(7): 600-606. 
Fonar, Y., Gutkovich, Y. E., Root, H., Malyarova, A., Aamar, E., Golubovskaya, V. M., Elias, S., 
Elkouby, Y. M. and Frank, D. (2011). Focal adhesion kinase protein regulates Wnt3a gene expression 
to control cell fate specification in the developing neural plate. Molecular Biology of the Cell, 22(13): 
2409-2421. 
Frame, S., Cohen, P. and Biondi, R. M. (2001). A common phosphate binding site explains the unique 
substrate specificity of GSK3 and its inactivation by phosphorylation. Molecular Cell, 7(6): 1321-
1327. 
Frankel, A., Rosen, K., Filmus, J. and Kerbel, R. S. (2001). Induction of Anoikis and Suppression of 
Human Ovarian Tumor Growth in Vivo by Down-Regulation of Bcl-X L Induction of Anoikis and 
Suppression of Human Ovarian Tumor Growth in Vivo by. Cancer Research, 61: 4837-4841. 
Frisch, S. M. and Jolla, L. (1996). Control of Adhesion-dependent Cell Survival by Focal Adhesion 
Kinase. The Journal of Cell Biology, 134(3): 793-799. 
Frisch, S. M. and Francis, H. (1994). Disruption of epithelial cell-matrix interactions induces 
apoptosis. Journal of Cell Biology, 124: 619-626. 
Frödin, M. and Gammeltoft, S. (1999). Role and regulation of 90 kDa ribosomal S6 kinase (RSK) in 
signal transduction. Molular and Cellular Endocrinology, 151: 65-77. 
Fu, W., Hall, J. E. and Schaller, M. D. (2012). Focal adhesion kinase-regulated signaling events in 
human cancer. Biomolecular Concepts, 3(3): 225-240. 
Fuchs, S. Y., Ougolkov, A. V., Spiegelman, V. S. and Minamoto, T. (2005). Oncogenic β-catenin 
signaling networks in colorectal cancer. Cell Cycle, 4(11): 1522-1539. ISSN: 1551-4005. 
 
Gawecka, J. E., Young-Robbins, S. S., Sulzmaier, F. J., Caliva, M. J., Heikkila, M. M., Matter, M. L. 
and Ramos, J. W. (2012). RSK2 Protein Suppresses Integrin Activation and Fibronectin Matrix 
Assembly and Promotes Cell Migration. Journal of Biological Chemistry, 287: 43424-43437. 
93 
  
 
 
Gayanilo, M., Passariello, C., Negro, A. and Danial, J. B. (2014). Anchored p90 Ribosomal S6 Kinase 
3 is Required for Cardiac Myocyte Hypertrophy. Circulation Research, 112: 128-139. 
Ge, C., Wu, S., Wang, W., Liu, Z., Zhang, J., Wang, Z., Li, R., Zhang, Z., Li, Z., Dong, S. and Wang, 
Y. (2015).  miR-942 promotes cancer stem cell-like traits in esophageal squamous cell carcinoma 
through activation of Wnt/β-catenin signalling pathway. Oncotarget, 6(13): 10964. 
Golubovskaya, V. M. (2014). Targeting FAK in human cancer: from finding to first clinical 
trials. Frontiers in Bioscience (Landmark edition), 19: 687. 
 
Golubovskaya, V. M., Figel, S., Ho, B. T., Johnson, C. P., Yemma, M., Huang, G., Zheug, M., 
Nyberg, C., Magis, A., Ostrov, D. A., Gelman, H.I. and Cance, W. G. (2012). A small molecule focal 
adhesion kinase (FAK) inhibitor, targeting Y397 site: 1-(2-hydroxyethyl)-3, 5, 7-triaza-1-
azoniatricyclo [3.3. 1.13, 7] decane; bromide effectively inhibits FAK autophosphorylation activity 
and decreases cancer cell viability, clonogenicity and tumor growth in vivo. Carcinogenesis, bgs120. 
 
Golubovskaya, V. M., Gross, S., Kaur, A. S., Wilson, R. I., Xu, L. H., Yang, X. H. and Cance, W. G. 
(2003). Simultaneous inhibition of focal adhesion kinase and SRC enhances detachment and apoptosis 
in colon cancer cell lines. Molecular Cancer Research, 1(10): 755-764. 
Golubovskaya, V. M., Kweh, F. A. and Cance, W. G. (2009).  Focal adhesion kinase and cancer. 
Histology and Histopathology, 24: 503-510. 
Golubovskaya, V. M., Zheng, M., Zhang, L., Li, J. L. and Cance, W. G. (2009). The direct effect of 
focal adhesion kinase (FAK), dominant-negative FAK, FAK-CD and FAK siRNA on gene expression 
and human MCF-7 breast cancer cell tumorigenesis. BMC cancer, 9(1): 280. 
Goode, N., Hughes, K., Woodgett, J. R. and Parker, P.  J. (1992).  Differential regulation of glycogen 
synthase kinase-3 beta by protein kinase C isotypes. Journal of Biological Chemistry, 267(24): 16878-
16882. 
Gordon, J. A. (1991). Use of vanadate as protein-phosphotyrosine phosphatase inhibitor. Methods in 
Enzymology, 201: 477-482. 
Graham, K., Serrels, A., Serrels, B., Brunton, V. G. and Frame, M. C. (2010). FAK Deletion 
Promotes Increased Radioresistance in a Wildtype Trp53 Mouse Squamous Cell Carcinoma Cell Line 
by p53 Mediated Induction of p21. International Journal of Radiation Oncology Biology, 78: S111-
S112. 
Grassilli, E., Narloch, R., Federzoni, E., Ianzano, L., Pisano, F., Giovannoni, R., Romano, G., 
Masiero, L., Leone, B. E., Bonin, S. and Donada, M. (2013). Inhibition of GSK3B bypass drug 
resistance of p53-null colon carcinomas by enabling necroptosis in response to 
chemotherapy. Clinical Cancer Research, 19(14): 3820-3831. 
 
Grimes, C. A. and Jope, R. S. (2001). The multifaceted roles of glycogen synthase kinase 3β in 
cellular signaling. Progress in Neurobiology, 65(4): 391-426. 
94 
  
 
 
Gu, J., Tamura, M., Pankov, R., Danen, E. H., Takino, T., Matsumoto, K. and Yamada, K. M. (1999). 
Shc and FAK differentially regulate cell motility and directionality modulated by PTEN. The Journal 
of Cell Biology, 146(2): 389-404. 
Guturi, K. K. N., Mandal, T., Chatterjee, A., Sarkar, M., Bhattacharya, S., Chatterjee, U. and Ghosh, 
M. K. (2012). Mechanism of β-catenin-mediated transcriptional regulation of epidermal growth factor 
receptor expression in glycogen synthase kinase 3 β-inactivated prostate cancer cells. Journal of 
Biological Chemistry, 287(22): 18287-18296. 
Halder, J., Landen, C. N., Lutgendorf, S. K., Li, Y., Jennings, N. B., Fan, D., Nelkin, G. M., 
Schmandt, R., Schaller, M. D. and Sood, A. K. ( 2005). Focal adhesion kinase silencing augments 
docetaxel-mediated apoptosis in ovarian cancer cells. Clinical Cancer Research, 11(24): 8829-8836. 
Han, M., Wen, J. K., Zheng, B., Cheng, Y. and Zhang, C. (2006). Serum deprivation results in 
redifferentiation of human umbilical vascular smooth muscle cells. American Journal of Physiology-
Cell Physiology, 291(1): C50-C58. 
Hansen, L., Arden, K. C., Rasmussen, S. B., Viars, C. S., Vestergaard, H., Hansen, T.,Meller, A. M., 
Woodgett, J. R. and Pedersen, O. (1997). Chromosomal mapping and mutational analysis of the 
coding region of the glycogen synthase kinase-3α and β isoforms in patients with 
NIDDM. Diabetologia, 40(8): 940-946. 
Hasan, R., Srivastava, G., Alyass, A., Sharma, R., Saraya, A., Chattopadhyay, T. K., DattaGupta, S., 
Walfish, P. G., Chauhan, S. S. and Ralhan, R. (2016). Prediction of recurrence free survival for 
esophageal cancer patients using a protein signature based risk model. Oncotarget, 5: 1-11. 
 
Heavey, S., O’Byrne, K. J. and Gately, K. (2014). Strategies for co-targeting the PI3K/AKT/mTOR 
pathway in NSCLC. Cancer Treatment Reviews, 40(3): 445-456. 
Hehlgans, S., Lange, I., Eke, I. and Cordes, N. (2009). 3D cell cultures of human head and neck 
squamous cell carcinoma cells are radiosensitized by the focal adhesion kinase inhibitor 
TAE226. Radiotherapy and Oncology, 92(3): 371-378. 
 
Hendricks, D. and Parker, M. I. (2002). Oesophageal cancer in Africa. IUBMB Life, 53(4-5): 263-268. 
 
Hill, M. W. and Mackenzie, I. C. (1984). The influence of differing connective tissue substrates on the 
maintenance of adult stratified squamous epithelia. Cell and Tissue Research, 237(3): 473- 478. 
Hinoi, T., Yamamoto, H., Kishida, M., Takada, S., Kishida, S., and Kikuchi, A. (2000). Complex 
formation of adenomatous polyposis coli gene product and Axin facilitates glycogen synthase kinase-
3β-dependent phosphorylation of β-catenin and down-regulates β-catenin. Journal of Biological 
Chemistry, 275(44): 34399-34406. 
Ho, Y. T., Yang, J. S., Li, T. C., Lin, J. J., Lin, J. G., Lai, K. C., Ma, C. Y., Wood, W. G. and Chung, 
J. G. (2009). Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous 
cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and-9. Cancer 
Letters, 279(2): 155-162. 
95 
  
 
 
 
Ho, Y. T., Yang, J. S., Li, T. C., Lin, J. J., Lin, J. G., Lai, K. C., Ma, C. Y., Wood, W. G. and Chung, 
J. G. (2009). Berberine suppresses in vitro migration and invasion of human SCC-4 tongue squamous 
cancer cells through the inhibitions of FAK, IKK, NF-κB, u-PA and MMP-2 and-9. Cancer 
Letters, 279(2): 155-162. 
 
Hwang, Y. P., Yun, H. J., Choi, J. H., Han, E. H., Kim, H. G., Song, G. Y., Kwon, K. I., Jeong, T. C. 
and Jeong, H. G. (2011). Suppression of EGF‐ induced tumor cell migration and matrix 
metalloproteinase‐ 9 expression by capsaicin via the inhibition of EGFR-mediated FAK/Akt, 
PKC/Raf/ERK, p38 MAPK, and AP‐ 1 signaling. Molecular Nutrition and Food Research, 55(4): 
594-605. 
Iamaroon, A., and Krisanaprakornkit, S. (2009). Overexpression and activation of Akt2 protein in oral 
squamous cell carcinoma. Oral Oncology, 45(10): e175-e179. 
Infusino, G. A. and Jacobson, J. R. (2012). Endothelial FAK as a therapeutic target in 
disease. Microvascular Research, 83(1): 89-96. 
 
Isohata, N., Aoyagi, K., Mabuchi, T., Daiko, H., Fukaya, M., Ohta, H., Ogawa, K., Yoshida, T. and 
Sasaki, H. (2009). Hedgehog and epithelial-mesenchymal transition signaling in normal and 
malignant epithelial cells of the esophagus. International Journal of Cancer. Journal International Du 
Cancer, 125(5): 1212-1221. doi:10.1002/ijc.24400. 
Jacquot, S., Merienne, K., De Cesare, D., Pannetier, S., Mandel, J. L., Sassone-Corsi, P. and Hanauer, 
A. (1998). Mutation analysis of the RSK2 gene in Coffin-Lowry patients: extensive allelic 
heterogeneity and a high rate of de novo mutations. The American Journal of Human Genetics, 63(6): 
1631-1640. 
Jamali, Y., Jamali, T. and Mofrad, M. R. K. (2013). An agent based model of integrin clustering: 
Exploring the role of ligand clustering, integrin homo-oligomerization, integrin–ligand affinity, 
membrane crowdedness and ligand mobility. Journal of Computational Physics, 244: 264-278. 
doi:10.1016/j.jcp.2012.09.010. 
James, G. T. (1978). Inactivation of the protease inhibitor phenylmethylsulfonyl fluoride in buffers. 
Analytical Biochemistry, 86(2): 574-579. 
Jankowski, J., Henders, K., Viaene, A., Baert, J. and Long, L. Q. (1995). Morphological analysis of 
gastro-esophageal diseases by molecular cell techniques. Microscopy Research and Technique, 31(3): 
184-192. 
John, J. K., Paraiso, K. H., Rebecca, V. W., Cantini, L. P., Abel, E. V., Pagano, N., Meggers, E., 
Mathew, R., Krepler, C., Izumi, V. and Fang, B. (2012). GSK3β inhibition blocks melanoma cell/host 
interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation. Journal 
of Investigative Dermatology, 132(12): 2818-2827. 
96 
  
 
 
Jones, S. W., Erikson, E., Blenis, J., Maller, J. L. and Erikson, R. L. (1988). A Xenopus ribosomal 
protein S6 kinase has two apparent kinase domains that are each similar to distinct protein kinases. 
Proceedings of the National Academy of Sciences of the United States of America, 85(10): 3377-3381. 
Jope, R. S. and Johnson, G. V. W. (2004). The glamour and gloom of glycogen synthase kinase-3. 
Trends in Biochemical Sciences, 29(2): 95-102. doi:10.1016/j.tibs.2003.12.004. 
Kallergi, G., Mavroudis, D., Georgoulias, V. and Stournaras, C. (2007). Phosphorylation of FAK, PI-
3K, and impaired actin organization in CK-positive micrometastatic breast cancer cells. Molecular 
Medicine-Cambridge MA then New York, 13(1-2): 79. 
Kang, S., Elf, S., Lythgoe, K., Hitosugi, T., Taunton, J., Zhou, W., Xiong, L., Wang, D., Muller, S., 
Fan, S. and Sun, S. Y. (2010). p90 ribosomal S6 kinase 2 promotes invasion and metastasis of human 
head and neck squamous cell carcinoma cells. The Journal of Clinical Investigation, 120(4): 1165-
1177. 
 
Kao, W. T., Lin, C. Y., Lee, L. T., Lee, P. P. H., Hung, C. C., Lin, Y. S., Chen, S. H., Ke, F. C., 
Hwang, J. J. and Lee, M. T. (2008). Investigation of MMP-2 and-9 in a highly invasive A431 tumor 
cell sub-line selected from a Boyden chamber assay. Anticancer Research, 28(4B): 2109-2120. 
Karelina, K., Alzate-Correa, D. and Obrietan, K. (2014). Ribosomal S6 kinase regulates ischemia-
induced progenitor cell proliferation in the adult mouse hippocampus. Experimental Neurology, 253: 
72-81. 
Katz, B. Z., Miyamoto, S., Teramoto, H., Zohar, M., Krylov, D., Vinson, C., Gutkind, J. S. and 
Yamada, K. M. (2002). Direct transmembrane clustering and cytoplasmic dimerization of focal 
adhesion kinase initiates its tyrosine phosphorylation. Biochimica et Biophysica Acta (BBA)-
Molecular Cell Research, 1592(2): 141-152. 
Kholodenko, B. N., Hoek, J. B., Westerhoff, H. V. and Brown, G. C. (1997). Quantification of 
information transfer via cellular signal transduction pathways. FEBS Letters, 414(2): 430-434. 
Kim, M., Datta, A., Brakeman, P., Yu, W. and Mostov, K. E. ( 2007). Polarity proteins PAR6 and 
aPKC regulate cell death through GSK-3β in 3D epithelial morphogenesis. Journal of Cell 
Science, 120(14): 2309-2317. 
Kim, M. J., Lee, J. H., Kim, Y. K., Myoung, H., and Yun, P. Y. (2007). The role of tamoxifen in 
combination with cisplatin on oral squamous cell carcinoma cell lines. Cancer Letters, 245(1): 284-
292. 
Kitano, A., Shimasaki, T., Chikano, Y., Nakada, M., Hirose, M., Higashi, T., Ishigaki, Y., Endo, Y., 
Takino, T., Sato, H., Sai, Y., Miyamoto, K., Motoo, Y., Kawakami, K. and Minamoto, T. (2013). 
Aberrant glycogen synthase kinase 3β is involved in pancreatic cancer cell invasion and resistance to 
therapy. PloS One, 8(2): e55289. 
Kline, E. R., Shupe, J., Gilbert-Ross, M., Zhou, W. and Marcus, A. I. (2013). LKB1 represses focal 
adhesion kinase (FAK) signaling via a FAK-LKB1 complex to regulate FAK site maturation and 
directional persistence. Journal of Biological Chemistry, 288(24): 17663-17674. 
97 
  
 
 
Kobayashi, T., Hino, S., Oue, N., Asahara, T., Zollo, M., Yasui, W. and Kikuchi, A. (2006). 
Glycogen synthase kinase 3 and h-prune regulate cell migration by modulating focal adhesions. 
Molecular Cell Biology, 26(3): 898-911, ISSN: 0270-7306. 
 
Koivisto, L., Alavian, K., Häkkinen, L., Pelech, S., McCulloch, C. A., and Larjava, H. (2003). 
Glycogen synthase kinase-3 regulates formation of long lamellipodia in human keratinocytes. Journal 
of Cell Science, 116(18): 3749-3760. 
Krieghoff, E., Behrens, J. and Mayr, B. (2006). Nucleo-cytoplasmic distribution of β-catenin is 
regulated by retention. Journal of Cell Science, 119(7): 1453-1463. 
Kuang, E., Wu, F. and Zhu, F. (2009). Mechanism of Sustained Activation of Ribosomal S6 Kinase 
(RSK) and ERK by Kaposi Sarcoma-associated Herpesvirus ORF45 multiprotein complexes retain 
active phosphorylated ERK and RSK and protect them from dephosphorylation. Journal of Biological 
Chemistry, 284(20): 13958-13968. 
 
Kulikov, R., Boehme, K. A. and Blattner, C. (2005). Glycogen synthase kinase 3-dependent 
phosphorylation of Mdm2 regulates p53 abundance. Molecular and Cellular Biology, 25(16): 7170-
7180. 
 
Kurio, N., Shimo, T., Fukazawa, T., Okui, T., Hassan, N. M. M., Honami, T., Horikiri, Y., 
Hatakeyama, S., Takaoka, M., Naomoto, Y. and Sasaki, A. (2012). Anti-tumor effect of a novel FAK 
inhibitor TAE226 against human oral squamous cell carcinoma. Oral Oncology, 48(11): 1159-1170. 
 
Kwong, K. Y., Zou, Y., Day, C. P. and Hung, M. C. (2002). The suppression of colon cancer cell 
growth in nude mice by targetingβ-catenin/TCF pathway. Oncogene, 21(54). 
 
Laemmli, U. K. (1970). Cleavage of Structural Proteins During the Assembly of the Head of 
Bacteriophage T4.  Nature, 227: 680-685. 
Languino, L. R., Singh, A., Prisco, M., Inman, G. J., Luginbuhl, A., Curry, J. M. and South, A. P. 
(2016). Exosome-mediated transfer from the tumor microenvironment increases TGFβ signaling in 
squamous cell carcinoma. American Journal of Translational Research, 8(5): 2432-2437. 
Le Guellec, S., Moyal, E. C. J., Filleron, T., Delisle, M. B., Chevreau, C., Rubie, H., Castex, M. P., de 
Gauzy, J. S., Bonnevialle, P. and Gomez-Brouchet, A. (2013). The β5/focal adhesion kinase/glycogen 
synthase kinase 3β integrin pathway in high-grade osteosarcoma: a protein expression profile 
predictive of response to neoadjuvant chemotherapy. Human Pathology, 44(10): 2149-2158. 
Leighton, I. A., Dalby, K. N., Caudwell, F. B., Cohen, P. T. and Cohen, P. (1995). Comparison of the 
specificities of p70 S6 kinase and MAPKAP kinase-1 identifies a relatively specific substrate for p70 
S6 kinase: the N-terminal kinase domain of MAPKAP kinase-1 is essential for peptide 
phosphorylation. FEBS Letters, 375(3): 289-293. 
Leong, M. L., Maiyar, A. C., Kim, B., O'Keeffe, B. A. and Firestone, G. L. (2003). Expression of the 
serum-and glucocorticoid-inducible protein kinase, Sgk, is a cell survival response to multiple types 
98 
  
 
 
of environmental stress stimuli in mammary epithelial cells. Journal of Biological Chemistry, 278(8): 
5871-5882. 
Levkau, B., Herren, B., Koyama, H., Ross, R. and Raines, E. W. (1998). Caspase-mediated cleavage 
of focal adhesion kinase pp125FAK and disassembly of focal adhesions in human endothelial cell 
apoptosis. The Journal of Experimental Medicine, 187(4): 579-586. 
Lewis, J. M., Cheresh, D. A. and Schwartz, M. A. (1996). Protein kinase C regulates alpha v beta 5-
dependent cytoskeletal associations and focal adhesion kinase phosphorylation. The Journal of Cell 
Biology, 134(5): 1323-1332. 
Li, B., Li, J., Xu, W. W., Guan, X. Y., Qin, Y. R., Zhang, L.Y., Law, S., Tsao, S. W. and Cheung, A. 
L. (2014). Suppression of esophageal tumor growth and chemoresistance by directly targeting the 
PI3K/AKT pathway. Oncotarget, 5(22): 11576. 
 
Li, D., Jin, L., Alesi, G. N., Kim, Y-M., Fan, J., Seo, J. H., Wang, D., Tucker, M., Gu, T-L., Lee, B. 
H., Taunton, J., Magliocca, K. R., Chen, Z. G.,Shin, D. M., Khuri, F. R. and Kang, S. (2013). The 
prometastatic ribosomal S6 kinase 2-cAMP response element-binding protein (RSK2-CREB) 
signaling pathway up-regulates the actin-binding protein fascin-1 to promote tumor metastasis. 
Journal of Biological Chemistry, 288: 32528-32538. 
Li, D. W., Sun, Y. J., Sun, Z. F. and Dong, P. (2012). Involvement of focal adhesion kinase in cellular 
proliferation, apoptosis and prognosis of laryngeal squamous cell carcinoma. The Journal of 
Laryngology and Otology, 126(11): 1127-1133. 
Li, J. P., Fu, Y. N., Chen, Y. R. and Tan, T. H. (2010). JNK pathway-associated phosphatase 
dephosphorylates focal adhesion kinase and suppresses cell migration. Journal of Biological 
Chemistry, 285(8): 5472-5478. 
 
Li, L. Y., Jiang, H., Xie, Y. M., Liao, L. D., Cao, H. H., Xu, X. E., Chen, B., Zeng, F. M., Zhang, Y. 
L., Du, Z. P. and Chen, H. (2015). Macrolide analog F806 suppresses esophageal squamous cell 
carcinoma (ESCC) by blocking β1 integrin activation. Oncotarget, 6(18): 15940. 
 
Li, M., Jiang, X., Liu, D., Na, Y., Gao, G. F. and Xi, Z. (2008). Autophagy protects LNCaP cells 
under androgen deprivation conditions. Autophagy, 4(1): 54-60. 
Lim, J., Kim, J. H., Paeng, J. Y., Kim, M. J., Hong, S. D., Lee, J. I., and Hong, S. P. (2005). 
Prognostic value of activated Akt expression in oral squamous cell carcinoma. Journal of Clinical 
Pathology, 58(11): 1199-1205. 
Lim, S. T., Chen, X. L., Lim, Y., Hanson, D. A., Vo, T. T., Howerton, K., K., Larocque, N., Fisher, S. 
J., Schlaepfer, D. D.  and Ilic, D. (2008). Nuclear FAK promotes cell proliferation and survival 
through FERM-enhanced p53 degradation. Molecular Cell, 29(1): 9-22. 
 
Liu, Y., Zhang, Y., Jia, K., Dong, Y. and Ma, W. (2015). Metformin inhibits the proliferation of A431 
cells by modulating the PI3K/Akt signaling pathway. Experimental and Therapeutic Medicine, 9(4): 
1401-1406. 
99 
  
 
 
 
Logue, J. S. and Morrison, D. K. (2012). Complexity in the signaling network: insights from the use 
of targeted inhibitors in cancer therapy. Genes and Development, 26(7): 641-650. 
Lu, Z., Jiang, G., Blume-Jensen, P. and Hunter, T. (2001). Epidermal growth factor-induced tumor 
cell invasion and metastasis initiated by dephosphorylation and downregulation of focal adhesion 
kinase. Molecular and Cellular Biology, 21(12): 4016-4031. 
Ly, D. P. and Corbett, S. (2005). The integrin alpha5beta1 regulates alphavbeta3-mediated 
extracellular signal-regulated kinase activation. The Journal of Surgical Research, 123(2): 200-205. 
doi:10.1016/j.jss.2004.08.015. 
Ma, G., Jing, C., Li, L., Huang, F., Ding, F., Wang, B., Lin, D., Luo, A. and Liu, Z. (2016). 
MicroRNA-92b represses invasion-metastasis cascade of esophageal squamous cell 
carcinoma. Oncotarget, 7(15): 20209-20222. 
 
Maccario, H., Perera, N. M., Davidson, L., Downes, C. P. and Leslie, N. R. (2007). PTEN is 
destabilized by phosphorylation on Thr366. Biochemical Journal, 405(3): 439-444. 
MacDonald, B. T., Tamai, K. and He, X. (2009). Wnt/β-catenin signaling: components, mechanisms, 
and diseases. Developmental Cell, 17(1): 9-26. 
Mai, W., Kawakami, K., Shakoori, A., Kyo, S., Miyashita, K., Yokoi, K., Jin, M., Shimasaki, T., 
Motoo, Y. and Minamoto, T. (2009). Deregulated GSK3 beta sustains gastrointestinal cancer cells 
survival by modulating human telomerase reverse transcriptase and telomerase. Clinical Cancer 
Research, 15(22): 6810-6819. ISSN: 1078-0432. 
 
Manoukian, A. S. and Woodgett, J. R. (2002). Role of glycogen synthase kinase-3 in cancer: 
regulation by Wnts and other signaling pathways. Advanced Cancer Research, 84: 203-229, ISSN: 
0065-230X. 
 
Marlowe, T. A., Lenzo, F. L., Figel, S. A., Grapes, A. T. and Cance, W. G. (2016). Oncogenic 
Receptor Tyrosine Kinases Directly Phosphorylate Focal Adhesion Kinase (FAK) as a Resistance 
Mechanism to FAK-Kinase Inhibitors. Molecular Cancer Therapeutics, 15(12): 3028-3039. 
 
Margadant, C., Kreft, M., de Groot, D-J., Norman, J. C. and Sonnenberg, A. (2012). Distinct roles of 
talin and kindlin in regulating integrin α5β1 function and trafficking. Current Biology, 22(17): 1554-
1563. doi:10.1016/j.cub.2012.06.060. 
Martin, M. J., Carling, D. and Marais, R. (2009). Taking the stress out of melanoma. Cancer 
Cell, 15(3): 163-164. 
Mendoza, M. C., Er, E. E. and Blenis, J. (2011). The Ras-ERK and PI3K-mTOR pathways: cross-talk 
and compensation. Trends in Biochemical Sciences, 36(6): 320-328. 
 
100 
  
 
 
Meng, X. N., Jin, Y., Yu, Y., Bai, J., Liu, G. Y., Zhu, J., Zhao, Y. Z., Wang, Z., Chen, F., Lee, K. Y. 
and Fu, S. B. (2009). Characterisation of fibronectin-mediated FAK signalling pathways in lung 
cancer cell migration and invasion. British Journal of Cancer, 101(2): 327-334. 
Mitra, S. K., Hanson, D. A. and Schlaepfer, D. D. (2005). Focal adhesion kinase: in command and 
control of cell motility. Nature Reviews Molecular Cell Biology, 6(1): 56-68. 
 
Mitra, S. K., and Schlaepfer, D. D. (2006). Integrin-regulated FAK-Src signaling in normal and 
cancer cells. Current Opinions in Cell Biology, 18: 516-523. 
Miyamoto, S., Teramoto, H. and Gutkind, J. S. (1996). Integrins Can Collaborate with Growth Factors 
for Phosphorylation of Receptor Tyrosine Kinases and MAP Kinase Activation: Roles of Integrin 
Aggregation and Occupancy of Receptors. The Journal of Cell Biology, 135(6): 1633-1642. 
Miyazaki, T., Kato, H., Nakajima, M., Sohda, M., Fukai, Y., Masuda, N., Manda, R., Fukuchi, M., 
Tsukada, K. and Kuwano, H. (2003). FAK overexpression is correlated with tumour invasiveness and 
lymph node metastasis in oesophageal squamous cell carcinoma. British Journal of Cancer, 89(1): 
140-145. 
Morin, P. J., Vogelstein, B. and Kinzler, K. W. (1996). Apoptosis and APC in colorectal 
tumorigenesis. Proceedings of the National Academy of Sciences, 93(15): 7950-7954. 
Nakakuki, T., Birtwistle, M. R., Saeki, Y., Yumoto, N., Ide, K., Nagashima, T., Brusch, L., 
Ogunnaike, B. A., Okada-Hatakeyama, M. and Kholodenko, B. N. (2010). Ligand-specific c-Fos 
expression emerges from the spatiotemporal control of ErbB network dynamics. Cell, 141(5): 884-
896. 
Neise, D., Sohn, D., Stefanski, A., Goto, H., Inagaki, M., Wesselborg, S., Budach, W., Stühler, K. and 
Jänicke, R. U. (2013). The p90 ribosomal S6 kinase (RSK) inhibitor BI-D1870 prevents gamma 
irradiation-induced apoptosis and mediates senescence via RSK-and p53-independent accumulation of 
p21WAF1/CIP1. Cell Death and Disease, 4(10): e859. 
Nguyen, T. L. (2008). Targeting RSK: an overview of small molecule inhibitors. Anti-Cancer Agents 
in Medicinal Chemistry (Formerly Current Medicinal Chemistry-Anti-Cancer Agents), 8(7): 710-716. 
Nolan, K., Lacoste, J. and Parsons, J. T. (1999). Regulated expression of focal adhesion kinase-related 
nonkinase, the autonomously expressed C-terminal domain of focal adhesion kinase. Molecular and 
Cellular Biology, 19(9): 6120-6129. 
 
Ohashi, S., Natsuizaka, M., Wong, G. S., Michaylira, C. Z., Grugan, K. D., Stairs, D. B., Kalabis, J., 
Vega, M. E., Kalman, R. A, Nakagawa, M., Klein-Szanto, A. J., Herlyn, M., Diehl, J. A., Rustgil, A. 
K. and Nakagawal, K. (2010). Epidermal growth factor receptor and mutant p53 expand an 
esophageal cellular subpopulation capable of epithelial-to-mesenchymal transition through ZEB 
transcription factors. Cancer Research, 70: 4174-4184. 
Oshimori, N., Oristian, D. and Fuchs, E. (2015). TGF-β promotes heterogeneity and drug resistance in 
squamous cell carcinoma. Cell, 160(5): 963-976. 
101 
  
 
 
Ougolkov, A. V., Bone, N. D., Fernandez-Zapico, M. E., Kay, N. E. and Billadeau, D. D. (2007). 
Inhibition of glycogen synthase kinase-3 activity leads to epigenetic silencing of nuclear factor kappa 
target genes and induction of apoptosis in chronic lymphocytic leukemia B cells. Blood, 110(2): 735-
742, ISSN: 0006-4971. 
 
Ougolkov, A. V., Fernandez-Zapico, M. E., Savoy, D. N., Urrutia, R. A. and Billadeau, D. D. 
(2005). Glycogen synthase kinase-3beta participates in nuclear factor kappa B mediated gene 
transcription and cell survival in pancreatic cancer cells. Cancer Research, 65(6): 2076-2081, ISSN: 
0008-5472. 
 
Owen, J. D., Ruest, P. J., Fry, D. W. and Hanks, S. K. (1999). Induced focal adhesion kinase (FAK) 
expression in FAK-null cells enhances cell spreading and migration requiring both auto-and activation 
loop phosphorylation sites and inhibits adhesion-dependent tyrosine phosphorylation of 
Pyk2. Molecular and Cellular Biology, 19(7): 4806-4818. 
Panetti, T. S. (2002). Tyrosine phosphorylation of Paxillin, FAK and p130Cas: Effects on cell 
spreading and migration. Frontiers in Biosciences, (11): 143-150. 
Pap, M. and Cooper, G. M. (1998). Role of glycogen synthase kinase-3 in the phosphatidylinositol 3-
Kinase/Akt cell survival pathway. Journal of Biological Chemistry, 273(32): 19929-19932, ISSN: 
0021-9258. 
 
Park, J. H., Cho, Y. Y., Yoon, S. W. and Park, B. (2016). Suppression of MMP-9 and FAK expression 
by pomolic acid via blocking of NF-κB/ERK/mTOR signaling pathways in growth factor-stimulated 
human breast cancer cells. International Journal of Oncology, 49(3):1230-1240. 
Parsons, J. T. (2003). Focal adhesion kinase: the first ten years. Journal of Cell Science, 116(8): 1409-
1416. doi:10.1242/jcs.00373. 
Petit, V. and Thiery, J. P. (2000). Focal adhesions: structure and dynamics. Biology of the Cell, 92: 
477-494. 
Powers, J. C., Asgian, J. L., Ekici, Ö. D. and James, K. E. (2002). Irreversible inhibitors of serine, 
cysteine, and threonine proteases. Chemical Reviews, 102(12): 4639-4750. 
Qi, Y., Wang, J. K., McMillian, M. and Chikaraishi, D. M. (1997). Characterization of a CNS cell 
line, CAD, in which morphological differentiation is initiated by serum deprivation. The Journal of 
Neuroscience, 17(4): 1217-1225. 
Qi, Z., Bu, X., Huang, P., Zhang, N., Han, S., Fang, L. and Li, J. (2007). Increased membrane/nuclear 
translocation and phosphorylation of p90 KD ribosomal S6 kinase in the brain of hypoxic 
preconditioned mice. Neurochemical Research, 32(9): 1450-1459. doi:10.1007/s11064-007-9331-z. 
Qian, X., Tan, C., Wang, F., Yang, B., Ge, Y., Guan, Z. and Cai, J. (2016). Esophageal cancer stem 
cells and implications for future therapeutics. OncoTargets and Therapy, 9: 2247. 
 
102 
  
 
 
Raab, M. S., Breitkreutz, I., Tonon, G., Zhang, J., Hayden, P. J., Nguyen, T., Fruehauf, J. H., Lin, B. 
K., Chauhan, D., Hideshima, T. and Munshi, N. C. (2009). Targeting PKC: a novel role for beta-
catenin in ER stress and apoptotic signaling. Blood, 113(7): 1513-1521. 
Rahman, T., Tsujikawa, T., Yamamoto, M., Chino, Y., Shinagawa, A., Kurokawa, T., Tsuchida, T., 
Kimura, H., Yoshida, Y. and Okazawa, H. (2016). Different Prognostic Implications of 18F-FDG 
PET Between Histological Subtypes in Patients With Cervical Cancer. Medicine, 95(9). 
Rangaswami, H., Schwappacher, R., Tran, T., Chan, G. C., Zhuang, S., Boss, G. R. and Pilz, R. B. 
(2012). Protein kinase G and focal adhesion kinase converge on Src/Akt/β-catenin signaling module 
in osteoblast mechanotransduction. Journal of Biological Chemistry, 287(25): 21509-21519. 
Rask, K., Nilsson, A., Brännström, M., Carlsson, P., Hellberg, P., Janson, P. O., Hedin, L. and 
Sundfeldt, K. (2003). Wnt-signalling pathway in ovarian epithelial tumours: increased expression of 
β-catenin and GSK3β. British Journal of Cancer, 89(7): 1298-1304. 
 
Redman, E. K., Brookes, P. S. and Karcz, M. K. (2013). Role of p90RSK in regulating the Crabtree 
effect: implications for cancer. Biochemical Society Transactions, 41(1): 124-126. 
 
Rees, J. R. E., Onwuegbusi, B., Save, V. E., Alderson, D. and Fitzgerald, R. C. (2006). In vivo and in 
vitro evidence for transforming growth factor-beta1-mediated epithelial to mesenchymal transition in 
esophageal adenocarcinoma. Cancer Research, 66(19): 9583-9590. doi:10.1158/0008-5472.CAN-06-
1842. 
Richards, S. A., Fu, J., Romanelli, A., Shimamura, A. and Blenis, J. (1999). Ribosomal S6 kinase 1 
(RSK1) activation requires signals dependent on and independent of the MAP kinase ERK. Current 
Biology, 9(15): 810-851. 
Rodrigo, J. P., Dominguez, F., Suárez, V., Canel, M., Secades, P. and Chiara, M. D. (2007). Focal 
adhesion kinase and E-cadherin as markers for nodal metastasis in laryngeal cancer. Archives of 
Otolaryngology–Head and Neck Surgery, 133(2): 145-150. 
Roseweir, A. K., Katz, A. A. and Millar, R. P. (2012). Kisspeptin-10 inhibits cell migration in vitro 
via a receptor-GSK3 beta-FAK feedback loop in HTR8SVneo cells. Placenta, 33(5): 408-415. 
Roux, P. P., Richards, S. A. and Blenis, J. (2003). Phosphorylation of p90 ribosomal S6 kinase (RSK) 
regulates extracellular signal-regulated kinase docking and RSK activity. Molecular and Cellular 
Biology, 23(14): 4796-4804. 
 
Saito, Y., Vandenheede, J. R. and Cohen, P. (1994). The mechanism by which epidermal growth 
factor inhibits glycogen synthase kinase 3 in A431 cells. Biochemical Journal, 303(1): 27-31. 
Santos, A., Bakker, A. D., Zandieh-Doulabi, B., de Blieck-Hogervorst, J. M. and Klein-Nulend, J. 
(2010). Early activation of the β-catenin pathway in osteocytes is mediated by nitric oxide, 
phosphatidyl inositol-3 kinase/Akt, and focal adhesion kinase. Biochemical and Biophysical Research 
Communications, 391(1): 364-369. 
103 
  
 
 
Sapkota, G. P., Cummings, L., Newell, F. S., Armstrong, C., Bain, J., Frodin, M., Grauert, M., 
Hoffmann, M., Schnapp, G., Steegmaier, M., Cohen, P. and Alessi, D. R. (2007). BI-D1870 is a 
specific inhibitor of the p90 RSK (ribosomal S6 kinase) isoforms in vitro and in vivo. Biochemical 
Journal, 401: 29-38. 
Sapkota, G. P., Kieloch, A., Lizcano, J. M., Lain, S., Arthur, J. S. C., Williams, M. R., Morrice, N., 
Deak, M. and Alessi, D. R. (2001). Phosphorylation of the protein kinase mutated in Peutz-Jeghers 
cancer syndrome, LKB1/STK11, at Ser431 by p90RSK and cAMP-dependent protein kinase, but not 
its farnesylation at Cys433, is essential for LKB1 to suppress cell growth. Journal of Biological 
Chemistry, 276(22): 19469-19482. 
Sasaki, H., Nagura, K., Ishino, M., Tobioka, H., Kotani, K. and Sasaki, T. (1995). Cloning and 
characterization of cell adhesion kinase β, a novel protein-tyrosine kinase of the focal adhesion kinase 
subfamily. Journal of Biological Chemistry, 270(36): 21206-21219. 
Serrels, A., McLeod, K., Canel, M., Kinnaird, A., Graham, K., Frame, M. C. and Brunton, V. G. 
(2012). The role of focal adhesion kinase catalytic activity on the proliferation and migration of 
squamous cell carcinoma cells. International Journal of Cancer, 131(2): 287-297. 
Severino, P., Alvares, A. M., Michaluart, P., Okamoto, O. K., Nunes, F. D., Moreira-Filho, C. A. and 
Tajara, E. H. (2008). Global gene expression profiling of oral cavity cancers suggests molecular 
heterogeneity within anatomic subsites. BMC Research Notes, 1(1):1. 
Shakoori, A., Mai, W., Miyashita, K., Yasumoto, K., Takahashi, Y., Ooi, A., Kawakami, K. and 
Minamoto, T. (2007). Inhibition of GSK-3 beta activity attenuates proliferation of human colon 
cancer cells in rodents. Cancer Sciences, 98(9): 1388-1393. ISSN: 
1347-9032. 
Shakoori, A., Ougolkov, A., Yu, Z. W., Zhang, B., Modarressi, M. H., Billadeau, D. D., Mai, 
M.,Takahashi, Y. and Minamoto, T. (2005). Deregulated GSK3beta activity in colorectal cancer: its 
association with tumor cell survival and proliferation. Biochemical and Biophysical Research 
Communications, 334(4): 1365-1373. ISSN: 0006-291X. 
Shaw, N. (2011). PI3K in Human Oesophageal Squamous Cell Carcinoma: A critical modulator in the 
PKB signalling pathway (Doctoral dissertation, Faculty of Science, University of the Witwatersrand). 
Shimizu, T., Ueda, J., Ho, J.C., Iwasaki, K., Poellinger, L., Harada, I. and Sawada, Y. (2012). Dual 
inhibition of Src and GSK3 maintains mouse embryonic stem cells, whose differentiation is 
mechanically regulated by Src signaling. Stem Cells, 30(7): 1394-1404. 
Sieg, D. J., Hauck, C. R., Ilic, D., Klingbeil, C. K., Schaefer, E., Damsky, C. H. and Schlaepfer, D. D. 
(2000). FAK integrates growth-factor and integrin signals to promote cell migration. Nature Cell 
Biology, 2(5): 249-256. 
Sieg, D. J., Ilić, D., Jones, K. C., Damsky, C. H., Hunter, T. and Schlaepfer, D. D. (1998). Pyk2 and 
Src-family protein-tyrosine kinases compensate for the loss of FAK in fibronectin-stimulated 
signaling events but Pyk2 does not fully function to enhance FAK-cell migration. The EMBO 
Journal, 17(20): 5933-5947. 
104 
  
 
 
Slack-Davis, J. K., Martin, K. H., Tilghman, R. W., Iwanicki, M., Ung, E. J., Autry, C., Luzzio, M. J., 
Cooper, B., Kath, J.C., Roberts, W.G. and Parsons, J.T. (2007). Cellular characterization of a novel 
focal adhesion kinase inhibitor. Journal of Biological Chemistry, 282(20): 14845-14852. 
 
Stambolic, V. and Woodgett, J. R. (1994). Mitogen inactivation of glycogen synthase kinase-3 beta in 
intact cells via serine 9 phosphorylation. Biochemical Journal, 303(3): 701-704. 
 
Stewart, A., Ham, C., and Zachary, I. (2002). The focal adhesion kinase amino-terminal domain 
localises to nuclei and intercellular junctions in HEK 293 and MDCK cells independently of tyrosine 
397 and the carboxy-terminal domain. Biochemical and Biophysical Research Communications, 
299(1): 62-73. 
Stratford, A. L., Fry, C. J., Desilets, C., Davies, A. H., Cho, Y. Y., Li, Y., Dong, Z., Berquin, I. M., 
Roux, P. P. and Dunn, S. E. (2008). Y-box binding protein-1 serine 102 is a downstream target of p90 
ribosomal S6 kinase in basal-like breast cancer cells. Breast Cancer Research, 10(6): 1. 
 
Sulzmaier, F. J. and Ramos, J. W. (2013). RSK isoforms in cancer cell invasion and 
metastasis. Cancer Research, 73(20): 6099-6105. 
Sun, T., Rodriguez, M. and Kim, L. (2009). Glycogen synthase kinase 3 in the world of cell 
migration. Development, Growth and Differentiation, 51(9): 735-742. 
Sun, Y., Shah, K. V., Müller, M., Munoz, N., Bosch, X. F. and Viscidi, R. P. (1994). Comparison of 
peptide enzyme-linked immunosorbent assay and radioimmunoprecipitation assay with in vitro-
translated proteins for detection of serum antibodies to human papillomavirus type 16 E6 and E7 
proteins. Journal of Clinical Microbiology, 32(9): 2216-2220. 
 
Sutherland, C., (2011). What are the bona fide GSK3 substrates? International Journal of Alzheimer’s 
Disease, 2011. Article ID 505607. doi:10.4061/2011/505607. 
Sutherland, C., Leighton, I. A. and Cohen, P. (1993). Inactivation of glycogen synthase kinase-3β by 
phosphorylation: new kinase connections in insulin and growth-factor signalling. Biochemical 
Journal, 296(1): 15-19. 
 
Syed, D. N., Lall, R. K., Khan, M. I., Shabbir, M. and Mukhtar, H. (2014). Fisetin inhibits 
p90RSK/YB-1 signaling and downregulates chemoresistance associated P-glycoprotein in A375 
melanoma cells. Cancer Research, 74(19): 3125-3125. 
 
Takahashi, T., Ueno, H., and Shibuya, M. (1999). VEGF activates protein kinase C-dependent, but 
Ras-independent Raf-MEK-MAP kinase pathway for DNA synthesis in primary endothelial 
cells. Oncogene, 18(13). 
 
Takahashi, Y. and Minamoto, T. (2005). Deregulated GSK3beta activity in colorectal cancer: its 
association with tumor cell survival and proliferation. Biochemical and Biophysical Research 
Commununications, 334(4): 1365-1373, ISSN: 0006-291X. 
 
105 
  
 
 
Taliaferro-Smith, L., Oberlick, E., Liu, T., McGlothen, T., Alcaide, T., Tobin, R., Donnelly, S., 
Commander, R., Kline, E., Nagaraju, G. P. and Havel, L. (2015). FAK activation is required for 
IGF1R-mediated regulation of EMT, migration, and invasion in mesenchymal triple negative breast 
cancer cells. Oncotarget, 6(7): 4757. 
 
ter Haar, E., Coll, J. T., Austen, D. A., Hsiao, H. M., Swenson, L. and Jain, J. (2001). Structure of 
GSK3β reveals a primed phosphorylation mechanism. Nature Structural and Molecular Biology, 8(7): 
593-596. 
Tichy, A., Salovska, B., Rehulka, P., Klimentova, J., Vavrova, J., Stulik, J. and Hernychova, L. 
(2011). Phosphoproteomics: Searching for a needle in a haystack. Journal of Proteomics, 74(12): 
2786-2797. 
Torchiaro, E., Lorenzato, A., Olivero, M., Valdembri, D., Gagliardi, P. A., Gai, M., Erriquez, J., 
Serini, G. and Di Renzo, M. F. (2016). Peritoneal and hematogenous metastases of ovarian cancer 
cells are both controlled by the p90RSK through a self-reinforcing cell autonomous 
mechanism.  Oncotarget, 7(1): 712. 
 
Towbin, H., Staehelin, T. and Gordon, J. (1992). Electrophoretic transfer of proteins from 
polyacrylamide gels to nitrocellulose sheets: procedure and some applications. 1979. Biotechnology 
24: 145-149. 
Tripathi, N. (2016). Discovery of inhibitors for focal adhesion kinase (FAK): Molecular modeling 
study for combating cancer. International Journal of Engineering Development and Research, 4(3): 
800-805. 
Turenne, G. A. and Price, B. D. (2001). Glycogen synthase kinase3 beta phosphorylates serine 33 of 
p53 and activates p53's transcriptional activity. BMC Cell Biology, 2(1): 1. 
Ubersax, J. A. and Ferrell Jr, J. E. (2007). Mechanisms of specificity in protein 
phosphorylation. Nature Reviews Molecular Cell Biology, 8(7): 530-541. 
Underwood, T. J., Derouet, M. F., White, M. J., Noble, F., Moutasim, K. A., Smith, E., Drew, P. A., 
Thomas, G. J., Primrose, J. N. and Blaydes, J. P. (2010). A comparison of primary oesophageal 
squamous epithelial cells with HET-1A in organotypic culture. Biology of the Cell, 102(12): 635-644. 
Uribe, P. and Gonzalez, S. (2011). Epidermal growth factor receptor (EGFR) and squamous cell 
carcinoma of the skin: molecular bases for EGFR-targeted therapy. Pathology-Research and 
Practice, 207(6): 337-342. 
Vachon, P. H. (2011). Integrin Signaling , Cell Survival , and Anoikis҅: Distinctions , Differences , 
and Differentiation. Journal of Signal Transduction, 2011. doi:10.1155/2011/738137. 
Vaidya, R. J., Ray, R. M. and Johnson, L. R. (2006). Akt-mediated GSK-3beta inhibition prevents 
migration of polyamine-depleted intestinal epithelial cells via Rac1. Cellular and Molecular Life 
Sciences, 63(23): 2871-2879. ISSN: 1420-682X. 
106 
  
 
 
Vanhaesebroeck, B. and Alessi, D. R. (2000). The PI3K-PDK1 connection: more than just a road to 
PKB. The Biochemical Journal, 346(3): 561-576. 
Van Miltenburg, M. H. A. M., Van Nimwegen, M. J., Tijdens, I., Lalai, R., Kuiper, R., Klarenbeek, 
S., Schouten, P. C., De Vries, A., Jonkers, J. and Van De Water, B. (2014). Mammary gland-specific 
ablation of focal adhesion kinase reduces the incidence of p53-mediated mammary tumour formation. 
British Journal of Cancer, 110(11): 2747-2755. doi:10.1038/bjc.2014.219. 
Veale, R. B. and Thornley, A. L. (1989). Increased Single Class Low-Affinity Egf Receptors 
Expressed by Human Esophageal Squamous Carcinoma Cell-Lines. South African Journal of 
Science, 85(6): 375-379. 
Vial, D. and McKeown-Longo, P. J. (2012). Epidermal growth factor (EGF) regulates α5β1 integrin 
activation state in human cancer cell lines through the p90RSK-dependent phosphorylation of filamin 
A. Journal of Biological Chemistry, 287(48): 40371-40380. 
 
Waaler, J., Machon, O., von Kries, J. P., Wilson, S. R., Lundenes, E., Wedlich, D., Gradl, D., 
Paulsen, J. E., Machonova, O., Dembinski, J. L., Dinh, H. and Krauss, S. (2011). Novel synthetic 
antagonists of canonical Wnt signaling inhibit colorectal cancer cell growth. Cancer Research, 71(1): 
197-205, ISSN: 1538-7445. 
 
Wang, F., Weaver, V. M., Petersen, O. W., Larabell, C. A., Dedhar, S., Briand, P., Lupu, R. and 
Bissell, M. J. (1998). Reciprocal interactions between β1-integrin and epidermal growth factor 
receptor in three-dimensional basement membrane breast cultures: a different perspective in epithelial 
biology. Proceedings of the National Academy of Sciences, 95(25): 14821-14826. 
Wang, X., Urvalek, A. M., Liu, J. and Zhao, J. (2008). Activation of KLF8 transcription by focal 
adhesion kinase in human ovarian epithelial and cancer cells. Journal of Biological Chemistry, 283: 
13934-13942. 
Wei, W. Q., Abnet, C. C., Lu, N., Roth, M. J., Wang, G. Q., Dye, B. A., Dong, Z. W., Taylor, P. R., 
Albert, P., Qiao, Y. L. and Dawsey, S. M. (2005). Risk factors for oesophageal squamous dysplasia in 
adult inhabitants of a high risk region of China. Gut, 54(6): 759-763. 
Willert, K., and Jones, K. A. (2006). Wnt signaling: is the party in the nucleus? Genes and 
Development, 20(11): 1394-1404. 
Wilson, C., Nicholes, K., Bustos, D., Lin, E., Song, Q., Stephan, J. P. and Settleman, J. (2014). 
Overcoming EMT-associated resistance to anti-cancer drugs via Src/FAK pathway 
inhibition. Oncotarget, 5(17): 7328-7341. 
 
Woo, M. S., Ohta, Y., Rabinovitz, I., Stossel, T. P. and Blenis, J. (2004). Ribosomal S6 kinase (RSK) 
regulates phosphorylation of filamin A on an important regulatory site. Molecular and Cellular 
Biology, 24(7): 3025-3035. 
 
Woodgett, J. R. (1990). Molecular cloning and expression of glycogen synthase kinase-3/factor 
A. The EMBO Journal, 9(8): 2431. 
107 
  
 
 
Wozniak, M. A., Modzelewska, K., Kwong, L. and Keely, P. J. (2004). Focal adhesion regulation of 
cell behavior. Biochimica et Biophysica Acta (BBA)-Molecular Cell Research, 1692(2): 103-119. 
 
Wu, J., Yang, L., Shan, Y., Cai, C., Wang, S. and Zhang, H. (2016). AURKA promotes cell migration 
and invasion of head and neck squamous cell carcinoma through regulation of the AURKA/Akt/FAK 
signaling pathway. Oncology Letters, 11(3): 1889-1894. 
Wu, J., Zuo, F., Du, J., Wong, P. F., Qin, H. and Xu, J. (2013). Icariside II induces apoptosis via 
inhibition of the EGFR pathways in A431 human epidermoid carcinoma cells. Molecular Medicine 
Reports, 8(2): 597-602. 
Xia, H., Li, F., Hu, X., Park, W., Wang, S., Jang, Y., Du, Y., Baik, S., Cho, S., Kang, T. and Kim, D. 
H. (2016). pH-Sensitive Pt Nanocluster Assembly Overcomes Cisplatin Resistance and 
Heterogeneous Stemness of Hepatocellular Carcinoma. ACS Central Science, 2(11): 802-811. 
Xian, W., Pappas, L., Pandya, D., Selfors, L. M., Derksen, P. W., de Bruin, M. and Brugge, J. S. 
(2009). Fibroblast Growth Factor Receptor 1–Transformed Mammary Epithelial Cells Are Dependent 
on RSK Activity for Growth and Survival. Cancer Research, 69(6): 2244-2251. 
 
Xu, L. H., Yang, X., Craven, R. J. and Cance, W. G. (1998). The COOH-terminal domain of the focal 
adhesion kinase induces loss of adhesion and cell death in human tumor cells. Cell growth and 
differentiation. The Molecular Biology Journal of the American Association for Cancer Research, 
9(12): 999-1005. 
 
Yamada, K. M. and Geiger, B. (1997). Molecular interactions in cell adhesion complexes. Current 
Opinion in Cell Biology, 9(1): 76-85. 
Yang, K., Gao, K., Hu, G., Wen, Y., Lin, C. and Li, X. (2016). cTgF enhances resistance to 5-FU-
mediating cell apoptosis through FaK/MeK/erK signal pathway in colorectal cancer. OncoTargets and 
Therapy, 9: 7285. 
Yntema, H. G., van den Helm, B., Kissing, J., van Duijnhoven, G., Poppelaars, F., Chelly, J., 
Moraine, C., Fryns, J-P., Hamel, B. C. J., Helibronner, H., Pander, H-J., Brunner, H. G. Rpoers, H-H., 
Cremers, F. and van Bokhoven, H. (1999). A novel ribosomal S6-kinase (RSK4; RPS6KA6) is 
commonly deleted in patients with complex X-linked mental retardation. Genomics, 62(3): 332-343. 
Yoneda, M., Guo, Y., Ono, H., Nakatsu, Y., Zhang, J., Cui, X., Iwashita, M., Kumamoto, S., 
Tsuchiya, Y., Sakoda, H. and Fujishiro, M. (2010). Decreased SIRT1 expression and LKB1 
phosphorylation occur with long-term high-fat diet feeding, in addition to AMPK phosphorylation 
impairment in the early phase. Obesity Research and Clinical Practice, 4(3): e201-e207. 
Yurdagul, A., Sulzmaier, F. J., Chen, X. L., Pattillo, C. B., Schlaepfer, D. D. and Orr, A. W. (2016). 
Oxidized LDL induces FAK-dependent RSK signaling to drive NF-κB activation and VCAM-1 
expression. Journal of Cell Science, 129(8): 1580-1591. 
 
Zachary, I., and Rozengurt, E. (1992). Focal adhesion kinase (p125FAK): a point of convergence in 
the action of neuropeptides, integrins, and oncogenes. Cell, 71(6): 891-894. 
108 
  
 
 
Zeng, X. and Kinsella, T. J. (2008). Mammalian target of rapamycin and S6 kinase 1 positively 
regulate 6-thioguanine-induced autophagy. Cancer Research, 68(7): 2384-2239. 
Zhang, L., Liu, J., Lei, S., Zhang, J., Zhou, W. and Yu, H. (2014). PTEN inhibits the invasion and 
metastasis of gastric cancer via downregulation of FAK expression. Cellular Signalling, 26(5): 1011-
1020. doi:10.1016/j.cellsig.2014.01.025. 
Zhang, Y., Lu, H., Dazin, P. and Kapila, Y. (2004). Squamous Cell Carcinoma Cell Aggregates 
Escape Suspension-induced, p53-mediated Anoikis Fibronectin and integrin αv mediate survival 
signals through focal adhesion kinase. Journal of Biological Chemistry, 279(46): 48342-48349. 
Zhao, J., Zheng, C. and Guan, J. (2000). Pyk2 and FAK differentially regulate progression of the cell 
cycle. Journal of Cell Science, 113(17): 3063-3072. 
Zhao, Y., Bao, Q., Schwarz, B., Zhao, L., Mysliwietz, J., Ellwart, J., Renner, A., Hirner, H., Niess, H., 
Camaj, P. and Angele, M. (2013). Stem cell-like side populations in esophageal cancer: a source of 
chemotherapy resistance and metastases. Stem Cells and Development, 23(2): 180-192. 
Zheng, H., Saito, H., Masuda, S., Yang, X. and Takano, Y. (2007). Phosphorylated GSK3β-ser9 and 
EGFR are good prognostic factors for lung carcinomas. Anticancer Research, 27(5B): 3561-3569. 
 
Zhong, X. and Rescorla, F. J. (2012). Cell surface adhesion molecules and adhesion-initiated 
signaling: understanding of anoikis resistance mechanisms and therapeutic opportunities. Cellular 
Signalling, 24(2): 393-401. doi:10.1016/j.cellsig.2011.10.005. 
Zhou, W., Wang, L., Gou, S. M., Wang, T. L., Zhang, M., Liu, T. and Wang, C. Y. (2012). ShRNA 
silencing glycogen synthase kinase-3 beta inhibits tumor growth and angiogenesis in pancreatic 
cancer. Cancer Letters, 316(2): 178-186. 
Zhou, Y., Uddin, S., Zimmerman, T., Kang, J. A., Ulaszek, J., and Wickrema, A. (2008). Growth 
control of multiple myeloma cells through inhibition of glycogen synthase kinase-3. Leukemia and 
Lymphoma, 49(10): 1945-1953. 
Zhu, W., Chen, J., Cong, X., Hu, S. and Chen, X. (2006). Hypoxia and serum deprivation-induced 
apoptosis in mesenchymal stem cells. Stem Cells, 24(2): 416-425. 
Zouq, N. K., Keeble, J. A., Lindsay, J., Valentijn, A. J., Zhang, L., Mills, D.,Turner, E. C., Streuli, C. 
H. and Gilmore, A. P. (2009). FAK engages multiple pathways to maintain survival of fibroblasts and 
epithelia: differential roles for paxillin and p130Cas. Journal of Cell Science, 122(Pt 3): 357-367. 
doi:10.1242/jcs.030478. 
 
 
 
 
109 
  
 
 
 
1. Appendix A 
1.1. Protein extraction: 
1.1.1. Phosphate buffer saline (1X), pH 7.3: 
136.9 mM                                        Sodium chloride 
2.68 mM                                           Potassium chloride 
10.1 mM                                           Disodium hydrogen phosphate decahydrate 
1.76 mM                                           Potassium dihydrogen phosphate 
Make up final volume with distilled water 
Autoclave to sterilize (store at 4°C) 
1.1.2. Laemmli double lysis buffer: 
125 mM                                         Tris-HCl, pH 6.8 
4.0 %                                               Sodium Dodecyl Sulphate 
20.0 %                                             Glycerol 
10.0 %                                              β-mercaptoethanol 
Make up to final volume with distilled water 
Autoclave to sterilize (store at 4°C) 
1.1.3. Sodium Orthovanadate: 
100 mM                                      Sodium Orthovanadate 
Make up to final volume with distilled water, pH 10 
1.1.4. Sodium Fluoride: 
1 M                                             Sodium Fluoride 
Make up to final volume with distilled water 
1.1.5. Phenylmethylsulfonyl Fluoride (PMSF): 
100 mM                                       PMSF 
  Make up to final volume with Methanol 
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1.2. Protein determination: 
1.2.1. 95 % Ethanol: 
95.0 %                                              Ethanol 
 
Make up to final volume with distilled water 
 
1.2.2. 7.5 % Trichloroacetic Acid (TCA): 
7.5 %                                                TCA 
 Make up to final volume with distilled water 
 
1.2.3. Coomassie Blue solution (0.25 %): 
0.25 %                                            Coomassie brilliant blue powder 
50.0 %                                             Methanol 
10.0 %                                             Glacial acetic acid 
Make up to final volume with distilled water 
1.2.4. Destain solution:  
12.0 %                                            Glacial acetic acid  
10.0 %                                             Methanol 
Make up to final volume with distilled water 
1.2.5. Elution solution: 
66.0 %                                        Methanol 
33.0 %                                        Distilled water 
1.0 %                                          Ammonia  
1.3. Sodium Dodecyl Sulphate Polyacrylamide Gel Electrophoresis 
(SDS-PAGE): 
1.3.1. Buffers: 
1.3.1.1. Electrophoresis tank buffer, pH 8.3:  
3.74 mM                                         SDS 
25.0 mM                                          Tris-HCl, pH 8.3 
192.5 mM                                       Glycine 
The pH of the solution was adjusted to 8.3 by using 5 N HCl   
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Make up to final volume with distilled water 
1.3.1.2. Separating Buffer: 
18.12 g                                           Tris 
The pH of the solution was adjusted to 8.8 by using 5N HCl   
Make up to final volume with distilled water 
1.3.1.3. Stacking Buffer: 
6.04 g                                            Tris 
The pH1 of the solution was adjusted to 6.8 by using 5 N HCl   
Make up to final volume with distilled water 
1.3.2. 50 mg/ml Sodium Dodecyl Sulphate Solution: 
50 mg/ml                                                SDS 
Make up to final volume with distilled water 
1.3.3. Gel solutions: 
1.3.3.1. Separating Gel: 
10.0 %                                            Acrylamide 
0.1 %                                                      N,N’-methylenebisacrylamide 
375.0 mM                                             Tris-HCl, pH 6.8 
0.2 %                                                      SDS 
Make up to final volume with distilled water 
Add 1 mM Ammonium Persulphate (APS) and 0.25 % N',N',N',N'-Tetramethylethylene-
diamine (TEMED) just before use 
1.3.3.2. Stacking Gel: 
5.0 %                                       Acrylamide 
0.1 %                                       N,N’-methylenebisacrylamide 
125 mM                                   Tris-HCl, pH 6.8 
0.2 %     SDS 
Make up to final volume with distilled water 
Add 1 mM Ammonium Persulphate (APS) and 0.25 % N',N',N',N'-Tetramethylethylene-
diamine (TEMED) just before use 
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1.3.4. SDS Overlay: 
400 µl                 50 mg/ml SDS 
Make up to 10ml with distilled water 
 
1.3.5. 0.25 % Coomassie Brilliant Blue Stain:  
 
As previously described (Appendix A, Section 2.3.) 
 
1.3.6. Destain solution:  
10 %                           Acetic Acid 
10 %                           Methanol 
 
Make up to final volume with distilled water 
 
1.4. Immunoblotting (Western Blot Analyses): 
1.4.1. Buffers: 
1.4.1.1. Transfer Buffer: 
25.0 mM                                     Tris-HCl, pH 8.3 
1.41 %                                        Glycine 
20.0 %                                        Methanol 
Make up to final volume with distilled water 
1.4.1.2. Tris-Buffer Saline (TBS) (1X): 
50.0 mM                                        Tris-HCl, pH 7.8 
150.0 mM                                      Sodium Chloride  
2.0 mM                                          Anhydrous Calcium Chloride 
 Make up to final volume with distilled water 
Autoclave to sterilize (store 4°C) 
1.4.1.3. Tris-Buffer Saline-Tween (TBS-T): 
50.0 mM                                          Tris-HCl, pH 7.8 
150.0 mM                                        Sodium chloride  
2.0 mM                                            Anhydrous calcium chloride 
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0.1 %                                               Tween 
 Make up to final volume with distilled water 
Store at 4°C 
1.4.1.4. TBS-for-Blotto Blocking buffer: 
50 mM                                            Tris-HCl, pH 7.8 
2.0 mM                                           Anhydrous Calcium Chloride 
5.0 %                                                Non-fat Milk Powder 
0.05 %                                              TritonX-100 
Make up to final volume with distilled water 
1.4.1.5. Blocking Solution: 
5.0 %          Non-fat milk powder 
Make up to final volume with appropriate buffer 
1.4.1.6. Phosphate buffer saline (1X), pH 7.3 
As previously described (Appendix A, Section 1.1.) 
 
1.4.2. Developer: 
6.40 M                                                            Metol 
0.60 M                                                            Sodium sulphite (anhydrous) 
80.0 mM                                                          Hydroquinone  (Quinol) 
0.45 mM                                                         Sodium Carbonate (anhydrous)  
34.0 mM                                                          Potassium Bromide 
Make up to final volume with distilled water 
Store at room temperature in the dark 
1.4.3. Fixer: 
0.8 M                                                       Sodium Trisulphate 
0.2 M                                                        Sodium Metasulphite 
Make up to final volume with distilled water 
Store at room temperature in the dark 
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1.4.4. SuperSignal ® West Pico Chemiluminescent Substrate Kit: 
50 %                                             Luminol Enhancer Solution 
50 %                                             Stable Peroxide Buffer 
Mix in a 1:1 ratio 
Store in the dark 
1.5. Specific Inhibition of p90RSK with BI-D1870: 
1.5.1. BI-D1870 working dilution 
10 µM BI-D1870 in 100 % Dimethyl Sulfoxide (DMSO) 
1.5.2. BI-D1870 Stock solution 
1 mg/ml                       BI-D1870 
Make up to final volume with 100 % DMSO 
1.6. Specific Inhibition of GSK3β with AR-A014418 
1.6.1. AR-A014418 working dilution 
10 µM in 100 % Dimethyl Sulfoxide (DMSO) 
1.6.2. AR-A014418 Stock solution 
5 mg/ml                          AR-A014418 
Make up to final volume with 100 % DMSO 
1.7. Tissue culture: 
1.7.1. Dulbecco`s Modified Eagles Medium (DMEM): 
1.370 %                                             DMEM 
0.370 %                                             Sodium Bicarbonate 
2.0 %                                                 Penicillin (500 U/ml)/Streptomycin (0.5 %) solution 
1.7.2. Hams F12 Medium Solution: 
1.070 %                                             Hams F12 Medium 
0.118 %                                             Sodium Bicarbonate 
2.0 %                                                Penicillin (500 U/ml)/Streptomycin (0.5 %) solution 
1.7.3. DMEM/Hams F12 Medium Solution: 
DMEM/Hams F12 Medium solutions mixed in a 3:1 ratio 
Filter sterilize (Store at 4°C) 
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1.7.4. Trypsin Solution: 
0.010 %                                        Trypsin 
Make up to final volume with PBS 
1.7.5. Ethylenediaminetetra-acetic acid (EDTA): 
0.004 %                                          EDTA 
Make up to final volume with PBS 
1.7.6. Trypsin/Ethylenediaminetetra-actetic acid (EDTA): 
Trypsin Solution/EDTA mixed in a 1:1 ratio 
Store at 4°C 
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2. Appendix B 
2.1. Representation of a standard curve: 
 
 
Figure B1. Representation of a standard curve used to estimate the 
concentration of protein within HOSCC whole cell extracts.  Seven BSA 
standards of known concentration (1, 3, 6, 9, 12, 16 and 20 µg/µl) were 
plotted in conjunction with their respective absorbance readings (at 595 nM). 
This was done to obtain a standard curve with the equation y = 0.0046x. The 
equation of the standard curve was then used to calculate the protein 
concentrations of the unknown HOSCC whole cell protein lysates. The R2 
value indicates how well the data is represented by the graph (linear 
regression).   
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2.2. The relative abundance of key phospho-proteins under standard tissue culture conditions. 
 
Table 4. Standard error in the mean (SEM) relative abundance of a few key phospho-proteins (expressed as % IOD) within 
the HOSCC cells under standard tissue culture conditions. 
Phospho-protein Cell line- SEM 
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
Phospho-FAK (Tyr397) 0 13 7 3 11 13 0 
Phospho-GSK3β (Ser9) 0 4 6 4 6 9 0 
Phospho-β-catenin (Ser33, Ser37 & Thr41) 0 N/A 0 7 4 8 8 
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Table 5. Standard Student’s t-test on the relative abundance of a few key phospho-proteins within the HOSCC cell lines 
when compared to the A431 cell line under standard tissue culture conditions. 
A star (*) represents statistical significance when compared to the A431 cell line (SS: Statistically significant; NS: not statistically 
significant; *: p <0 .05; **: p < 0.01; ***: p < 0.001)  
Phospho-
protein 
Cell line 
HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-value P-
value 
Phospho-FAK 
(Tyr397) 
NS 4.54 0.1380 ** 11.02 0.0081 ** 14 0.005 NS 2.82 0.0668 NS 4.193 0.0525 *** 1493762 ҅0.0001 
Phospho-GSK3β 
(Ser9) 
** 12.48 0.0064 ** 10.46 0.009 ** 17.69 0.0032 * 5.579 0.0307 NS 2.499 0.0878 *** 5881 ҅0.0001 
Phospho-β-
catenin (Ser33, 
Ser37 and 
Thr41) 
N/A N/A N/A * 5 0.0154 NS 4.124 0.0541 * 5.227 0.0347 NS 1.833 0.2082 * 9.62 0.0106 
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2.3. The relative abundance of key phospho-proteins within the HOSCC cells post RSK inhibition (10 µM BI-
D1870). 
 
Table 6. Standard Student’s t-test on the relative abundance of a few key phospho-proteins within each HOSCC cell line 
post RSK inhibition (10 µM BI-D1870) when compared to its equivalent comparative control (0.1 % DMSO). 
A star (*) represents statistical significance when compared to the A431 cell line (SS: Statistically significant; NS: not statistically 
significant; *: p <0 .05; **: p < 0.01; ***: p < 0.001)  
Phospho-
protein 
Cell line  
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-value P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P- 
value 
Phospho-
FAK 
(Tyr397) 
NS 0.1571 0.8833 * 3.682 0.0254 NS 0.09051 0.9323 NS 1.88 0.1420 NS 2.025 0.1344 
 
NS 0.5663 0.5920 
 
NS 2.484 0.0726 
Phospho-
GSK3β 
(Ser9) 
NS 0.4106 0.6956 NS 0.8233 0.4888 NS 1.758 0.1574 NS 1.758 0.1574 
 
NS 2.052 0.1546 
 
** 5.124 0.0022 NS 0.9103 0.4568 
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Table 7. The mean and standard error in the mean (SEM) of the cellular levels of a few key phospho-proteins (expressed 
as % IOD) within the HOSCC cells post RSK inhibition (BI-D1870). 
(BI-D+: with 10 µM BI-D1870; BI-D-: without 10 µM BI-D1870/containing 0.1 % DMSO). 
Phospho-protein Cell line   
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
mean SEM Mean SEM Mean SEM Mean SEM mean SEM mean SEM mean SEM 
Phospho-
FAK 
(Tyr397) 
BI-D+ 35 9 28 4 50 11 51 4 53 5 137 19 126 20 
BI-D- 37 12 53 6 48 10 41 3 33 9 153 21 210 27 
 
2.4. The relative abundance of key phospho-proteins within the HOSCC cells post RSK inhibition (10 µM BI-
D1870, 24 hours after serum stimulation), GSK3β inhibition (10 µM AR-A014418) and RSK/GSK3β 
inhibition (10 µM BI-D1870/ 10 µM AR-A014418). 
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Table 8. The mean and standard error in the mean (SEM) of the cellular levels of a few key phospho-proteins (expressed 
as % IOD) within the HOSCC cells post RSK inhibition (10 µM BI-D1870, 24 hours after serum stimulation), GSK3β 
inhibition (10 µM AR-A014418) and RSK/GSK3β inhibition (10 µM BI-D1870/ 10 µM AR-A014418).  
(BI-D+: with 10 µM BI-D1870; BI-D-: without 10 µM BI-D1870/containing 0.1 % DMSO; AR+: with 10 µM AR-A014418; AR-: without 10 µM AR-
A014418/containing 0.187 % DMSO; BI-D+/AR+: with 10 µM BI-D1870/AR-A014418; BI-D-/AR-: without 10 µM BI-D1870/AR-A014418 (containing 0.287 % 
DMSO)) 
     Phospho- 
      protein 
Inhibitor Cell line   
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
Mean SEM mean SEM mean SEM mean SEM Mean SEM mean SEM mean SEM 
Phospho-
FAK 
(Tyr397) 
BI-D+ 73 9 33 1 25 3 67 8 144 12 107 8 148 3 
BI-D- 48 4 25 1 17 3 99 7 85 6 120 17 92 7 
AR+ 64 13 22 7 74 3 42 4 45 5 160 21 90 6 
AR- 77 11 46 6 27 6 22 1 78 5 231 14 62 12 
BI-D+/ AR+ 75 7 31 15 41 5 95 3 110 6 169 15 81 8 
BI-D- /AR- 87 10 36 7 43 6 114 4 134 7 266 9 186 31 
Phospho-
GSK3β 
(Ser9) 
BI-D+ 83 22 24 5 29 10 46 8 54 1 4 4 75 1 
BI-D- 137 23 68 7 77 0,1 79 5 38 16 73 3 55 4 
AR+ 94 44 142 3 81 17 80 5 42 3 74 29 41 5 
AR- 139 28 325 1 55 4 92 13 17 2 127 2 56 8 
BI-D+/ AR+ 146 8 86 30 30 8 131 10 10 2 43 7 8 4 
BI-D- /AR- 145 23 219 11 35 6 165 14 62 4 144 10 120 30 
Phospho-β-
catenin 
(Ser33, 
Ser37 & 
Thr41) 
BI-D+ 136 23 N/A N/A 18 4 29 7 114 14 63 16 154 4 
BI-D- 91 9 N/A N/A 37 3 39 8 144 15 106 2 113 7 
AR+ 90 4 N/A N/A 61 6 88 5 70 6 73 3 94 37 
AR- 78 9 N/A N/A 25 1 42 7 168 4 97 8 158 40 
BI-D+/ AR+ 100 4 N/A N/A 51 5 174 8 94 13 124 5 131 3 
BI-D- /AR- 130 7 N/A N/A 70 6 177 4 206 10 102 1 135 18 
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Table 9. Standard Student’s t-test on the relative abundance of a few key phospho-proteins within each HOSCC cell line 
post RSK inhibition (10 µM BI-D1870, 24 hours after serum stimulation) when compared to its equivalent comparative 
control (0.1 % DMSO). 
 A star (*) represents statistical significance when compared to the A431 cell line (SS: Statistically significant; NS: not statistically 
significant; *: p <0 .05; **: p < 0.01; ***: p < 0.001)  
Phospho-
protein 
Cell line  
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P- 
value 
Phospho-
FAK 
(Tyr397) 
NS 2.534 0.0875 * 7.463 0.0105 NS 1.887 0.1332 * 2.988 0.0405 
 
NS 4.77 0.0896 NS 0.6927 0.5399 
 
** 7.361 0.0064 
Phospho-
GSK3β 
(Ser9) 
NS 1.639 0.1770 
 
** 5.165 0.0083 
 
NS 4.753 0.1319 NS 0.8174 0.4826 * 6.802 0.0226 * 13.42 0.0121 NS 5.52 0.1092 
Phospho-
β-catenin 
(Ser33, 
Ser37 
and 
Thr41) 
NS 1.785 0.1818 
 
- N/A N/A * 3.681 0.0242 NS 0.8875 0.4687 NS 1.404 0.2964 NS 2.587 0.1179 
 
** 5.203 0.0099 
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Table 10. Standard Student’s t-test on the relative abundance of a few key phospho-proteins within each HOSCC cell line 
post GSK3β inhibition (10 µM AR-A014418) when compared to its equivalent comparative control (0.1 % DMSO). 
A star (*) represents statistical significance when compared to the A431 cell line (SS: Statistically significant; NS: not statistically 
significant; *: p <0 .05; **: p < 0.01; ***: p < 0.001)  
Phospho-
protein 
Cell line  
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P- 
value 
Phospho-
FAK 
(Tyr397) 
NS 0.756 0.5300 NS 2.526 0.0657 * 7.374 0.0397 
 
NS 4.978 0.0978 ** 4.978 0.0089 NS 2.849 0.0543 NS 2.044 0.1358 
Phospho-
GSK3β 
(Ser9) 
NS 0.8438 0.5019 * 56.46 0.0108 NS 1.492 0.2648 NS 0.8174 0.4826 * 6.802 0.0226 NS 1.814 0.3194 NS 1.612 0.1964 
Phospho-β-
catenin 
(Ser33, 
Ser37 and 
Thr41) 
NS 1.169 0.3294 - N/A N/A NS 5.905 0.0965 
 
** 5.182 0.0098 
 
* 17.01 0.0365 NS 2.861 0.1589 
 
NS 1.123 0.3249 
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Table 11. Standard Student’s t-test on the relative abundance of a few key phospho-proteins within each HOSCC cell line 
post RSK/GSK3β inhibition (10 µM BI-D1870/ 10 µM AR-A014418) when compared to its equivalent comparative control 
(0.1 % DMSO). 
A star (*) represents statistical significance when compared to the A431 cell line (SS: Statistically significant; NS: not statistically 
significant; *: p <0 .05; **: p < 0.01; ***: p < 0.001)  
Phospho-
protein 
Cell line 
A431 HT29 WHCO1 WHCO3 WHCO5 SNO WHCO6 
SS t-value P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P-
value 
SS t-
value 
P- 
value 
Phospho-
FAK 
(Tyr397) 
NS 1.009 0.756 NS 0.3078 0.7788 
 
NS 0.3354 0.7548 
 
* 4.483 0.0136 NS 2.654 0.0569 
 
** 5.518 0.0083 NS 3.221 0.1638 
Phospho-
GSK3β 
(Ser9) 
NS 0.01016 0.9933 
 
* 4.084 0.0352 
 
NS 0.4605 0.6705 NS 1.934 0.1325 
 
** 12.45 0.0010 ** 7.922 0.0020 NS 3.703 0.0623 
Phospho-
β-catenin 
(Ser33, 
Ser37 and 
Thr41) 
* 3.933 0.0239 - N/A N/A NS 2.527 0.0666 NS 0.3449 0.7546 ** 6.636 0.0034 * 4.23 0.0479 NS 0.2675 0.8127 
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Table 12. The relative abundance of key proteins within the HOSCC cells as determined by Shaw (2012) and Driver (2006). 
Protein Cell line 
WHCO1 
(%) 
WHCO3 
(%) 
WHCO5 
(%) 
SNO (%) WHCO6 
(%) 
HT29 (%) 
Phospho-
PKB 
(Ser473) 
10 0 50 22 100 30 
PTEN 100 80 50 30 20 N/A 
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2.5. Net change in the cellular levels of key phospho-proteins. 
 
Comparative studies were performed obtaining the percentage difference between the relative 
abundance of a phospho-protein when an HOSCC cell line is exposed to an inhibitor (or set 
of inhibitors) (IODT) as opposed to DMSO (control) (IODC) (exposed to 0.1 % DMSO). The 
net change in the cellular levels of a specific phospho-protein, post inhibition, was 
determined as outlined below. Normalized densitometric data, optical density, obtained by 
western blot analyses for each experimental condition, was utilized to determine the net 
change in the cellular levels of a specific phospho-protein as outlined below: 
 
                             𝑁𝑒𝑡 𝑐ℎ𝑎𝑛𝑔𝑒 𝑖𝑛 𝑡ℎ𝑒 𝑐𝑒𝑙𝑙𝑢𝑙𝑎𝑟  
𝑙𝑒𝑣𝑒𝑙𝑠 𝑜𝑓𝑒𝑎𝑐ℎ 𝑝ℎ𝑜𝑠𝑝ℎ𝑜 − 𝑝𝑟𝑜𝑡𝑒𝑖𝑛 (%) =
(𝐼𝑂𝐷𝑇 − 𝐼𝑂𝐷𝐶)
𝐼𝑂𝐷𝐶
× 100 
 
 
2.6. Normalisation of the densitometric data by fixed point. 
 
The data was normalised as outlined by Degasperi and colleagues (2014). The Normalisation 
by fixed point was employed in the current study. However, instead of dividing all the 
replicated data by a measurement of a single condition, all of the data was normalised using a 
ratio two measurements, the whole cell A431 cells/Whole cell WHCO6 cells. This made use 
of the densitometric data of both the loading control and the comparative control to normalize 
the data. Normalising the data based on 2 measurements reduced some of the biological 
variability of using the reference point mechanism to normalise data.  
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2.6. Plagiarism Report 
 
 
Note: The methods and materials, appendices and reference list were omitted to reduce the 
risk of false positives.  
